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Abstract
During cardiac hypertrophy individual cardiac myocytes increase in size, which is accompanied by
augmented protein synthesis and selective induction of a subset of genes. These phenotypic changes
of myocytes are a result from altered intracellular signaling mechanisms and molecules. B-type
natriuretic peptide (BNP) gene was selected as a target gene for the study of cardiac signaling
mechanisms, since it is activated by mechanical, neural and humoral stimuli during myocyte
hypertrophy.
To generate hypertrophy of cardiac myocytes, neonatal rat cardiac myocytes were subjected to
exogenous hypertrophic agonists such as endothelin-1 (ET-1) or to cyclic mechanical stretch. The
role and regulation of transcription factors were studied by utilizing promoter analysis together with
site-specific mutations and measurement of DNA binding activity and phosphorylation. GATA-4
mediated signaling was inhibited by blocking DNA binding with decoy oligonucleotides or by
decreasing GATA-4 synthesis via adenoviral antisense delivery. ET-1 activated GATA-4 via serine
residue phosphorylation, and this effect was mediated via p38 kinase. Similarly, GATA-4 binding
activity was increased by ET-1 and mechanical stretch, but it was essential for activation of BNP gene
only in the latter stimulation. Importantly, downregulation of GATA-4 protein levels prevented
mechanical stretch induced hypertrophy of cardiac myocytes. In contrast, separate mechanism for an
ET-1 specific signaling was composed of p38 kinase regulated ETS-like transcription factor-1 (Elk-
1). Finally, the effect of mechanical stretch on endogenous endothelin-1 (ET-1) synthesis in cardiac
cells was studied. Intrinsic ET-1 synthesis was activated in stretched cardiac myocytes, yet the levels
of ET-1 were relatively low.
This work suggests that GATA-4 transcription factor is required for mechanical stretch mediated
hypertrophic program, and Elk-1 may act as a downstream effector of ET-1 in cardiac myocytes.
Taken together, induction of ET-1 and BNP genes as well as activation of GATA-4 and Elk-1
transcription factors are regulated via a network of mitogen activated protein kinase pathways.
Keywords:  endothelin-1, hypertrophy, mechanical stretch, natriuretic peptides, protein
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References1 Introduction 
Cardiac overload initiates a process which aims to maintain and adapt the cardiovascular 
system to altered hemodynamics. During this process, myocardium undergoes 
hypertrophy and remodeling. At the level of individual cardiac myocytes, the cell 
morphology is altered (increase in cell size and myofibrillar re-organization) and the 
protein synthesis is activated (Lorell & Carabello 2000). These phenotypic changes of 
myocytes are a result of altered intra-cellular signaling and extensive genetic re-
programing. During and prior to the 1980s identification of genes associated with cardiac 
hypertrophy were accompanied by the discovery of natriuretic peptides in the heart 
(Ruskoaho 1992). Since then, this has been followed by the characterization of the 
complex gene regulatory mechanisms, and with molecular biology approaches further 
insight of the signaling mechanisms and of the development of cardiac hypertrophy has 
been achieved (Hunter & Chien 1999). 
B-type natriuretic peptide (BNP) is a member of the natriuretic peptide family (Nakao 
et al. 1996), and it is released by cardiac myocytes into circulation (Ruskoaho 1992). 
Given that BNP gene expression and secretion is activated during cardiac hypertrophy 
and overload (Magga et al. 1998), its regulatory mechanisms may share mutual aspects 
with hypertrophic signaling cascades. Therefore, BNP gene provides a target gene for the 
study of intracellular signaling activated during myocyte hypertrophy. Earlier studies 
have identified GATA-4 as a major nuclear factor that mediates induction of a 
hypertrophic pattern of genes including BNP (Marttila et al. 2001), angiotensin II (Ang 
II) receptor-1a (AT1a) and β-myosin heavy chain (β-MHC) during hemodynamic loading. 
In addition, Hautala and coworkers have demonstrated that the activation of GATA-4 
binding on rat BNP gene by pressure overload is mediated by endogenous endothelin-1 
(ET-1) (Hautala  et al. 2001). Yet, the underlying molecular mechanisms activating 
GATA-4 are poorly defined.  
In the present study, the hypertrophic response and cardiac gene regulation in cultured 
neonatal rat cardiac myocytes were studied. When combined to approaches of molecular 
biology, this experimental model allows delicate approaches to investigate the 
intracellular signal transduction. The first goal of this study was to evaluate the role and 
regulation of GATA-4 and mitogen activated protein kinases (MAPK) in cardiac   18
hypertrophic response. Secondly, the present study was aimed at identification of novel 
regulatory mechanisms of rat BNP and ET-1 genes.  2 Review of the literature 
2.1  Growth of cardiac myocytes 
In normal adult heart, myocardial mass increases mainly due to enlargement of individual 
myocytes (for reviews, see Swynghedauw 1999, Lorell & Carabello 2000). Cardiac 
pressure overload in conditions such as aortic stenosis or hypertension results in parallel 
addition of sarcomeres and increases width of myocytes, which in turn augment left 
ventricular wall thickness (Lorell & Carabello 2000). However, when mechanical and 
neurohumoral stress are sustained, the adaptive mechanisms eventually fail and further 
myocardial remodeling leads to ventricular dilation and impairment of cardiac contractile 
function. Cardiac output is reduced until it is inadequate to maintain efficient blood 
circulation of the whole organism and the syndrome of congestive heart failure occurs 
(Hunter & Chien 1999, Lorell & Carabello 2000). At the cellular level, cardiac growth 
and failure is due to a complex pattern of signaling mechanisms and molecules. 
2.1.1  Mechanical stress 
Mechanical loading of cardiac myocytes activates anabolic growth response with 
increased  de novo protein synthesis. Schreiber et al. performed pioneer studies using 
isolated working guinea-pig hearts and radioactive amino acid labeling, and found that 
total protein synthesis including myosin and collagen, but not myoglobin, was induced by 
3 hours of increased aortic pressure (Schreiber et al. 1970). In rats with aortic stenosis in 
vivo, radioactive labeling of proteins remained unchanged for 1 or 2 days, peaked at 5–6 
days, and returned to basal levels at 2–3 weeks (Zimmer et al. 1972, Ray et al. 1987). 
The effect of direct mechanical load on protein synthesis has been confirmed in a 
stretched culture of neonatal rat ventricular myocytes (Sadoshima & Izumo 1997).  
Mechanical stress alters the phenotype of individual cardiac myocytes profoundly, 
including hypertrophy and selective regulation of gene expression (Sadoshima & Izumo   20
1997). Initiation of hypertrophic growth is accompanied by a rapid and transient 
expression of immediate early genes (e.g. c-jun, c-fos, c-myc and Egr-1) (Komuro et al. 
1990, for review, see Yamazaki  et al. 1995b) followed by activation of a pattern of 
cardiac genes, including atrial natriuretic peptide (ANP) and BNP (for reviews, see 
Ruskoaho 1992, Tokola et al. 2001), α-skeletal actin (α-skA), β-MHC (Izumo et al. 
1987), whereas relative expression of different isoforms of genes is simultaneously 
decreased (i.e. α-MHC) (Nakao et al. 1997, Hunter & Chien 1999). Increased load may 
liberate local growth promoting factors in the heart. Such autocrine and/or paracrine 
factors include Ang II (Sadoshima et al. 1993), transforming growth factor-β1 (TGF-β1) 
(Liang & Gardner 1998), basic fibroblast growth factor (bFGF) (Kaye et al. 1996) and 
ET-1 (Yamazaki et al. 1996). In the heart, locally released ET-1 may mediate, at least in 
part, the hypertrophic responses of myocytes to Ang II or TGF-β1 (Ito  et al. 1993, 
Harada et al. 1997a, Liang & Gardner 1998). 
2.1.2  Endothelin-1 
The discovery of endothelin (ET, later named ET-1) as a major endothelium-derived 21 
amino acid vasoconstrictor peptide (Yanagisawa  et al. 1988) was followed by the 
identification of three closely related 21 amino acid isopeptides, ET-2, ET-3 and ET-4 
(Inoue et al. 1989, Saida et al. 1989). ETs are produced in a variety of tissues and cells, 
but the expression of ET isoforms is tissue specific (Giannessi  et al. 2001). ET-1 is 
synthesized predominantly by vascular endothelial cells (Yanagisawa et al. 1988) and 
constitutes the most important isoform in the cardiovascular system. Besides endothelial 
cells irrespective of their origin, ET-1 is synthesized by cardiac cells (Suzuki et al. 1993, 
Harada et al. 1997a) and vascular smooth muscle cells (Lerman et al. 1991) as well as by 
the kidney and central nervous system (Giannessi et al. 2001). ET-2 is produced within 
the kidney and intestine and, to a lesser extent, in the myocardium, placenta and uterus 
and in endothelial cells (Levin 1995). ET-2 appears to have vasoconstrictor properties 
similar to those of ET-1, while ET-3 shows reduced vasoconstrictive action with respect 
to the other isoforms (Douglas & Hiley 1990, Saito et al. 1991). ET-3 has been found in 
the brain and, together with ET-4 (Saida et al. 1989), in the gastro-intestinal tract, lung 
and kidney (Matsumoto et al. 1989), but not in endothelial cells or cardiac tissue (Bloch 
et al. 1989). 
The initial product of the human ET-1 gene, a 212 amino acid preproET-1, is cleaved 
at dibasic sites by furin-like endopeptidase to generate a 38 amino acid peptide, big ET-1, 
which is found in the peripheral circulation (Giannessi  et al. 2001). Big ET-1 has 
approximately 140-fold lower vasoconstrictor potency than ET-1, while preproET-1 does 
not show any vasoconstrictor action (Kimura  et al. 1989). Therefore, the proteolytic 
cleavage of big ET-1 to mature ET-1 by distinct membrane-bound metalloproteases, 
endothelin converting enzymes (ECE) (for review, see Russell & Davenport 1999) or 
alternatively by chymase, a non-ECE metalloprotease or vascular smooth muscle cell 
chymase (for review, see Luscher & Barton 2000), is of functional significance.   21
Fig. 1. Regulators of ET-1 production. 
Synthesis of ET-1 in endothelial cells is activated by pathophysiological stimuli including 
mechanical strain and oxygen deprivation (Kourembanas et al. 1991, Macarthur et al. 
1994). Similarly, production of ET-1 has been reported to be augmented in mechanically 
strained cultured neonatal rat cardiac myocytes and fibroblasts in vitro (Yamazaki et al. 
1996) as well as in pressure overloaded rat heart due to aortic banding in vivo (Ito et al. 
1994). Multiple vasoactive factors regulate ET-1 production (Fig. 1), such as Ang II, ET-
1, interleukin-1 (IL-1), phenylephrine (PE), TGF-β1 and tumor necrosis factor-α (TNF-
α), which upregulate and ANP, nitric oxide and prostacyclin which inhibit ET-1 synthesis 
(for review, see Giannessi  et al. 2001). ET-1 is mainly secreted to basolateral 
compartment (> 80%) by endothelial cells, suggesting an important role for ET-1 as a 
local regulator of vascular tone rather than a circulating hormone (Wagner et al. 1992). 
ETs generate their biological effects via binding to distinct cell membrane receptors, 
named ETA and ETB receptors (Arai et al. 1990, Sakurai et al. 1990,  for review, see 
Luscher & Barton 2000). ET receptors contain seven transmembrane α-helices and 
belong to a family of guanine nucleotide binding proteins (G proteins) coupled receptors 
(GPCRs). In the cardiovascular system, ETA receptors are found in vascular smooth 
muscle cells and cardiac myocytes, whereas ETB receptors are localized on endothelial 
cells and cardiac fibroblasts, and to some extent, to vascular smooth muscle cells and 
macrophages (Modesti et al. 1999, for review, see Luscher & Barton 2000). The rank 
order of affinities between the two receptors is different: ET-1 = ET-2 >> ET-3 and ET-
1 = ET-2 = ET-3, for ETA and ETB receptors, respectively (Giannessi et al. 2001).  
ETA and ETB receptors on smooth muscle mediate contraction, cell proliferation and 
hypertrophy (de Nucci et al. 1988). Endothelial ETB receptors stimulate the production of 
nitric oxide and prostacyclin, and induce vasorelaxation (for review, see Schiffrin 2001). 
Therefore, the ETA/B of smooth muscle cells and ETB receptors of endothelial cells appear 
to have contrasting effects in the context of vasoconstriction and vasodilation. 
Intravenous infusion of ET-1 results in a transient decrease in mean arterial pressure and 
peripheral vascular resistance, which is followed by long-lasting vasoconstriction and 
increased blood pressure (Yanagisawa  et al. 1988). Whether vasoconstriction or 
ET-1 synthesis
Ang II
IL-1
PE
TNF-α
TGF-β 
Hypoxia
Mechanical load
ANP 
Nitric oxide 
Prostacyclin  22
vasodilation is the dominating effect of ET-1 under normal conditions may depend on the 
vascular bed (Russell et al. 1997). Pathophysiological conditions, such as hypertension, 
hypercholesterolemia, diabetes and heart failure (for review, see Harrison 1996), involve 
endothelial dysfunction and decreased nitric oxide generation and/or bioavailability (for 
review, see Harrison 1997) that may accentuate deleterious vascular effects of 
endogenous ET-1 (Haynes & Webb 1998). Interestingly, ETB dependent vasodilatation in 
mesenteric vascular bed is attenuated (Montagnani et al. 2000), whereas ETB mediated 
contraction of aortic vascular smooth muscle cells is enhanced (Batra et al. 1993) in 
spontaneously hypertensive rats (SHR) as compared to normotensive Wistar-Kyoto rats. 
ET-1 has potent inotropic and chronotropic effects on the heart (Ishikawa et al. 1988a, 
1988b, Moravec et al. 1989), which is accompanied by enhanced efficacy of oxygen 
consumption (Takeuchi et al. 2001). In cultured rat neonatal cardiac myocytes, a selective 
ETA receptor antagonist (BQ-123) inhibits protein synthesis induced by Ang II (Ito et al. 
1993), ET-1 (Ito  et al. 1993), TGF-β1 (Harada  et al. 1997a) and mechanical stretch 
(Yamazaki  et al. 1996), suggesting that ET-1 is a growth factor of 
myocytes.  Furthermore, ET-1 is capable of inducing morphology (Shubeita et al. 1990) 
and a pattern of cardiac gene expression characteristic of hypertrophic cardiac myocytes. 
ET-1 activates immediate early genes (Shubeita et al. 1990), induces ANP and BNP gene 
expression and secretion (Shubeita et al. 1990, Harada et al. 1997a) as well as contractile 
protein genes including α-skA, myosin light chain-2 (MLC-2) (Ito et al. 1991) and MHC 
genes (Wang et al. 1992). In parallel to these direct trophic effects on myocytes, due to 
peripheral vasoconstriction, ET-1 increases mechanical stress of the cardiac muscle. In 
hypertensive experimental animal models, including deoxycorticosterone acetate 
(DOCA)-salt and aldosterone-salt, DOCA-salt-treated SHRs, Dahl salt-sensitive rats, 
one-kidney, one-clip Goldblatt hypertensive rats and stroke prone SHRs, there is 
overexpression of ET-1 mRNA in the endothelium and blood pressure lowering upon 
administration of pharmacological ET receptor antagonists (for review, see Schiffrin 
2001). Notably, there is also evidence that functional ET-system is not obligatory for 
hypertension, since in adult SHR rats ET receptor antagonism is not effective in lowering 
blood pressure or attenuating blood vessel hypertrophy (Li & Schiffrin 1995). More 
evidence for the role of ET-1 in the development of cardiac hypertrophy and failure was 
obtained when ET receptor antagonists were used in experimental animal models. 
Chronic administration of ETA antagonist (BQ-123) improved long-term survival and 
attenuated the end-organ damage of rats with heart failure (Sakai et al. 1996). Treatment 
with the mixed ETA/B antagonist (bosentan) was equally effective and improved systemic 
hemodynamics, left ventricular function and remodeling (Mulder  et al. 2000) and 
survival of rats with heart failure (Mulder et al. 1997). 
Elevated ET-1 plasma concentrations have been detected in various cardiovascular 
conditions in humans, such as severe hypertension, hyperlipidemia, advanced 
atherosclerosis, congestive heart failure, and after myocardial infarction (for reviews, see 
Levin 1995, Schiffrin 2001). In humans with essential hypertension, 4-week treatment 
with bosentan was reported to decrease blood pressure to a similar extent as treatment 
with angiotensin convertase enzyme inhibitor, enalapril (Krum et al. 1998). Thereafter, 
long-term bosentan treatment of patients with congestive heart failure demonstrated that 
bosentan treatment was associated with adverse effects and initial worsening of heart 
failure (Mylona & Cleland 1999). Therefore, the role of long-term treatment with ET   23
receptor antagonists in cardiac hypertrophy and failure or in essential hypertension is yet 
to be elucidated, and development of compounds with fewer side-effects and/or 
alternative timing and dosing of treatment may be required. However, the ETA/B 
antagonist bosentan may provide an effective therapy for human pulmonary arterial 
hypertension (Rubin et al. 2002). 
ET-gene targeted mouse revealed important novel functions for ET-1 during fetal 
development (see Table 1). Mice with homozygous disruption of the ET-1 or ETA gene 
were not viable due to severe craniofacial and cardiac abnormalities (Kurihara  et al. 
1994, 1995b). These developmental defects of transgenic ET-1 or ETA null mice included 
poorly developed mandible, abnormal thyroid and hyoid structures with tracheo-
esophageal narrowing, maldevelopment of auditory structures and interruptions of aortic 
arch, absence of right subclavian artery, ventricular septal defects and double outlet right 
ventricle and, occasionally, persistent truncus arteriosus (Kurihara et al. 1994, 1995a, 
1995b). Cardiac changes resemble those of animals with defects in the cardiac neural 
crest per se, yet the migration of neural crest cells was not affected. It has been suggested 
that neural crest cells in the local mesenchyme, which express ETA, require ET-1 
stimulation for normal proliferation and differentiation (Maemura et al. 1992, for review 
see Hunley & Kon 2001). Heterozygous ET-1 (+/−) mice survived with lower plasma and 
tissue ET-1 levels than their wild-type siblings (Kurihara et al. 1994). These mice had 
elevated blood pressure, suggesting a predominantly vasodilatory role for ET-1 (Kurihara 
et al. 1994). However, it has been suggested that the craniofacial developmental 
abnormalities that occur when the ET-1 gene is inactivated may result in hypoxemia that 
could contribute to elevated blood pressure (Schiffrin 2001). In addition, transgenic mice 
with endothelial-cell specific inactivation of the ET-1 gene demonstrated a 15 mm Hg 
reduction in mean, systolic, and diastolic blood pressures in comparison to the genetically 
matched control groups (Kedzierski & Yanagisawa 2001). 
In contrast to the effects of inactivated ET-1/ETA system, mice with inactivation of ET-
3 or ETB gene displayed white coat spotting and aganglionic megacolon due to lack of 
epidermal melanocytes and myenteric ganglia (Baynash et al. 1994, Hosoda et al. 1994), 
respectively. ECE-1 null mice developed a phenotype containing the features of both ET-
1/ETA and ET-3/ETB null mice (Yanagisawa et al. 1998). ECE-2 null mice were healthy 
into adulthood, fertile and had a normal life span, but when both ECE-1 and ECE-2 genes 
were deleted, the defects in cardiac outflow structures became more severe than those in 
ECE-1 single knockout embryos (Yanagisawa et al. 2000). Mice overexpressing ET-1 
gene under the direction of its own promoter displayed at the age of 12–14 months renal 
manifestations, including prominent interstitial fibrosis, renal cysts and 
glomerulosclerosis (Hocher et al. 1997, Shindo et al. 2002), and likely based on the renal 
damage, salt-sensitive hypertension (Shindo  et al. 2002). In agreement with ET-1 
overexpressing transgenic mice, transgenic rats overexpressing human ET-2 gene 
developed renal interstitial and glomerular sclerosis accompanied by decreased creatinine 
clearance at 12 months (Liefeldt et al. 1999). These transgenic rats had also reduced heart 
weight and when nitric oxide synthase was inhibited and potential compensatory 
mechanism was unmasked, enhanced blood pressure was detected (Liefeldt et al. 1999). 
An additional study supported an important role for ET-1 in the kidney, when rats 
carrying a naturally occurring deletion in the ETB receptor gene (Spotting lethal rats, sl) 
that resulted in congenital distal intestinal aganglionosis, were rescued from this   24
developmental defect using a dopamine-hydroxylase ETB transgene (Gariepy  et al. 
1998). These dopamine-hydroxylase ETB transgene rescued sl rats displayed salt sensitive 
hypertension (Gariepy et al. 2000).  
Table 1. Summary of the ET system transgenic animal models. 
Targeted gene  Phenotype 
Deletion  
ET-1  homozygous: lethal, craniofacial and cardiac abnormalities 
  heterozygous: elevated blood pressure 
  endothelial homozygous: lowered blood pressure 
ETA  identical phenotype to ET-1 deletion 
ET-3  white coat spotting, lack of melanocytes in hair bulbs and retinal choroid, 
aganglionic megacolon and death within 4 weeks 
ETB  white coat spotting, aganglionic megacolon and death within 4 weeks when 
intestinal abnormalities rescued, a salt-sensitive hypertension 
  craniofacial, cardiac and pigmentary abnormalities 
ECE-1  more severe cardiac phenotype than in ECE-1 mutants 
ECE-1/2  at 12–14 months, renal abnormalities and salt-sensitive hypertension 
Overexpression ET-1  at 6 months, renal abnormalities and at 12 months, decreased creatinine 
clearance 
  at 12 months, reduced heart weight 
ET-2  at 12 months, enhanced hypertension when nitric oxide synthase inhibited 
2.2  Signaling to nucleus 
2.2.1  Heterotrimeric G Proteins 
Heterotrimeric G proteins are composed of two functional subunits, α-subunit and βγ-
dimer (Simon et al. 1991) , which dissociate from each other and become active after 
guanine diphosphate (GDP)-bound form of α-subunit is activated by the exchange of 
GDP for guanine triphosphate (GTP) (Fig. 2). The innate GTPase activity of α-subunits 
returns them to the inactive state through hydrolysis of GTP (Neves  et al. 2002), a 
process which is promoted by a family of regulators of G protein signaling (RGS) 
(Watson et al. 1996). Heterotrimeric G proteins are classified into subfamilies according 
to the α-subunit, and each subfamily has a different preference for the corresponding 
downstream signaling pathways. Bacterial toxins alter the activities of Gs and Gi/o 
proteins via covalent modifications of α subunits. αs subunit can be covalently modified 
by cholera toxin (CTX) resulting in constitutive activation of Gs, whereas αi subunits and 
Gi/o are inhibited by pertussis toxin (PTX) (Schnabel & Bohm 1996). The other two 
subfamilies, Gq and G12,13 proteins are insensitive to PTX and CTX. Activation of Gs 
protein stimulates adenylyl cyclase, leading to a generation of cyclic adenosine   25
monophosphate (cAMP) and activation of protein kinase A, whereas Gi proteins inhibit 
adenylyl cyclase (Rockman  et al. 2002). GTP-bound Gαq protein activates 
phosphoinositide phospholipase-β2 (PLC-β2), leading to generation of inositol-
trisphosphate (IP3) and diacylglycerol (DAG), accompanied by mobilization of calcium 
and activation of protein kinase C (PKC) (Nishizuka 1984, Nishizuka 1986), respectively. 
Dissociated Gβγ has a potential to activate small GTP binding protein Ras and initiate Tyr 
kinase cascade leading to activation of mitogen activated protein kinase (MAPK) (van 
Biesen et al. 1995). Furthermore, Gq may activate MAPK independently of Gβγ via a 
mechanism that is PKC dependent (Hawes et al. 1995). G12,13 proteins were discovered 
due to sequence similarity to known Gα proteins, and their precise function and the 
receptors to which they endogenously couple are not yet well-defined (Neves  et al. 
2002). However, Gα12,13 proteins have been reported to activate small G proteins Ras and 
RhoA (Dhanasekaran & Dermott 1996). 
ET receptors belong to a subfamily of GPCRs with a promiscuous nature, which can 
activate multiple types of G proteins (for review, see Sugden & Clerk 1998b). Binding of 
agonist to GPCR alters the conformation of the receptor and leads to receptor association 
with heterotrimeric G proteins within the plasma membrane and subsequent activation of 
G proteins (Hall & Lefkowitz 2002). ETA is mainly thought to associate with Gq 
(Takigawa et al. 1995) and Gs proteins (Takagi et al. 1995), but a linkage with G12/13 
(Mao et al. 1998) and also with PTX-sensitive G proteins have been reported (Takigawa 
et al. 1995, Pönicke et al. 1999). ETB couples with Gq (Takagi et al. 1995) and G13 
proteins (Kitamura et al. 1999). In addition, in an unstimulated state, ETB is coupled to 
Go and in an activated state, depending on the agonist used, ETB will be bound to Gαi 
(Kitamura  et al. 1999). In reconstituted phospholipid vesicles, both ET receptors 
activated Gq protein with similar EC50 values (concentration resulting in 50% of maximal 
activation), while ETA displayed a 2–3-fold higher maximal extent of Gq activation (Doi 
et al. 1999). Therefore, while both ET receptors are able to activate Gq dependent 
signaling cascades, ETA may act as a more potent activator. In contrast, in the same 
model both ET receptors activated Gi proteins to a similar maximal extent, but ETA 
displayed a 4-fold higher EC50 value (Doi et al. 1999), suggesting that ETB is preferred as 
an activator of Gi protein. Taken together, although ETA and ETB may exert contrasting 
effects via Gs and Gi proteins in the generation of cAMP, respectively, ET receptor 
associated G proteins appear partially mutual and overlapping. The hypertrophic effect of 
ET-1 on cardiac myocytes has been linked to Gq protein dependent mechanism (for 
review, see Adams & Brown 2001), yet there is also evidence for a PTX sensitive 
mechanism (Gi/o) (Pönicke et al. 1999).    26
Fig. 2.  Regulatory cycle of heterotrimeric G proteins, for abbreviations see page 25. 
2.2.2  Small G Proteins 
The low molecular weight GTPases, referred to as small G proteins, constitute a 
superfamily of proteins with a size of 20–25 kDa (for review, see Clerk & Sugden 2000). 
They share common features with heterotrimeric G proteins: Firstly, the activation by the 
exchange of GDP to GTP, a process enhanced by guanine nucleotide exchange factors 
(GEFs) or inhibited by guanine nucleotide dissociation inhibitors. Secondly, inactivation 
by returning to a GDP-bound state, which is enhanced by GTPase activating proteins (for 
review, see Vojtek & Der 1998). Small G proteins regulate cell survival, growth, division, 
vesicle transport and the arrangement of cellular cytoskeleton, and these effects involve 
conserved pathways of MAPKs, phosphatidylinositol 3´-kinases (PI3K) and also small G 
protein specific effectors, such as Rho kinases (for reviews, see Vojtek & Der 1998, Clerk 
& Sugden 2000, Sah et al. 2000). Ras, Rho and Rab are the small G protein families that 
have been studied in the heart. However, the requirement of the small G proteins as 
mediators of human cardiac hypertrophy remains to be determined (Clerk & Sugden 
2000). 
The Ras family consists of 3 classical isoforms: Ras (HRas, KRas and NRas), Rap and 
Ral (Clerk & Sugden 2000). Ras genes were originally identified as the transforming 
elements of the Harvey and Kirsten strains of the rat sarcoma virus (HRas and Kras, 
respectively), and thereafter mutated alleles of Ras genes have been detected in various 
human tumors (for review, see Bar-Sagi 2001). Typically, extracellular peptide growth 
factors such as FGFs, bind to their corresponding transmembrane receptors that undergo 
autophosphorylation, leading to association with adapter proteins that bring GEFs in 
apposition to the membrane bound Ras-GDP, which finally activates Ras (for review, see 
Sugden & Clerk 2000). In cultured cardiac myocytes, Ras signaling is activated by 
hypertrophic GPCR agonists including PE (LaMorte et al. 1994), ET-1 (Chiloeches et al. 
1999) and Ang II (Sadoshima & Izumo 1996). The mechanism of Ras activation by these 
GPCRs has been linked to activation of non-receptor Tyr kinases, such as the oncogenic 
Src family of Tyr kinases (Sadoshima & Izumo 1996, Kovacic et al. 1998), which are 
capable of increasing activity of GEFs on Ras (Sadoshima & Izumo 1996). In addition,   27
mechanical stretch of neonatal rat cardiac myocytes, activates Ras via a mechanism 
involving integrin signaling, focal adhesion Tyr kinase (FAK) and Src (Sadoshima & 
Izumo 1993, Aikawa et al. 2002). Interestingly, the Src family of Tyr kinases has been 
reported to activate and likely to mediate at least some of the hypertrophic changes 
demonstrated with neonatal rat cardiac myocytes including activation of ANP and BNP 
gene expression (Kovacic  et al. 1998, Fuller  et al. 1998b, He & Lapointe 2001). In 
addition, constitutively active Ras induces transcription of cardiac genes associated with 
hypertrophy, including ANP, BNP, β-MHC and α-skA (Thuerauf & Glembotski 1997, 
Fuller  et al. 1998a, 1998b). Expression of dominant negative Ras appears to inhibit 
development of the hypertrophic phenotype of cultured myocytes (Clerk & Sugden 
2000), and expression of dominant negative Ras downregulates induction of human BNP 
promoter in neonatal rat cardiac myocytes by mechanical stretch (Liang et al. 1997) and 
IL-1β (He & Lapointe 1999). However, the potential requirement of Ras as a mediator of 
human cardiac hypertrophy remains to be determined (Clerk & Sugden 2000). 
The Rho subfamily includes RhoA, Rac1 and Cdc42 proteins, divided into these three 
groups according to amino acid sequence identities and cellular functions (Sah et al. 
2000). Rac1 is activated by both ET-1 and PE, whereas RhoA only by ET-1 in cultured 
cardiac myocytes (Clerk et al. 2001). Initially, Rho proteins have been shown to regulate 
fibroblast actin cytoskeleton in response to serum stimulation (for review, see Sah et al. 
2000). Thereafter, studies have been performed utilizing neonatal rat cardiac myocyte 
culture and hypertrophic stimuli together with inhibition of Rho signaling. Inhibition of 
RhoA decreases activation of ANP and MLC-2 gene expression in response to PE or 
constitutive active Gq (Sah  et al. 1996, Hines & Thorburn 1998), whereas in the 
regulation of re-arrangement of sarcomeres the role of RhoA remains controversial (Sah 
et al. 1996, Thorburn  et al. 1997). Constitutively active Rac1 activates hypertrophic 
phenotype in cultured cardiac myocytes (Pracyk  et al. 1998) and partially mediates 
activation of human BNP promoter in neonatal rat cardiac myocyte culture by ET-1, 
lysophosphatidic acid, isoproterenol and IL-1β (He & Lapointe 1999, He et al. 2000, He 
& Lapointe 2001). 
2.2.3  Integrins and cytoskeleton 
Integrins are non-covalently associated heterodimeric transmembrane receptors 
composed of α and β subunits that couple components of the extracellular matrix with the 
actin cytoskeleton (for review, see Parsons 1996). Integrins are primary sensors of the 
extracellular matrix (ECM) environment and may thus act as transmitters of mechanical 
signals to the cytoskeleton (Sadoshima & Izumo 1997). Cardiac myocytes express α1, 
 α3,  α5,  α6,  α7,  α9, and α10 together with β1, β3 and β5 subunits, while the expression 
pattern of subunits can be temporally and developmentally modified (for review, see Ross 
& Borg 2001). Furthermore, integrins are functionally associated with the Ras and Rho 
families of small G proteins as well as with Tyr kinase signaling mediated by FAK and 
Src (Parsons 1996).    28
Pressure overload induced by aortic constriction activates genes of α1,  α3,  α5 and  α7 
and β1 and β3 subunits in rodent heart (Ross & Borg 2001). In the cat right ventricle, 
induction of pressure overload by pulmonary artery banding mobilizes β3 integrin to the 
cytoskeletal fraction after 4 hours of banding and both to cytoskeletal and membrane-
bound fraction at 48 hours, while these changes returned to baseline by 1 week 
(Kuppuswamy et al. 1997). In addition, the feline model of cardiac hypertrophy in vivo 
(Kuppuswamy et al. 1997, Laser et al. 2000) as well as mechanically stretched or PE-
stimulated neonatal rat cardiac myocytes have revealed an increased association of 
activated FAK and Src with integrins and/or cytoskeleton (Aikawa et al. 2002). By using 
cultured neonatal rat cardiac myocytes and adenoviral (Ross et al. 1998) or plasmid (Wei 
et al. 2001) mediated overexpression of β1 integrin, it has been reported that β1 integrin 
augments ANP, MLC-2 and α-skA gene expression by PE and RhoA overexpression, 
respectively. Moreover, inhibition of integrin signaling in neonatal rat cardiac myocytes 
decreases PE induced hypertrophic response (Ross et al. 1998) as well as induction of 
human BNP promoter by mechanical stretch (Liang et al. 2000a). 
2.2.4  SA channels 
Studies using mechanically stretched myocytes and myocardium undergoing 
hypertrophic remodeling have demonstrated altered electrophysiological properties that 
have led to a hypothesis that the cell membrane mechanosensitive or stretch activated 
(SA) ion channels participate in the conversion of physical forces and neurohumoral 
stimuli to cardiac contractility, gene expression, and ultimately, to hypertrophic 
phenotype (Swynghedauw 1999, Tavi et al. 2001). Activation of the cell membrane SA 
channels increases Ca
2+ influx to myocyte leading to further intracellular Ca
2+ release and 
increase in intracellular Ca
2+ (Sigurdson et al. 1992). Studies have been conducted by 
using Gd
3+, a known inhibitor of SA channels, although not all the potential SA channels 
are sensitive to Gd
3+ (Sadoshima & Izumo 1997). In isolated superperfused rat atria 
stretched by increasing intra-atrial pressure, Gd
3+ has been shown to inhibit increased 
ANP release and BNP mRNA levels (Laine et al. 1996), while in cultured neonatal rat 
cardiac myocytes, mechanical stretch activates protein synthesis and c-fos gene 
expression in a Gd
3+-insensitive manner (Sadoshima & Izumo 1997). Therefore, the exact 
role of the Gd
3+-insensitive SA channels (Zhang  et al. 2000) or the pattern of ion 
channels activated by mechanical stress, including K
+ATPase, a delayed K
+ rectifier, Cl
− 
and L-type Ca
2+ channel, remains to be elucidated in cardiac mechanotransduction 
(Sadoshima & Izumo 1997).  
2.2.5  Calcium activated signaling 
Since Ca
2+ is a second messenger activating multiple signaling cascades, it has been 
suggested that in addition to the effects of altered Ca
2+ handling on cardiac contractile   29
parameters (Morgan 1991), Ca
2+ may directly alter gene expression in the heart (for 
review, see Nicol et al. 2000). Many of the actions of Ca
2+ are mediated via its interaction 
with calmodulin (CaM), which is an intracellular sensor for Ca
2+, and selectively 
activates downstream signaling pathways in response to local changes in [Ca
2+] (Chin & 
Means 2000). The major signaling pathways that are both directly activated by Ca
2+ and 
sufficient to promote the development of cardiac hypertrophy include particular 
Ca
2+/CaM regulated kinase and phosphatase pathways and PKC isozymes (Frey et al. 
2000) (Fig. 3). 
Major cardiac Ca
2+/CaM dependent enzymes include Ca
2+/CaM dependent protein 
kinase (CaMK), myosin light chain kinase (MLCK) and the phosphatase calcineurin 
(Frey et al. 2000, Molkentin & Dorn II 2001). In the heart, the main CaMKII isoform is 
CaMKIIδ, which is localized to the nucleus, whereas other isoforms are localized to the 
sarcoplasmic reticulum (Zhang  et al. 2002). Increased intracellular [Ca
2+] results in 
autophosphorylation of CaMKII, which switches it to a Ca
2+-independent state and 
prolongs its activation. CaMKI, which is ubiquitously expressed, and CaMKIV, mainly 
expressed in testis and brain, are activated by upstream Ca
2+/CaM dependent protein 
kinases (Chien 2000, Frey et al. 2000). CaMKII isoforms associated with sarcoplasmic 
reticulum are capable of phosphorylating Ca
2+-cycling proteins and hence of altering Ca
2+ 
re-uptake and release (Frey et al. 2000). In cultured cardiac myocytes, pharmacological 
inhibitors of CaMKII have been reported to attenuate both ET-1 induced hypertrophy 
(Zhu et al. 2000) and mechanical stretch activated BNP gene transcription (Liang et al. 
1997). Moreover, overexpression of CaMKIIδ in the heart of transgenic mice is sufficient 
to promote hypertrophic growth (Zhang  et al. 2002) as well as is cardiac-specific 
overexpression of either CaMKI or CaMKIV (Passier et al. 2000). MLCK is activated by 
Ca
2+/CaM leading to subsequent phosphorylation of its single main substrate, ventricular 
specific isoform of myosin light chain-2 (MLC-2). In cultured neonatal ventricular 
myocytes, phosphorylation of MLC-2 is increased by hypertrophic agonists (PE or Ang 
II), whereas MLCK overexpression activates sarcomeric protein assembly, but not the 
number of ANP positive cardiac myocytes (Aoki  et al. 2000). The importance of 
activated MLCK in the development of cardiac hypertrophy in vivo remains 
undetermined. 
In addition to kinases of the heart, Ca
2+/CaM activates phosphatases, including 
calcineurin (Molkentin et al. 1998). Activation of calcineurin by the Ca
2+/CaM complex 
results in dephosphorylation of its substrates including nuclear factor of activated T-cells 
(NFAT) (Jain et al. 1993) or Ets-like gene-1 (Elk-1) (Sugimoto et al. 1997). Interaction of 
Ca
2+/CaM and calcineurin has been reported to increase in failing human heart, and the 
cardiac calcineurin activity is augmented in experimental animal models of cardiac 
hypertrophy (for review, see Olson & Molkentin 1999). In addition, by using cultured 
neonatal cardiac myocytes, a constitutively active calcineurin has been reported to 
activate human BNP promoter synergistically with transcription factors including its 
substrate nuclear factor of activated T-cells-3 (NFAT3) and GATA-4 (Molkentin et al. 
1998), whereas an inhibition of calcineurin was shown to prevent ET-1, 1% serum, Ang II 
or PE induced hypertrophy (Taigen et al. 2000, Zhu et al. 2000). Importantly, calcineurin 
or the nuclear localized mutant of its substrate (mutant of NFAT3) were sufficient to 
produce cardiac hypertrophy when overexpressed in the heart of transgenic mice 
(Molkentin  et al. 1998). Later, however, when transgenic lines with cardiac-specific   30
calcineurin overexpression were crossed with NFAT3 and NFAT4 deficient transgenic 
mice, only the lack of NFAT4 was able to attenuate calcineurin-dependent cardiac 
hypertrophy (Wilkins  et al. 2002). Pharmacological inhibition of calcineurin has 
produced conflicting results in prevention of cardiac hypertrophy in various experimental 
rodent models (for review, see Bueno et al. 2002). This may be due to lack of well-
tolerated calcineurin inhibitors, and since calcineurin is not a cardiac-restricted enzyme, 
the inhibitors (cyclosporine or FK506) are relatively toxic and have immunosuppressive, 
nephrotoxic and hypertensive effects (Sugden 1999, Bueno  et al. 2002). In human 
hypertrophied cardiac tissue higher calcineurin activity was detected as compared with 
normal cardiac tissue (Haq et al. 2001, Ritter et al. 2002). Yet, patients maintained with 
immunosuppressive therapy of cyclosporine and hence with at least partially inhibited 
calcineurin activity, can develop cardiac hypertrophy (McKinsey & Olson 1999), 
demonstrating that there are additional pathways and that calcineurin signaling is not 
indispensable for hypertrophy (Sugden 1999). 
PKC was originally identified as a kinase activated by limited proteolysis, and later it 
was shown to be activated by lipids and Ca
2+ (Mackay & Mochly-Rosen 2001). The 
classical PKC (cPKC) isozymes (α, βI, βII and γ) are activated by the second messengers 
Ca
2+
 and DAG in the presence of phosphatidylserine (PS), whereas the Ca
2+-insensitive 
PKC subfamilies include novel PKCs (δ, ε, η and θ) that talso require PS and DAG for 
full activation and the atypical PKCs (ζ and λ) that are activated by other lipids than 
DAG (Molkentin & Dorn II 2001, Mackay & Mochly-Rosen 2001). In the heart, 
pathophysiological stimuli such as ischemia and either acute or chronic mechanical 
overload have been reported to increase PKC activity as well as hypertrophic agonists 
(ET-1, PE) in cultured cardiac myocytes (for review, see Molkentin & Dorn II 2001). 
Moreover, the PKC pathways have been suggested to provide a link for GPCR to 
multiple intracellular signaling cascades, including Tyr kinases, such as FAK, and 
MAPKs (Nicol et al. 2000).  
The presence of multiple PKC isozymes and their differential regulation have 
complicated the evaluation of PKC pathways in cardiac hypertrophy. For instance, in 
transgenic mice with cardiac calcineurin overexpression, only the activation of PKCα, βI 
and θ isozymes was detected, whereas in aortic banded rats PKCα, βI-II, ε and λ activity 
was increased (De Windt  et al. 2000). By using pharmacological inhibitors of PKC 
together with isolated perfused rat heart preparation, it was demonstrated that PKC 
contributes to the increased BNP release and mRNA levels in mechanically loaded right 
atria (Magga  et al. 1997b) as well as to increased ANP release by ET-1-infusion 
(Pitkänen et al. 1991). In cultured neonatal rat cardiac myocytes, the overexpression of 
PKC isozymes increases transcription of hypertrophy associated genes, such as ANP, 
BNP, β-MHC and MLC-2 (Thuerauf & Glembotski 1997, Sugden & Clerk 1998b), and 
PKC has been linked to a post-transcriptional stabilization of BNP mRNA by PE 
(Hanford & Glembotski 1996). Depletion of PKCα in cultured neonatal rat cardiac 
myocytes with antisense oligonucleotides attenuates ET-1 induced secretion of ANP and 
BNP and also inhibits PE activated release of ANP, while the inhibition of PKCα was 
insufficient to prevent increased protein synthesis by PE and ET-1 (Kerkelä et al. 2002). 
Yet, adenoviral PKCα overexpression was shown to induce hypertrophic phenotype to 
neonatal rat ventricular myocytes (Braz  et al. 2002), and transgenic mice with an 
increased number of L-type Ca
2+ channels had elevated PKCα activity already prior to   31
the development of cardiac hypertrophy and failure (Muth et al. 2001). Contrastingly, 
mice with cardiac-specific overexpression of PKCβ isoforms develop cardiac 
hypertrophy (Bowman et al. 1997, Wakasaki et al. 1997), whereas targeted inactivation 
of the PKCβ gene in mice is not sufficient to prevent cardiac hypertrophy induced by PE-
infusion or aortic banding (Roman  et al. 2001). Cardiac-specific overexpression of 
constitutive active PKCε or peptide activator molecules of either PKCε or PKCδ 
isozymes are all sufficient to produce cardiac hypertrophy with preserved contractile 
function in transgenic mice (Takeishi et al. 2000, Chen et al. 2001). However, in failing 
human hearts, increased PKC activity has been linked to elevated expression of Ca
2+-
sensitive PKCα, βI and βII isozymes (Bowling et al. 1999). Taken together, there is 
cumulative in vitro and in vivo evidence suggesting an important role for PKC pathways 
as mediators of hypertrophic signals, but the precise pattern of the isozymes involved 
remains undetermined. 
Fig. 3. Ca
2+-activated hypertrophic signaling cascades. 
2.2.6  Mitogen-activated protein kinases 
MAPK pathways provide an important signaling machinery between external stimuli and 
the nucleus (for review, see Robinson & Cobb 1997). At the core of each MAPK cascade, 
there is a three-kinase module consisting of a MAPK kinase kinase (MAPKKK), a 
MAPK kinase (MAPKK) and a MAPK (Fig. 4). Activation of MAPK is initiated by 
phosphorylation of MAPKKK leading to a cascade of site-specific phosphorylations of 
Thr and Tyr residues within catalytic domains of the enzymes transmitted through the 
module. Finally, the dually phosphorylated and hence active MAPK is capable of 
catalyzing phosphorylation of its substrates, which are selected, at least partially, due to 
MAPK´s preference to Pro-directed Ser/Thr residue motifs (Nicol et al. 2000). According 
to the sequence homology, MAPKs are divided into subfamilies, of which extracellular   32
signal-regulated kinase (ERK or ERK1/2), p38 MAPK (p38) and c-Jun N-terminal kinase 
(JNK) have been under intensive investigation in cardiac myocytes (Sugden & Clerk 
1998b). Yet, there are additional ERK3/4 and ERK5 subfamilies in mammals, but their 
role is presently less clearly understood (Widmann et al. 1999). MAPKs are gathered 
together with their selective upstream and downstream effectors by specific scaffold or 
adaptor proteins, which is likely to enhance specificity as well as temporal and spatial 
organization of MAPK signaling (Schaeffer & Weber 1999). Since MAPK activation is 
transient in most in vitro models, it has been suggested that these enzymes may serve as 
an initiative trigger in hypertrophic signal transduction (Sugden & Clerk 1998b). 
Fig. 4. MAPK modules for ERK, JNK and p38 pathways. 
2.2.6.1  ERK 
Originally, in 1982 it was noted that growth factors, including platelet-derived and 
epidermal growth factors, increased Tyr residue phosphorylation of a 42-kDa cellular 
protein (Cooper et al. 1982). Thereafter, Ser/Thr-kinases activated by insulin-receptor Tyr 
kinase were identified (Ray & Sturgill 1988). Finally, separate findings were united, and 
the 42 kDa Ser/Thr-kinase that was phosphorylated at Thr/Tyr residues in response to 
insulin was identified as the same protein that was Tyr phosphorylated by growth factors, 
phorbol esters and viral transformation (for review, see Widmann et al. 1999). Notably, 
the Thr-Glu-Tyr motif phosphorylation was required for its activation (Widmann et al. 
1999). When the cDNA for this first MAPK was isolated in 1990, it was named 
extracellular signal-regulated kinase-1 (ERK1) (Boulton  et al. 1990). After ERK1, 
additional ERKs, ERK2 and ERK3, were rapidly isolated (Boulton et al. 1991). Later, the 
components of MAPK module for ERK have been described (Widmann et al. 1999). 
ERK1 and ERK2 (44 kDa and 42 kDa, respectively) are expressed in cardiac 
myocytes and transiently activated by a wide range of stimuli including mechanical load 
(both  in vitro and in vivo), oxidative stress, cytokines (IL-1β, cardiotrophin-1 and   33
leukemia inhibitory factor), phorbol esters and various factors coupled with Tyr kinase 
receptors or GPCR, such as insulin and insulin-like growth factor or ET-1, PE and Ang II, 
respectively (for reviews, see Sugden & Clerk 1998b, Michel et al. 2001). Stimuli that do 
not activate hypertrophic growth and may rather act as anti-hypertrophic agents, such as 
ANP or bradykinin, have also been reported to activate ERK (Michel et al. 2001). The 
mechanism that activates ERK is sequentially through phosphorylation of Raf family of 
kinases (MAPKKK), leading to MAPK or ERK kinase (MEK1/2, MAPKK) and ERK 
(MAPK) activation (Sugden & Clerk 1998b). Phosphorylation and activation of Raf is a 
result of Ras activation, which in turn has been shown to be dependent of PKC and Src 
(Sugden & Clerk 1998b). In cardiac myocytes, ET-1 mediated ERK activation appears to 
involve PTX-insensitive G protein (Gq) (Bogoyevitch et al. 1995) and small G proteins 
Ras and Rac1 (Clerk et al. 2001). 
All the upstream components in the activation of the ERK cascade including PKC, 
Src, Ras and also Raf have been associated with the hypertrophic responses of cultured 
cardiac myocytes, including the activation of ANP and BNP gene transcription (Zou et al. 
1996, Fuller et al. 1998b, He et al. 2000, He & Lapointe 2001). However, while Ras 
activates Raf, Ras has additional downstream effectors and thus provides a branching 
point in signal propagation (Fuller et al. 1998a). Evidence for the role of MEK1/2 and 
ERK1/2 as mediators of hypertrophic growth signals in neonatal rat cardiac myocyte 
culture have been obtained by using specific MEK1 inhibitors as well as by transfection 
of kinase active or dominant negative plasmids, antisenses and adenoviral expression 
vectors. However, contradicting results has been obtained with similar approaches by 
other investigators (Thorburn et al. 1995, Gillespie-Brown et al. 1995, Thorburn et al. 
1997,  for review, see Bueno & Molkentin 2002). Transgenic mice with cardiac-myocyte 
specific overexpression of MEK1 develop concentric cardiac hypertrophy with preserved 
cardiac contractile function and partial resistance to ischemia and reperfusion-induced 
apoptosis, suggesting that the ERK cascade has growth promoting effects in the heart. In 
human hearts, ERK phosphorylation has been shown to increase in failure rather than in 
compensated hypertrophy (Haq et al. 2001, Takeishi et al. 2002).  
2.2.6.2  p38 
Four separate p38 isoforms (α, β, γ and δ) have been described, and they have been 
detected in human cardiac tissue, with likely the highest levels for α, followed by β, γ and 
δ levels (Stein et al. 1997, Lemke et al. 2001). A characteristic feature of all p38 MAPKs 
is that they are activated by Thr-Gly-Tyr motif phosphorylation in the activation loop 
domain (Widmann  et al. 1999). The p38 is activated through phosphorylation by 
MAPKK3/6 which may in turn act as substrates for several different MAPKKK (Sugden 
& Clerk 1998b). Complexity of p38 signaling mechanisms is further increased due to the 
mixed lineage kinases that may serve as MAPKKKs for both p38 and JNK cascades. 
MAPKK4 is capable of directly activating either p38 or JNK pathways (Sugden & Clerk 
1998b, Widmann et al. 1999).   34
p38 MAPKs are termed stress-activated protein kinases alongside with JNKs, because 
they are activated by osmotic stress (sorbitol) and also pro-apoptotic stimuli (anisomycin) 
(Sugden & Clerk 1998a). In cardiac myocytes, p38 MAPK has been shown to be 
activated by ischemia-reperfusion, mechanical load and electrical pacing as well as by a 
number of vasoactive peptides through their receptors, including prostaglandin F2α, 
neuropeptide Y,  Ang II, α1-and β-adrenoreceptor agonists and by muscarinic and ETA 
receptors (Liang & Gardner 1999, Liang et al. 2000b, Sugden & Clerk 1998b, Liang & 
Gardner 1999, Michel et al. 2001). Activation of cardiac p38 by ET-1 and Ang II has 
been reported to be PTX-insensitive, while by neuropeptide Y and α1- adrenoreceptor 
contrastingly as PTX-sensitive (Michel  et al. 2001), suggesting that diverse 
heterotrimeric G proteins are involved in activation of the p38 module. In contrast to 
ERK, phorbol esters (such as phorbol myristate acetate, PMA) that substitute DAG and 
activate ERK via PKC-dependent mechanism, do not activate either p38 or JNK (Sugden 
& Clerk 1998b). However, prolonged exposure of cardiac myocytes to PMA that depletes 
PKC activation has been shown to attenuate activation of p38 by α1- adrenoreceptor and 
ET-1, but not by Ang II (Clerk et al. 1998). Activation of p38 in cultured neonatal rat 
cardiac myocytes by mechanical stretch appears to involve cascade initiating from 
integrins and is propagated through FAK, Src and Ras (Aikawa  et al. 2002), while 
additional activity of the Rho family of small G proteins (Rac1, RhoA and Cdc42) may 
be required (Aikawa et al. 2001). 
Interestingly, electrical pacing induced early activation of p38 (at 0.5 and 1 hours) was 
shown to decline clearly below basal levels at later time points examined (at 24–72 
hours) in neonatal rat cardiac myocyte culture (Hines et al. 1999). This in vitro result is 
consistent with three independent studies that reported decreased levels of 
phosphorylated p38 in failing human hearts due to ischemic or idiopathic dilative 
cardiomyopathy (Lemke  et al. 2001, Takeishi  et al. 2002, Communal  et al. 2002), 
whereas two studies have suggested a sustained activation of p38 in failing hearts (Cook 
et al. 1999, Haq et al. 2001). Mechanical loading of hypertrophied heart using isolated 
rat heart preparation (Langendorf) has been reported to decrease p38 MAPK activity, and 
this attenuation was prevented by AT1 antagonist (valsartan) treatment (Yasaka & 
Hayashida 2001). Vice versa, in patients with cardiac failure, mechanical unloading of the 
hypertrophied heart by left ventricular assist device has been reported to increase cardiac 
p38 MAPK, but to decrease ERK and JNK activity (Flesch et al. 2001). Taken together, 
there results suggest that different levels of p38 MAPK activity may exist during 
progression of cardiac hypertrophy and in the transition to the overt cardiac failure. 
Studies utilizing overexpression of the enzymes of p38 MAPK module in cardiac 
myocytes have revealed contrasting effects between different isozymes (Wang  et al. 
1998a, Liao  et al. 2001). In cultured neonatal cardiac myocytes adenoviral 
overexpression of constitutive active MAPKK3 and MAPKK6 enzymes resulted in 
hypertrophic growth, while MAPKK3 activated additionally apoptotic cell death. The 
apoptotic and hypertrophic effects were shown to be mediated via p38 α and β, 
respectively (Wang  et al. 1998a). In transgenic mice, cardiac overexpression of 
MAPKK3 or MAPKK6 did not induce cardiac hypertrophy and the hearts were fibrotic 
(Liao  et al. 2001). MAPKK3-expressing hearts had increased end-diastolic chamber 
volume and a thinned ventricular wall, associated with heterogeneous myocyte atrophy,   35
whereas MAPKK6-hearts had reduced end-diastolic ventricular cavity size, a modest 
increase in myocyte size, and no significant myocyte atrophy (Liao et al. 2001). 
2.2.6.3  JNK 
A new MAPK, JNK, was biochemically identified in 1991. It was distinguished from the 
ERK by two characteristics: it was activated by cell stress such as ultraviolet irradiation, 
and it phoshorylated domains of c-Jun distinct from that of ERK (for review, see 
Widmann et al. 1999). The family of JNK comprises JNK1-3 (in the heart JNK1 and 
JNK2), but different splicing and exon usage yields at least 10 different JNK isoforms 
(Michel et al. 2001). All JNKs are activated by Thr-Pro-Tyr motif phosphorylation in the 
activation loop domain (Widmann et al. 1999). JNK is activated through phosphorylation 
by MAPKK4/7 which may in turn act as substrates for MEKK1-2 (MEK kinase-1-2) 
(Molkentin & Dorn II 2001). Also Ras activates JNK, but the activation is mediated 
though Rac/Cdc42 or MEKK rather than via Raf-like kinase as in ERK activation 
(Sugden & Clerk 1998b). Upstream of the JNK module, numerous stress activated 
kinases have been implicated in non-myocytes, but in cardiac myocytes they have been 
relatively poorly characterized (Sugden & Clerk 1998b). 
As originally identified, a main mechanism of JNK activation also in the heart is 
cellular stress, including hyperosmotic shock, low concentrations of protein synthesis 
inhibitors such as anisomycin, cardiotoxic agent daunomycin, hypoxia/reoxygenation and 
reactive oxygen species as well as mechanical stretch and pacing of cardiac myocytes 
(Sugden & Clerk 1998a, Michel et al. 2001). In contrast to ERK activation, mechanical 
stretch induced JNK activation has been reported to be independent of extracellular Ca
2+ 
levels or PKC activity (Komuro  et al. 1996). Notably, JNK is activated by various 
cytokines IL-1β, TNF-α, leukemia inhibitory factor and via GPCRs including α1-and β-
adrenoreceptors, ETA and AT1 receptors, but the activation levels are lower than those 
achieved by cellular stress stimuli (Michel  et al. 2001). However, by inhibiting Gq-
dependent signaling in the pressure-overloaded heart of transgenic mice ERK and JNK 
activation was abolished together with cardiac hypertrophy, whereas p38 activation was 
not changed (Esposito  et al. 2001). Thus, Gq-coupled receptor agonists may have a 
significant role in the activation of cardiac JNK in vivo.  
Transgenic mice with inactivation of the MEKK1 gene in the heart, an upstream 
kinase of JNK (and also to a lesser extent of ERK), developed dilation of the hearts at 14 
days and upregulation ANP mRNA levels in response to pressure overload (Sadoshima et 
al. 2002). However, the JNK activation and cytokine upregulation was inhibited together 
with apoptosis and inflammation (Sadoshima et al. 2002). Therefore, MEKK1-mediated 
activation of JNK appeared to have rather a protective than a pro-hypertrophic role in 
pressure-overloaded hearts. Interestingly, in cultured neonatal rat cardiac myocytes the 
expression of JNK has been reported to antagonize MEKK1- or hypertrophic agonist (PE, 
ET-1 or LIF) induced ANP promoter activity (Nemoto et al. 1998). In transgenic mice 
with aortic banding or in cultured neonatal rat cardiac myocytes stimulated by ET-1, the 
inactivation of cardiac MAPKK4 gene, an immediate upstream kinase of JNK and p38,   36
resulted in inhibition of hypertrophic growth (Choukroun et al. 1998, 1999). In cultured 
neonatal cardiac myocytes, adenoviral overexpression of MAPKK7, which specifically 
activates JNK, has been shown to induce hypertrophy, including an increase in cell size, 
elevated ANP mRNA levels and sarcomere re-organization (Wang  et al. 1998b). In 
contrast, co-activation of both JNK (by MAPKK7) and p38 (by MAPKK3 or MAPKK6) 
led to an induction of cytopathic responses and suppression of hypertrophic responses 
(Wang et al. 1998b). Taken together, the role of JNK activation in the heart must be 
interpreted in the context of parallel pathways, since the effects appear to vary depending 
on the MAPK cascade co-activated. As another example of this signaling network, 
transgenic mice with cardiac hypertrophy due to cardiac calcineurin overexpression had 
elevated JNK and ERK activity, but p38 was inactivated (De Windt et al. 2000, Lim et al. 
2001). The level of JNK activity in studies using specimens of human failing hearts 
appears to be controversial, as some studies report that activity is not altered or is 
decreased (Communal et al. 2002, Takeishi et al. 2002), while other studies demonstrate 
increased JNK activity (Cook et al. 1999, Haq et al. 2001). 
2.2.7  Mitogen-activated protein kinase phosphatases 
The magnitude and duration of signaling through MAPKs are critical determinants of the 
biological effect. This reflects a balance between activities of upstream activators and a 
complex regulatory network of protein phosphatases. MAPKs are activated via dual 
phosphorylation of Thr and Tyr residues at the catalytic domain, and the inactivation 
occurs through dephosphorylation of these residues by Tyr and Ser/Thr phosphatases or 
by dual specificity (Thr/Tyr) MAPK phosphatases (MKP) (for review, see Keyse 2000). 
There are at least 9 separate MKP isozymes and, in addition to the tissue specific 
expression of certain isozymes, they display different intracellular localizations and 
distinct substrate specificities, such as preference for ERK, p38 or JNK (Keyse 2000). 
MKP-1 was identified as an immediate early gene responsive for oxidative stress from 
the cDNA library of human skin fibroblasts and was shown, therefore, to be regulated at 
least at the level of transcription (for review, see Haneda et al. 1999). Later, it has been 
shown that murine MKP-1 homologue (3CH134) was sufficient to prevent Ras-induced 
ERK activity and, vice versa, when 3CH134 de novo synthesis was blocked with 
cycloheximide, a sustained ERK activation was found in NIH3T3 fibroblasts (Haneda et 
al. 1999). 
In neonatal rat cardiac myocytes, the co-transfection of MKP-1 expression plasmid 
has been shown to antagonize the activation of ANP, MLC-2, β-MHC and α-skA 
promoters by ET-1 or PE (Fuller et al. 1997), and adenoviral overexpression of MKP-1 
was sufficient to prevent PE induced activation of ERK, JNK and p38 and hypertrophic 
morphology (Bueno et al. 2001). Furthermore, the effects of cardiac specific expression 
of MKP-1 in transgenic mice have been shown to depend on the level of transgene 
expression. High levels of MKP-1 mRNA resulted in an inhibition of normal cardiac 
growth leading to ventricular dilatation, whereas transgenic mice with lower MKP-1 
mRNA levels preserved normal cardiac growth, but had attenuated hypertrophy in   37
response to pressure overload (Bueno et al. 2001). Studies of MKP-1 substrate specificity 
are controversial, but at least other MKPs have been shown to have a distinct order of 
preference for substrate MAPK (Haneda et al. 1999). However, at postnatal day 4, i.e. 
clearly prior to detectable hypertrophy, transgenic mice with cardiac calcineurin 
overexpression had increased MKP-1 levels accompanied by attenuated p38 activity, but 
with normal ERK activity (Lim et al. 2001). Therefore, MKPs may provide an additional 
twist in the complex regulation of MAPKs: MKPs are activated as a feed-back 
mechanism, but they may selectively tune signaling through different MAPK modules. 
2.3  Transcription factors 
Eukaryotic cells contain proteins that contribute to the initiation of every RNA 
polymerase II primary transcript that eventually becomes mRNA. In addition to the 
general transcriptional machinery, there are approximately 2000–3000 transcription 
factors identified thus far that share two characteristic features: a DNA binding domain 
that interacts with gene-specific regulatory sites, and a domain that exhibits 
transcriptional activation potential (for review, see Brivanlou & Darnell, Jr. 2002). 
Transcription factors may exhibit a specific combinatorial distribution in different cell 
types that helps to direct determination (choice of cell fate) and differentiation (synthesis 
of recognized cell-specific proteins). In addition, transcription factors may be only 
minimally active until cells are exposed to the appropriate stimulus (Brivanlou & Darnell, 
Jr. 2002). There are also proteins that interact with coactivators or positive-acting 
transcription factors and/or a member of the transcription machinery to inhibit their 
activity (for review, see Courey & Jia 2001). Therefore, the transcriptional activity of a 
gene is due to the duel between its present transcriptional activator and repressor proteins, 
which are, in turn, mainly selected by the cis-acting promoter elements of the gene. 
2.3.1  GATA-4 
The family of GATA transcription factors consists of six proteins (GATA-1-6), all of 
which are typically developmental/cell type specific factors (for reviews, see Orkin 1998, 
Charron & Nemer 1999, Molkentin 2000). GATA-1-3 are important regulators of 
hematopoietic stem cells and their derivatives, whereas GATA-4, -5, and -6 genes are 
expressed in various mesoderm and endoderm-derived tissues such as heart, liver, lung, 
gonad, and gut (Molkentin 2000). A characteristic feature of GATA factors is a domain of 
two adjacent zinc fingers (Cys-X2-Cys-X17-Cys-X2-Cys) that directs preferential 
binding to the nucleotide sequence element 5´-(A/T)GATA(A/G)-3´ of target gene 
promoters (Evans & Felsenfeld 1989). Similar to GATA-1, protein domain deletion 
analysis of GATA-4 protein has demonstrated that the C-terminal zinc finger region is 
sufficient and required for DNA binding (Morrisey et al. 1997). In addition, deletion 
analysis showed that a nuclear localization sequence (NLS) is present within the basic   38
domain adjacent to the C-terminal finger, and two separate transcriptional activation 
domains are present within the N terminus of the protein (Morrisey et al. 1997). These 
transcriptional activation domains are partially conserved in GATA-5 and -6, suggesting 
similarity in transcriptional activation mechanisms with GATA-4 (Molkentin 2000). 
Initially, GATA-4 was demonstrated to exhibit a developmentally regulated and tissue-
specific expression pattern in mice, and GATA-4 mRNA was found in the heart, intestinal 
epithelium, primitive endoderm and gonads (Arceci et al. 1993). In mice, GATA-4 is one 
of the earliest transcription factors expressed in developing cardiac cells (Heikinheimo et 
al. 1994). Abundant GATA-4 mRNA is present in both the endocardium and myocardium 
of the folding heart tube, and GATA-4 continues to be expressed in cardiac myocytes 
throughout the life of the animal (Arceci et al. 1993, Heikinheimo et al. 1994). After the 
initial studies that identified GATA-4 as a cardiac transcription factor, the role of GATA-4 
during embryonic development has emerged (for review, see Charron & Nemer 1999). 
Transgenic mice with inactivation of the GATA-4 gene died during embryonic 
development due to the failure of ventral morphogenesis and heart tube formation (Kuo 
et al. 1997, Molkentin et al. 1997). Later, it was found that the endodermal expression of 
GATA-4 was sufficient to rescue the developmental defects of these mice (Narita et al. 
1997). Moreover, overexpression of GATA-4 or GATA-6 in embryonic stem cells has 
been shown to induce differentiation towards extraembryonic endoderm (Fujikura et al. 
2002). In transgenic mice with inactivated GATA-4 gene, however, the differentiation of 
cardiac myocytes was not impaired and cardiac ANP and α-MHC genes were expressed 
normally, suggesting that upregulation of endogenous GATA-6 mRNA was potentially 
compensating the lack of GATA-4 (Kuo  et al. 1997, Molkentin  et al. 1997). Taken 
together, expression of GATA-4 in endoderm is indispensable for ventral morphogenesis 
of mice, but not for differentiation of cardiac myocytes, in which GATA-6 may be 
capable of replacing GATA-4. 
Notably, it has been shown that GATA binding elements of α-MHC promoter are 
required for activity of the promoter in the heart, and that α-MHC promoter could be 
activated in skeletal muscle by co-transfection of GATA-4 expression plasmid (Molkentin 
et al. 1994). This was followed by studies identifying other sarcomeric genes, such as 
cardiac troponin C and I, that due to GATA elements in the promoter region showed a 
cardiac expression pattern (Liang & Molkentin 2002). In addition to the sarcomeric 
proteins, also genes for ANP, BNP and corin, a cardiac enzyme processing natriuretic 
peptides, and multiple other genes including Na
+/Ca
2+-exchanger, acetylcholine receptor-
M2, cardiac-restricted ankyrine repeat protein (CARP), adenosine receptor-A1 and 
carnitine palmitoyltransferase-1β were identified as GATA-4 inducible genes (Liang & 
Molkentin 2002, Pan et al. 2002). Yet, high levels of GATA-4 are found in other tissues 
than the heart, such as gonads, and thus additional mechanisms may direct cardiac-
restricted expression of these genes. 
Since it was found that GATA-4 may induce various cardiac-specific promoters 
activated in both embryonic and hypertrophic heart, a potential role for GATA-4 in the 
development of cardiac hypertrophy came under investigation. First, it was found that 
intact GATA binding elements of β-MHC or AT1 genes were required for the full 
induction in pressure-overloaded rat hearts (Hasegawa et al. 1997, Herzig et al. 1997). 
Furthermore, functional GATA elements of gene promoters have been shown to be 
indispensable for the activation of adenylosuccinate synthetase-1 transcription by pacing   39
in neonatal rat cardiac myocytes (Xia et al. 2000) and for rat BNP promoter induction in 
the hearts of nefrectomized rats (Marttila et al. 2001). Importantly, it was noted that in 
the hearts of arginine-vasopressine infused rats, activation of GATA-4 DNA binding was 
mediated via endogenous ET-1 (Hautala et al. 2001). In perfused rat hearts, mechanical 
loading has been reported to activate GATA-4 binding through endogenous ET-1 and Ang 
II, and when infused, both substances were sufficient to induce GATA-4 DNA binding 
activity (Hautala et al. 2002). In addition, exogenous ET-1 and PE have been shown to 
activate GATA-4 DNA binding in cultured neonatal cardiac myocytes (Hautala et al. 
2001, Liang et al. 2001a). In support with a multiple line of evidence that GATA-4 may 
have a role in cardiac hypertrophy, overexpression of GATA-4 or GATA-6 was shown to 
activate hypertrophic growth in cultured rat neonatal cardiac myocytes and in the hearts 
of transgenic mice (Liang et al. 2001a). 
Fig. 5. Functional domains of GATA-4 protein. 
GATA-4 has been shown to cooperate with a number of other transcription factors in vitro 
(for review, see Molkentin 2000) (Fig. 5). Specifically, the C-terminal Zn-finger domain 
of GATA-4 that is required for DNA binding has been found to interact physically and to 
be required for transcriptional co-activation in concert with several transcription factors, 
including GATA-6, dHAND, myocyte enhancer factor-2, NFAT3, Nkx-2.5, p300, serum 
response factor (SRF) and Yin Yang-1 (Durocher et al. 1997, Molkentin et al. 1998, 
Belaguli et al. 2000, Morin et al. 2000, Bhalla et al. 2001, Dai et al. 2002). In contrast, 
the N-terminal Zn-finger domain of GATA-4 was found to associate with Friend of 
GATA-2 (FOG-2) corepressor, resulting in repression of GATA-4 mediated ANP and 
BNP transcription (Charron et al. 1999, Tevosian et al. 1999). Interestingly, when GATA-
4 with a single amino acid substitution blocking the interaction with FOG-2 was 
expressed in transgenic mice, these mice had phenotypical similarities to transgenic mice 
lacking the FOG-2 gene, suggesting that this interaction is indispensable for proper 
cardiac morphogenesis (Crispino  et al. 2001). However, altogether the hierarchy and 
regulation of GATA-4 interactions is relatively poorly characterized, and little is known   40
about the significance of these in vitro interactions during embryonic development or 
cardiac hypertrophy. 
2.3.2  Elk-1 
The first member of the family of ETS transcription factors, Ets-1, was discovered as part 
of avian E26 (E-Twenty-Six) retrovirus genome (for review, see Yordy & Muise-
Helmericks 2000). All ETS factors characterized since then share a highly conserved 
DNA binding domain that is termed ETS domain, by which they recognize a core DNA 
motif, 5´-GGA(A/T)-3´, known as ETS binding sequence (EBS) (Nye et al. 1992). ETS 
factors have been implicated in transforming and tumor-associated products as well as 
cell-cycle and apoptosis regulator genes, and they regulate hematopoiesis and the 
development of the central neural system, bone and cartilage, mammary glands and 
vasculature (Sementchenko & Watson 2000, Bartel et al. 2000). Ternary complex factors 
(TCF) form a subgroup of ETS factors that are recruited to a low affinity EBS by serum 
response factor (SRF) on a serum response element contained within many immediate 
early gene promoters, such as c-fos (Yordy & Muise-Helmericks 2000). In addition, c-fos 
promoter is activated via a Ras-response element, which is composed of an EBS and 
flanking binding sites for Activator Protein-1 (AP-1) complex. This EBS has been shown 
to bind Ets-1 and -2 (Yordy & Muise-Helmericks 2000).  
An extensively studied TCF, ETS-like gene-1 (Elk-1), is a target of all three MAPK 
cascades and is capable of activating c-fos promoter with SRF (Fig. 6) in response to a 
large number of extracellular signals including serum, lipopolysaccharide, growth factors 
and UV irradiation (Treisman 1994, Price et al. 1996). This ubiquitous interaction 
between Elk-1 and SRF on the c-fos promoter is also important for the induction of c-fos 
gene in response to mechanical load of the rat heart or to PE in cultured neonatal rat 
cardiac myocytes (Aoyagi & Izumo 1993, Babu et al. 2000). Elk-1 and subsequently its 
target gene c-fos are transiently activated through site-specific phosphorylation of Elk-1 
(Yang et al. 1999) and returned to inactive state both via dephosphorylation of Elk-1 and 
by recruitment of the mSin3A-histone deacetylase (HDAC) 1 corepressor complex (Yang 
et al. 2001). Recruitment of HDAC corepressor by Elk-1 correlated temporally with the 
downregulation c-fos mRNA levels (Yang et al. 2001). In addition to c-fos, only the gene 
for  α-MHC has been shown to be regulated via functional EBS in cardiac myocytes 
(Gupta et al. 1998). Taken together, there are multiple Ets factors present in the heart 
(Maroulakou & Bowe 2000), and many cardiac genes contain potential EBS in their 
promoters (Gupta et al. 1998), but the functional role of Ets factors in cardiac myocytes 
is still undefined.   41
Fig. 6. Regulation of gene transcription via ternary complex of Elk-1 and SRF. Modified 
according to Yordy et al. 2000. 
2.3.3  Nkx-2.5 
The Csx (cardiac-specific homeobox) or Nkx-2.5 gene was identified as a murine 
homologue to Drosophila homeobox gene tinman (Lints et al. 1993). Targeted disruption 
of Nkx-2.5 in transgenic mice was shown to result in abnormal heart morphogenesis, 
growth retardation, and embryonic lethality (Lyons  et al. 1995). In these mice, the 
expression of MLC-2, the earliest known marker of ventricular differentiation was absent, 
while  β-MHC expression remained intact (Lyons  et al. 1995). Transgenic mice that 
overexpress human Nkx-2.5 in the heart and skeletal muscle had normal transthoracic 
echocardiography, but cardiac mRNA levels of ANP, BNP, MLC-2 and CARP were 
increased, whereas GATA-4 mRNA levels were not altered (Takimoto et al. 2000). Nkx-
2.5 may have an important role in human cardiac development, since heterozygous 
mutations of Nkx-2.5 have been associated with human congenital heart disease 
characterized by atrioventricular conduction defects (Kasahara et al. 2000). Moreover, 
when the mutant Nkx-2.5 with impaired DNA binding was expressed under the direction 
of  β-MHC promoter, the transgenic mice were born apparently normal, but the 
accumulation of mutant protein in myocardium resulted in progressive conduction defects 
and cardiac failure (Kasahara et al. 2001). Interestingly, while GATA-4 interacts with 
SRF and Nkx-2.5 to regulate cardiac genes (Durocher et al. 1997, Belaguli et al. 2000), 
GATA-6 may analogically interact with Nkx-3.2 and SRF in the smooth muscle cells of 
arteries (Nishida et al. 2002).   42
2.3.4  AP-1 
The AP-1 complex is a dimer of transcription factors composed of fos (v-fos, c-fos, fosB, 
Fra-1, Fra-2),  jun (v-jun, c-jun,  junB,  junD) or activating transcription factor (ATF) 
protein families (for review, see Karin  et al. 1997). Like the immediate early genes, 
ubiquitous AP-1 complex is rapidly activated via MAPK mediated phosphorylation by a 
variety of extracellular growth and stress stimuli (Shaulian & Karin 2002). When 
activated, the AP-1 complex binds to a palindromic binding sequence (5´-TGACGTCA-
3´) in the regulatory region of its target genes (Karin et al. 1997). Different dimers of AP-
1 bound to the gene regulatory element accomplish a number of variable effects on cell 
growth, proliferation and survival (Shaulian & Karin 2002). A number of genes expressed 
in cardiac myocytes contain AP-1 elements in their promoter region, including ANP 
(Kovacic-Milivojevic & Gardner 1993), BNP (Grepin et al. 1994), ET-1 (Kawana et al. 
1995), α-skA (Bishopric et al. 1992), and AT1a (Herzig et al. 1997). Increased AP-1 
complex formation associates with pressure overload of rat heart due to aortic banding 
(Herzig et al. 1997), ventricular wall stretch of perfused rat heart (Cornelius et al. 1997, 
Hautala  et al. 2002), isoproterenol-infusion induced cardiac remodeling in rats 
(Takemoto  et al. 1999) and activated renin- Ang II- aldosterone system in double 
transgenic rats with the human renin and angiotensinogen genes (Fiebeler et al. 2001) as 
well as in hearts of Ang II-infused rats (Suo et al. 2002). However, likely due to different 
compositions of the dimer, the AP-1 complex is able to mediate either induction or 
repression of cardiac gene transcription (Kovacic-Milivojevic & Gardner 1993). Direct 
evidence for the role of AP-1 complex in the development of cardiac hypertrophy is 
poorly available, but adenoviral production of the dominant negative mutant of c-jun in 
neonatal rat cardiac myocytes inhibits hypertrophy induced by ET-1 and PE (Omura et al. 
2002). Interestingly, factors of the AP-1 complex have been shown to regulate gene 
expression together with GATA and ETS factors (Kawana et al. 1995, Yordy & Muise-
Helmericks 2000). 
2.4  Natriuretic peptides 
2.4.1  Natriuretic peptide family 
The isolation of the first natriuretic peptide, ANP, was preceded by separate observations 
including the identification of granules in atrial myocytes and the finding that elevated 
left atrial pressure stimulated urine output (for review, see Ruskoaho 1992). Later, it was 
found that the abundance of atrial granules was regulated by age or by changes in dietary 
sodium and water (Ruskoaho 1992). The functional role of these granules became 
elucidated by De Bold and coworkers who injected atrial extract intravenously into intact 
rats, which produced natriuresis and diuresis (de Bold et al. 1981). This was followed by 
the identification of ANP and its precursors in atrial tissue (Nakayama  et al. 1984, 
Greenberg et al. 1984, Yamanaka et al. 1984). After characterization of ANP, structurally   43
and functionally related mammalian peptides, BNP and C-type natriuretic peptide (CNP) 
were identified (Sudoh et al. 1988, 1990). A common structural feature shared by these 
three natriuretic peptides is the conserved 17 amino acid ring structure (Ruskoaho 1992). 
During rodent embryonic and neonatal development, ANP is expressed in atrial and 
ventricular myocytes, but in adults atria contain 100-150 and 1000 times more ANP 
mRNA and protein, respectively, than the left ventricle (Ruskoaho 1992). Similarly, in 
adult rats BNP mRNA levels are higher in atria than in ventricles, but when related to 
tissue weight, total amount of mRNA is 3-fold higher in ventricles (Ogawa et al. 1991b). 
In adult human tissues, BNP mRNA has been detected in the central nervous system, 
lung, thyroid, adrenal, kidney, spleen, small intestine, ovary, uterus, and striated muscle 
(Gerbes  et al. 1994). However, in adult human tissues, the level of ANP and BNP 
mRNAs have been found to be approximately 10–100 times lower than in ventricle, and 
in rats, ANP and BNP transcripts have been detected even less in extracardiac rat tissues 
(1000 times less than in ventricles) (Gerbes et al. 1994). Distinct from the expression of 
ANP and BNP in the heart, the production of CNP in rats and humans was reported to be 
limited to the neural system or to a lesser extent, the kidney and gastrointestinal tract 
(Komatsu et al. 1991). In addition, the family of natriuretic peptides has expanded due to 
the identification of related peptides from salmon and green mamba (Schweitz et al. 
1992, Majalahti-Palviainen et al. 2000). 
All the natriuretic peptides exert their biological functions via binding to specific 
natriuretic peptide receptors- A, -B or -C (NPRA, NPRB and NPRC) (Nakao et al. 1992b, 
Potter & Hunter 2001). NPRA/B receptors are coupled to guanylyl cyclase and ligand 
binding to the receptor increases intracellular levels of cGMP (Potter & Hunter 2001). 
NPRA/B are both present in the adrenal glands and the kidney, but NPRA receptor is the 
most abundant type in large blood vessels, while there are also some NPRB receptors 
which predominate in the brain (Levin et al. 1998). Due to the affinities of the receptors 
for different natriuretic peptides, the primary ligands for NPRA are ANP and BNP, 
whereas NPRB binds preferably CNP (Ruskoaho 1992, Yandle 1994). NPRC has no well-
defined second messengers, and is rather internalized and degraded after ligand binding, 
suggesting a role as a clearance receptor (Nakao et al. 1992b). The biological effects of 
natriuretic peptides antagonize those of the renin-Ang II-aldosterone system: natriuretic 
peptides decrease blood pressure, increase water and salt excretion, and promote 
vasodilatation and inhibit the release or actions of pressor hormones, such as Ang II, ET-
1, renin and vasopressin (for reviews, see Ruskoaho 1992, Levin et al. 1998).  
Characteristic for the biosynthesis of both ANP and BNP is the production of initial 
immature peptides, which are then cleaved to release biologically active hormones into 
circulation (Ruskoaho 1992). In atrial myocytes, after cleavage of a 25 amino acid signal 
peptide, the resulting 126 amino acid proANP is stored in granules, and during or soon 
after exocytosis, processed by cardiac Ser protease corin (Yan et al. 2000, Wu et al. 
2002) into the N-terminal fragment of 98 amino acids and the biologically active ANP of 
28 C-terminal amino acids (Ruskoaho 1992). In contrast, while preproBNP is subjected 
to analogical stepwise cleavage, the main storage form is the circulating and mature BNP 
of 45 or 32 amino acids in rats or humans, respectively (Nakao et al. 1992a). In response 
to acute atrial stretch, the release of ANP and BNP was reported to occur simultaneously 
(Mäntymaa  et al. 1993), suggesting a regulated secretory pathway for both peptide 
hormones in atrial tissue. However, ventricular myocytes contain only a few granules   44
(Ruskoaho 1992), and a constitutive secretory pathway has been suggested to release the 
natriuretic peptides from ventricular tissue (Wei et al. 1993).  
Initially, volume loading was found to increase the release of ANP from rat atria (Lang 
et al. 1985), suggesting that atrial wall tension, reflecting increased intravascular volume, 
stimulates its secretion. Indeed, in humans as well as in experimental animal models the 
increase or decrease in volume load enhances or attenuates the atrial release of ANP into 
circulation, respectively (Ruskoaho 1992). Later, similarly to atrial tissue, mechanical 
stretch was shown to constitute a major determinant of ANP and BNP release from 
ventricle (Kinnunen  et al. 1992, 1993). A number of studies using classical animal 
models with chronically overloaded hearts from pressure overload due to aortic 
constriction and SHRs to volume overload due to aorto-caval shunt or DOCA 
supplementation, have demonstrated a relation between an increased cardiac load and 
hypertrophy and augmented natriuretic peptide synthesis (Ruskoaho 1992, Magga et al. 
1994, de Bold et al. 1996, Tokola et al. 2001). In addition, mechanical stretch in vitro and 
numerous hypertrophic agonists, such as PE, Ang II and ET-1, activate natriuretic peptide 
gene expression in cultured neonatal rat cardiac myocytes (Tokola  et al. 2001, 
Luodonpää  et al. 2001). In humans, progressive increase in ANP and BNP plasma 
peptide and cardiac mRNA levels have been found to associate with the severity of heart 
failure (Wei et al. 1993, de Boer et al. 2001). More specifically, the measurement of 
circulating ANP and BNP (or their more stable N-terminal fragments released 
equimolarly) may improve the detection of congestive heart failure. In general population 
with a low prevalence of asymptomatic left ventricular hypertrophy or systolic 
dysfunction, measurement of BNP and N-terminal ANP may have only limited usefulness 
for screening of these conditions (Vasan et al. 2002). However, in a population with a 
higher risk for heart failure, such as in patients with acute dyspnea (Davis et al. 1994), 
the measurement of BNP levels may prove a useful laboratory routine. Low plasma BNP 
concentration provides strong evidence against heart failure, and when elevated, it may 
accurately indicate prognosis of the disease (Richards  et al. 2001). Importantly, 
circulating BNP levels may provide valuable insight for monitoring the treatment of 
congestive heart failure (Troughton et al. 2000, Latini et al. 2002). 
The use of transgenic mouse models to alter natriuretic peptide genes has been a 
fruitful approach in both gain-of-function and loss-of-function models. First, ANP 
overexpression was directed by transthyretin gene promoter into liver, resulting in a 5- to 
8-fold increase in circulating ANP, hypotension, decrease in peripheral vascular 
resistance, and heart weight (Steinhelper et al. 1990, Barbee et al. 1994). In contrast, 
inactivation of the endogenous proANP gene led to a susceptibility to salt-sensitive 
hypertension that was more pronounced in homozygous than heterozygous mice (Barbee 
et al. 1994). With a similar approach as with ANP, targeting BNP overexpression to liver 
by using human serum amyloid P component/mouse BNP fusion gene the plasma BNP 
levels increased by from 10- to 100-fold, resulting in hypotension (Ogawa et al. 1994). In 
addition, as an extracardiac manifestation, high BNP levels induced skeletal overgrowth 
(Suda et al. 1998). Inactivation of BNP gene has been found to induce cardiac fibrosis, 
while baseline blood pressure and heart weight were not significantly altered (Tamura et 
al. 2000). Inactivation of CNP gene has been shown to induce dwarfism due to impaired 
endochondral ossification (Chusho  et al. 2001). Besides the genes for natriuretic 
peptides, their receptors have been subjected to genetic manipulations in mice. NPRA   45
gene deficient mice on a normal diet have been reported to develop hypertension and 
eventually cardiac hypertrophy accompanied by interstial fibrosis and increased mortality 
(Lopez et al. 1995, Oliver et al. 1997). In the hearts of NPRA deficient mice, the area of 
cardiomyocytes together with ANP protein and mRNA levels is increased (Kishimoto et 
al. 2001). Cardiac-restricted NPRA gene overexpression driven by β-MHC promoter 
decreased the heart weight and size of individual myocytes without alteration in blood 
pressure (Kishimoto et al. 2001). Furthermore, when these mice were crossed with NPRA 
deficient mice (rescue of only cardiac NPRA expression), increases in myocyte area and 
ANP levels were attenuated, suggesting a local and guanylyl cyclase mediated inhibitory 
mechanism for cardiac growth (Kishimoto et al. 2001). Interestingly, transgenic mice 
with different copy numbers of NPRA gene (from 1 to 4) have been generated, and they 
demonstrated that decreased NPRA expression leads to a salt-sensitive increase in blood 
pressure, whereas increased NPRA expression lowers blood pressure and protects against 
high dietary salt (Oliver et al. 1998). Collectively, transgenic models of ANP and BNP 
suggest a pivotal role for ANP and BNP in maintenance of blood pressure homeostasis 
together with the protection from excessive volume load and likely with the prevention of 
cardiac hypertrophic and fibrotic changes. In addition, it appears that at least CNP is 
important for the normal growth of bones, an effect that is likely mediated via NPRB. 
2.4.2  Regulation of BNP transcription  
Expression of a gene and the resulting protein levels is genarally subject to multi-step 
regulation, which includes both transcriptional and post-transcriptional mechanisms such 
as RNA processing and transport, mRNA degradation and stabilization as well as 
regulation of translation and the post-translational processing of the generated protein. In 
the context of the BNP gene, the regulation process results in a tissue-specific expression 
pattern accompanied by an induction of synthesis during hypertrophic response of cardiac 
myocytes. 
The rapid inducibility of BNP gene transcription resembles that of immediate early 
genes, such as c-fos (Magga et al. 1994). BNP mRNA levels were already increased at 1-
2 hours in the left atrium and ventricle of arginine-vasopressine or PE infused 
spontaneously hypertensive rats (Magga  et al. 1994, 1997a). In addition, mechanical 
loading of perfused rat atrium was reported to increase the levels of BNP mRNA acutely 
at 2 hours, which was blocked by the transcriptional inhibitor actinomycin D, but not by 
the protein synthesis inhibitor cycloheximide (Magga  et al. 1997b). Similarly, 
mechanical stretch of cultured neonatal rat cardiac myocytes was shown to increase BNP 
mRNA levels mainly via transcriptional activation (Liang et al. 1997) rather than also via 
PKC and ERK mediated stabilization of BNP transcript, as demonstrated in the same 
model by PE treatment (Hanford & Glembotski 1996). Endogenous ET-1, but not Ang II, 
appears to participate in the regulation of basal and stretch activated BNP transcription in 
the atrium, but not in the ventricle (Magga et al. 1997a). BNP gene transcription and 
mRNA levels during Ang II infusion for 2 weeks have been compared by using the 
reporter plasmid driven by a promoter containing a 2.2 kb upstream sequence from   46
transcription start site of rat BNP gene that was injected into rat myocardium, and in 
parallel, by standard northern blot analysis for BNP mRNA levels (Suo et al. 2002). 
Transient, early induction of BNP promoter activity preceded the increase in BNP mRNA 
levels, but the injected promoter was reactivated after 3 days and sustained for at least 2 
weeks, whereas the BNP mRNA levels remained at the level of control animals (Suo et 
al. 2002). In conclusion, induction of BNP gene expression is due to a balance between 
transcriptional activation and mRNA stability, mechanisms that may either act in parallel 
or antagonize each other. 
Fig. 7. Regulatory elements of rat BNP promoter and their impact on basal activity (%). 
The 5´-flanking region of BNP promoter contains a number of potential consensus 
sequences for binding of transcription factors (Fig. 7). Transfection of BNP promoter 
deletions fused to reporter genes (luciferase) into cardiac myocytes have led to the 
identification of crucial elements for BNP promoter activity (Grepin et al. 1994, Thuerauf 
et al. 1994, Lapointe et al. 1996, Thuerauf & Glembotski 1997). BNP promoter contains 
a proximal activator element that is composed of an AP-1-like element, an M-CAT and 
two GATA elements in rats and of two M-CAT elements and a GATA element in humans 
(Grepin et al. 1994, Thuerauf et al. 1994, Lapointe et al. 1996). This proximal activator 
element of BNP is required for basal promoter activity and is also sufficient to direct 
activity of the promoter fragment to cardiac myocytes (Grepin et al. 1994, Lapointe et al. 
1996). More specifically, the mutations of MCAT and GATA elements have been shown 
to inhibit baseline BNP promoter activity in cultured neonatal rat cardiac myocytes 
(Grepin  et al. 1994, Lapointe  et al. 1996, He  et al. 2002). Similarly, mutations and 
deletions of AP-1-like and GATA elements of rat BNP promoter inhibit activity of 
reporter when injected to adult rat myocardium (Marttila et al. 2001). In addition to the 
proximal activator element, deletion analysis of BNP promoter has revealed a presence of 
the repressor element spanning from −535 to −398 bp and from −906 to −500 bp in rats 
and humans, respectively (Thuerauf  et al. 1994, Lapointe  et al. 1996). Recently, the 
repressor element of human BNP promoter has been more specifically examined, and it 
has been shown to contain at least a neuron restrictive silencer factor binding element 
(NRSE) at −552 to −522 bp (Ogawa et al. 2002).   47
The well-conserved activator elements responsible for the basal activity of BNP 
promoter also participate in the inducible expression of BNP. Yet, some elements of BNP 
promoter appear to be species-specific (Tokola et al. 2001). In the context of human BNP 
promoter M-CAT elements have been shown to partially mediate the activation by IL-1β 
and MAPKKK6 (an upstream kinase of p38 MAPK) (He & Lapointe 1999) and 
isoprotenerol (He et al. 2000), but not by ET-1 (He et al. 2000). The activation of human 
BNP promoter by ET-1 has been inhibited by PTX (He & Lapointe 2001), Src inhibitor 
PP1 (He & Lapointe 2001), pharmacological inhibitors of ERK and p38 MAPK kinases 
(Liang et al. 2000b), expression of dominant negative Rac1 (Liang et al. 2000b), and by 
mutation of proximal GATA element (Liang et al. 2000b). In comparison, activation of 
human BNP promoter by mechanical stretch has been inhibited by a wide range of 
pharmacological inhibitors, including inhibitors of PKC, MAPK, ERK, p38 MAPK, Tyr 
kinase (genistein), CaM (W-7) and CaMK (Liang et al. 1997, Liang & Gardner 1999), as 
well as by mutation of three NF-κB binding elements, which are not found in rat BNP 
promoter (Liang & Gardner 1999). In the context of rat BNP promoter, M-CAT and 
duplicate GATA elements have been reported to mediate the PE-induced activity to a 
similar extent as they mediate basal promoter activity (98% and 60%, respectively) 
(Thuerauf & Glembotski 1997). The fold-activation of rat BNP promoter with mutations 
of MCAT and/or GATA elements by PE remained unchanged when compared that of 
intact rat BNP promoter (Thuerauf & Glembotski 1997), and thus, the inducibility was 
not actually affected by the mutations. Human BNP promoter has been shown to contain 
an NFAT binding element at −927 bp that was required for synergistic induction by 
activated calcineurin, NFAT3 and GATA-4 (Molkentin  et al. 1998). The signaling 
pathways that have been implicated in BNP gene activation by mechanical stretch and 
ET-1 are summarized in Fig. 8. 
Most of the studies of the BNP promoter have been carried out by using neonatal rat 
cardiac myocyte cultures, yet a couple of reports are available of experimental adult rat 
models. Marttila and coworkers used plasmids driven by rat BNP promoter that were 
injected into rat myocardium, and they found that proximal GATA elements are essential 
for the induction in response to hemodynamic overload due to bilateral nefrectomy 
(Marttila et al. 2001). In another report, by using a transgenic mouse model with a human 
BNP promoter region (−408 bp to +100 bp) driven luciferase gene, it was demonstrated 
that this BNP promoter fragment is cardiac-specific and activated by myocardial 
infarction induced by coronary artery ligation (He et al. 2001).   48
Fig. 8. Mechanisms implicated in BNP gene activation by mechanical stretch and ET-1. 
 3 Aims of the research 
The aim of the present study was to evaluate the signaling mechanisms involved in the 
hypertrophic response of cardiac myocytes by utilizing rat BNP as a target gene.  
Specifically the aims were: 
1.  to study the mechanisms activating GATA-4 transcription factor and rat BNP gene. 
2.  to evaluate the role of GATA-4 DNA binding activity in the hypertrophic response of 
cardiac myocytes by ET-1. 
3.  to identify regulatory mechanisms of rat BNP gene that mediate activation by ET-1. 
4.  to study the stretch-responsive transcription factors and promoter elements regulating 
rat BNP gene. 
5.  to investigate mechanisms of ET-1 generation in stretched cardiac cells 4 Materials and methods 
4.1  Materials 
The following reagents from the following suppliers were used in this study: ABI PRISM 
BigDye Terminators Kit (Applied Biosystems, Foster City, CA, USA), Alexa Fluor 488 
and 568 Phalloidin (Molecular Probes Europe BV, Leiden, The Netherlands), Ang II, Bay 
K8644, bovine serum albumin (BSA), CaCl2, Dulbecco´s modified Eagle´s medium F-12 
(DMEM/F12), Dulbecco´s phosphate buffered saline (PBS), ET-1, insulin-transferrin-
sodium-selenite media supplement, L-glutamine, PE, penicillin-streptomycin, sodium 
puryvate and 3´,3´,5´-triiodo-L-thyronine (T3) (Sigma Chemicals, St. Louis, Missouri, 
MO, USA), Bioflex collagen I-coated cell culture plates (Flexcell International, 
McKeesport, PA, USA), Bio-Rad Protein Assay (Bio-Rad Laboratories Inc., Hercules, 
CA, USA), bosentan (a gift from Dr. M. Clozel, Actelion Pharmaceuticals Ltd., Basel, 
Switzerland), BQ610 (Peninsula Laboratories Inc., San Carlos, CA, USA), collagenase 
type Worthington (CLS II) (Millipore, Freehold, NJ, USA), fetal bovine serum (FBS) 
(Gibco Europe, Paisley, Scotland, UK), FuGENE 6 transfection reagent (Roche 
Biochemicals, Mannheim, Germany), Rous Sarcoma Virus promoter driven β-
galactosidase (β-gal) expression plasmid, pGL3- basic plasmid, SB203580, PD98059 and 
Luciferase Assay System (Promega Co., San Diego, CA, USA), Seize X Protein G 
Immunoprecipitation Kit (Pierce Biotechnology, Rockford, IL, USA), and Luminescent 
β-galactosidase Detection Kit II (Clontech Laboratories Inc., Palo Alto, CA, USA). 
Nested Deletion Kit (Amersham Pharmacia Biotech, Buckinghamshire, England, UK). 
Oligonucleotides were purchased from Sigma-Genosys (Cambridge, England, UK) 
except NFκB and SIE oligonucleotides from Santa Cruz Biotechnology, [α
32P]dCTP and 
[
3H]-leucine (Amersham, Buckinghamshire, England, UK), QuickChange Site-Directed 
Mutagenesis Kit (Stratagene, La Jolla, CA, USA), Quick Prime Kit (Amersham 
Pharmacia Biotech, Buckinghamshire, England, UK), rigid bottomed cell culture plates 
(Falcon, Plymouth, England, UK). PhosphoPlus p38 MAP Kinase Antibody Kit was 
purchased from Cell Signaling Technology (Beverly, MA, USA) and antibodies against 
Elk-1 and GATA-4 from Santa Cruz Biotechnology (Santa Cruz, CA, USA).   51
4.2  Experimental protocols 
Table 2. Summary of the experimental protocols 
Study Stimulus  Methods 
I ET-1  cell  culture 
   western  blotting 
    kinase activity assays 
    protein synthesis assay 
   EMSA 
    rat BNP promoter activity assay 
II  Ang II, ET-1 and PE  cell culture 
   EMSA 
    decoy oligonucleotide strategy 
    RIA, RNA isolation and northern blotting 
    rat BNP promoter activity assay 
    protein synthesis assay 
    sarcomeric staining and microscopy 
III  Ang II, ET-1 and mechanical 
stretch 
cell culture and mechanical stretching 
    RIA, RNA isolation and northern blotting 
    rat BNP promoter activity assay 
   EMSA 
    sarcomeric staining and microscopy 
IV  mechanical stretch  cell culture and mechanical stretching 
    RIA, RNA isolation and northern blotting 
    rat BNP promoter activity assay 
   EMSA 
   adenoviral  transfection 
    sarcomeric staining and microscopy 
V  mechanical stretch and TPA  cell culture and mechanical stretching 
    RIA, RNA isolation, northern blotting 
   quantitative  PCR 
    kinase activity assays 
    rat ppET-1 promoter activity assay   52
4.3  Preparation of oligonucleotides and plasmid constructs 
4.3.1  Generation of decoy oligonucleotides 
To generate DNAse resistant decoy oligonucleotides, a 30 bp single stranded 
phosphorothioated oligonucleotide (ODN) 5´-TGTGTCTGATAAATCAGAGATAACC 
CCACC-3´ (GATA ODN) was selected to match the region of (∆−68/−97) of rat BNP 
promoter (Dagnino et al. 1991). Scrambled sequence oligomer was used as a control, 5´-
TAAATTGGCCAAGTGTAGCT CCGTTTGTGA-3´ (CONTROL ODN). Both ODNs 
with their complementary sequence ODNs were heated to +80°C and annealed at room 
temperature for 2 hours. GATA and CONTROL ODNs with fluorescein isothiocyanate 
(FITC) label in their 3´-end and all oligonucleotides used in electrophoretic mobility shift 
assay (EMSA) were annealed similarly.  
4.3.2  Generation of reporter plasmids 
Rat BNP-luciferase plasmids were obtained by subcloning appropriate 5´deletions of the 
BNP promoter in the pXP-2 (Grepin et al. 1994) or in the pGL3-basic (Promega Co., San 
Diego, CA, USA). To prepare different rat BNP promoter driven pXP-2 reporters, an 
insert of −2.2 kb to +75 bp (or shorter regions of this insert) was cloned from 5´-flanking 
region of rat BNP and inserted into pXP-2 reporter. This plasmid contained firefly 
luciferase coding region and SV 40 splicing and polyadenylation signals. Both the rat 
BNP promoter fragment-driven pXP-2 and a reporter containing three GATA-binding 
consensus sequences linked to pXP-1 plasmid were a generous gift from Dr. M. Nemer 
(Institut de Recherches Cliniques de Montréal, Montreal, Canada) (Grepin et al. 1994). 
To generate rat BNP promoter driven pGL3-basic, a rat BNP fragment was generated by 
PCR, with rat genomic EMBL3-λ-clone as a template and using the following primers: 
sense 5´-GGGATTTGAACTCAGG-3´ with KpnI,MluI linker and antisense 5´-
CACTAGCCTCTCAGCAACG-3´ with BamH1 linker. Subsequently, the PCR-product 
was digested with KpnI and BamH1 and cloned to KpnI-BglII-site of pGL3-basic 
resulting in a (∆−5kbp/+4) BNP promoter construct. (∆−5kbp/+4) BNP-pGL3 construct 
was used to produce a (∆−534/+4) BNP-pGL3 by nested deletion. Site-directed mutations 
to two adjacent (−91 and −80) GATA-sites of (∆−534/+4) BNP-pGL3 were prepared with 
QuickChange Site-Directed Mutagenesis Kit and the resulting construct is referred to 
here as (∆−534/+4) BNP Gmut. Primers for mutagenesis were (coding strand shown, 
mutated nucleotides bold): 5´-GCTACCAGAGTGCCCAGCCTCCGTGCAGCCCGG 
CCC-3´, 5´-CTGGAAGTGTTTTTGACAGTTCACCCCATAAAGCCCC-3´ and 5´-
GGCAGGAATGTGTCTTGCAAATCAGATGCAACCCCACCCCTAC-3´, for ETS 
binding sequence at −498 bp, AP-1 binding sequence at −373 bp and tandem GATA 
binding sequence at −90 and −81 bp of 5´-flanking rat BNP promoter. All mutations were 
confirmed with automated nucleotide sequencing utilizing ABI PRISM BigDye 
Terminators Kit and ABI PRISM 3700 DNA Analyzer. pGL3-basic driven by −2.2 kb   53
fragment of rat preproET-1 (ppET-1) promoter (ppET-1-luc) has been described 
previously (Paul et al. 1995). As a control for transfection efficiency, a Rous Sarcoma 
Virus promoter-driven β-galactosidase expression plasmid was used. Plasmids encoding 
wild type and dominant negative mutant of MEK1 (pCMV-MEK1, pCMV-
MEK1(K97M)) were kind gifts from Dr K. L. Guan (University of Michigan, Ann Arbor, 
MI, USA), a dominant negative MKK6 (pCMV-MKK6AL) from Dr. J. R. Woodgett 
(University of Toronto, Toronto, Canada) and plasmids expressing of p38α kinase 
(pCMV-FLAG-p38α) and wild type and dominant negative mutant c-Jun N-terminal 
kinase-1 (pCDNA-FLAG-JNK1, pCDNA-FLAG-JNK1(APF)) from Dr. R. Davis 
(University of Massachusetts, Worcester, MA, USA). 
4.4  Cell culture 
4.4.1  Preparation of cell cultures 
Primary cultures of neonatal rat ventricular myocytes were prepared from 1- to 3-day-old 
Sprague-Dawley rats (Tokola et al. 1994). After decapitation of rats, the anterior thoracic 
wall was excised and heart was subjected to retrograde perfusion of collagenase solution 
(collagenase 1g/l, 25 µM CaCl2 in PBS) by clamping the aorta with forceps together with 
direct injection of collagenase solution to left ventricle. Subsequently, the ventricles were 
excised and minced with scalpel. Cells were dissociated by incubating minced ventricles 
repeatedly in collagenase solution, which was collected and filtrated from cellular debris. 
Thereafter, suspension of cells was centrifuged (1000 rpm, 5 minutes) 2 times 
accompanied by discarding of the supernatant and replacing it with a fresh culture 
medium, which consisted of DMEM/F12 with glutamine, penicillin-streptomycin and 
10% FBS. The washed cells were preplated for 30–60 min on 10 cm diameter cell culture 
plates, and unattached myocytes were collected with medium and attached non-myocytes 
were propagated to generate non-myocyte cultures. The amount of viable cells was 
counted from trypan blue dyed cells with light-microscope in Bürger´s chamber. 
Myocytes were seeded on culture plates at the density of 0.2 million cells per square 
centimeter. The next day the medium for myocytes was replaced with complete serum 
free medium (CSFM: DMEM/F12, 2.5 mg/ml BSA, 1 µM insulin, 2.56 mM L-glutamine, 
32 nM selenium, 2.8 mM sodium puryvate, 5.64 µg/ml transferrin, 1 nM T3, 100 IU/ml 
penicillin-streptomycin), which was used in all experiments. Non-myocytes were grown 
in 10% FBS containing medium, until from 24 hours prior to and during the experiments 
CSFM was used. To prepare cultures of human umbilical endothelial cells (HUVEC), a 
method described by Jaffe and coworkers was used (Jaffe et al. 1973). Umbilical cords 
were washed in PBS, cannulated and digested for 15 minutes with collagenase (0.5 g/l, 
25 µM CaCl2 in PBS) at room temperature and then perfused with cell culture medium 
(M199) and the cell suspension was centrifuged and resuspended in culture medium. 
HUVECs were grown in Medium 199 (Sigma) supplemented with 20% FBS (Gibco), 20 
µg/ml endothelial cell growth supplement (ECGS, Sigma), 12 U/ml heparin (Sigma), 100   54
U/ml penicillin, 100 µg/ml streptomycin and 2 mM L-glutamine. The cell cultures were 
propagated for two passages before the experiments were performed. More than 95% of 
HUVECs stained positive for endothelial cell marker, which was confirmed by measuring 
immunostaining with polyclonal rabbit antibody for human von Willebrandt factor (vWF) 
with avidin-biotin modification. The rat neonatal fibroblast and myocyte cultures stained 
negative for (vWF). For stretch experiments, cells were grown on flexible-bottomed 
collagen I coated cell culture plates, which were subjected to cyclical mechanical stretch 
by using computer controlled (FX-2000, Flexcell International, McKeesport, PA, USA) 
vacuum suction under the bottom of Bioflex cell culture plates. Experimental conditions 
of cell culture experiments are described in detail in articles I–V.  
Continuous cell line of COS-1 cells was grown on 10 cm diameter cell culture plates 
in DMEM with 10% FBS, 4 mM L-glutamine adjusted to contain 1.5 g/l of sodium 
bicarbonate and 4.5 g/l of glucose (Sigma). These cells were courtesy of Dr. Jukka 
Hakkola (University of Oulu, Finland), who originally obtained cells from American 
Type Culture Collection (Manassas, VA, USA). 
4.4.2  Transfection of cells and reporter gene analysis 
Cells were subjected to FuGENE 6 transfection reagent mediated transfection on the 
second day of culture for 6 hours, followed by washing and further culturing of cells. In 
adenovirus experiments, infections were performed to myocytes 4 hours after switching 
to CSFM at a multiplicity of infection (MOI) of 4 by adding the appropriate recombinant 
adenovirus to the culture media overnight. The media were replaced every 24 h. After 
experiments, the cells were washed twice with PBS and quickly frozen at −70°C. For 
reporter gene analysis, after 24 hours of exposure of cells to chemicals or mechanical 
stretch, the cells were lysed with cell lysis buffer (Promega). 10–20 µl aliquots of cell 
lysates were assayed for the activity of luciferase and β-galactosidase enzymes with 
Luciferase Assay System and Luminescent β-galactosidase Detection Kit II, respectively. 
A luminometer (model RS, Labsystems Luminoscan, Helsinki, Finland) was used to 
measure luminescence. 
4.4.3  Microscope analysis and cell staining 
Rat neonatal ventricular myocytes were cultured on collagen-coated glass coverslips (Rat 
tail collagen, type I, Sigma) and transfected with 3´-FITC (fluorescein-isothiocyanate) 
labeled ODNs (phosphorothioated oligodeoxynucleotides). The localization of 3´-FITC-
ODNs in spontaneously beating ventricular myocytes was examined with Axiovert 100M 
inverted microscope (Zeiss) repeatedly from 0 to 48 hours. Transfection efficiency was 
measured as a ratio of fluorescent nuclei containing spontaneously beating myocytes to non-
fluorescent spontaneously beating myocytes. Representative images were taken at 24 and 48 
hours with a laser confocal microscope (LSM 510, Carl Zeiss, Göttingen, Germany).   55
Differential interference contrast (DIC) and green fluorescence channels were used. For the 
analysis of sarcomeric protein organization, cells were exposed to mechanical stretch or ET-
1 (100 nM) for 24 hours and subsequently fixed with 4% paraformaldehyde for 15 minutes, 
and  α-actin filaments were labeled with Alexa Fluor 488 or 568 Phalloidin (Molecular 
Probes Europe BV, Leiden, The Netherlands). Subsequent images of actin filaments and, 
when designated, also of FITC-labeled ODNs were collected using green and red 
fluorescence channels (LSM 510, Carl Zeiss, Göttingen, Germany). 
4.5  Isolation and analysis of cytoplasmic RNA 
RNA was isolated from cultured neonatal rat ventricular myocytes by the guanidine 
isothiocyanate-CsCl method (Chirgwin et al. 1979) and stored at −70°C until northern 
blot hybridization was performed. In northern blot hybridization the size and amount of 
specific mRNA molecules in total RNA preparations were determined (Alwine  et al. 
1979). For each northern blot analysis, 4–8 µg of total RNA was used from each sample. 
A full length rat ANP cDNA probe (Flynn et al. 1985) (a generous gift from Dr. Peter L. 
Davis, Queen´s University, Kingston, Canada), a 390 bp fragment of rat BNP cDNA 
probe (Ogawa et al. 1991a) (a generous gift from Dr. Kazuwa Nakao, Kyoto University 
School of Medicine, Kyoto, Japan) and a 482 bp rat ribosomal 18S probe (Majalahti-
Palviainen et al. 2000) were used. Probes for α-skA and GATA-4 were made by the RT-
PCR technique and confirmed by sequencing to correspond bases 2950 to 3184 of rat α-
skA and 1196 to 2613 of rat GATA-4 (GenBank Accession Numbers v01218 and l22761, 
respectively). All probes were labeled with [α
32P]dCTP  with Quick Prime Kit. The 
membranes were hybridized overnight at +42°C in 5x SSC (saline sodium citrate, 1x 
SSC = 0.15 M NaCl, 0.015 M trisodium citrate, pH 7), 0.5% sodium-dodechyl sulfate 
(SDS), 5x Denhardt´s solution, 50% formamide and 100 µg/ml sheared herring sperm 
DNA. After hybridization the membranes were washed in 0.1 x SSC, 0.1% SDS 3 times 
for 20 minutes at +55°C and exposed with a PhosphorImager screen and analyzed with 
ImageQuant (Molecular Dynamics, Sunnyvale, CA, USA). The hybridization signals of 
ANP and BNP were normalized to that of 18S to correct for potential differences in 
loading and/or transfer. ET-1 mRNA and 18S RNA levels were also measured by real-
time quantitative RT-PCR analysis using Taqman chemistry on an ABI 7700 Genetic 
Analyzer (Applied Biosystems) (Piuhola et al. 2003). Forward and reverse primers and 
probes for detection were designed with Primer Express (Applied Biosystems) program 
and default settings. 
4.6  Radioimmunoassay of Ir-ANP and Ir-BNP 
Immunoreactive (Ir)-ANP and BNP levels were measured by radioimmunoassays from 
the cell culture medium as previously described (Tokola et al. 1994). For ANP and BNP 
radioimmunoassay the incubation medium samples were diluted 1:50–100 and 1:25–50,   56
respectively, and incubated in duplicates of 100 µl with 100 µl of rabbit ANP antiserum 
(Vuolteenaho  et al. 1985) or rabbit BNP antiserum (Ogawa  et al. 1991b) at +4°C. 
Synthetic rat ANP99-126 and rat BNP51-95 (BNP-45), ranging from 0–500 pg per tube, were 
incubated as standards. The ANP and BNP tracers were prepared by chloramine-T 
iodination of synthetic rat [Tyr0]- ANP99-126 and rat BNP51-95 followed by reverse phase 
liquid chromatography purification. After incubation for 48 hours at +4°C the 
immunocomplexes were precipitated with sheep antiserum directed against rabbit 
gammaglobulin in the presence of 500 µl 8% Polyethyl Glycol 6000, pH 7, followed by 
centrifugation (3000 g, 15 minutes). The sensitivities of the BNP and ANP assays were 2 
fmol and 1 fmol per tube, respectively. 50% displacements of the respective standard 
curve occurred at 16 and 25 fmol/tube. The intra and inter-assay variations were less than 
10% and 15%, respectively. The ANP antiserum recognized ANP and proANP with equal 
avidity, but did not cross-react with BNP or CNP (< 0.01%). The BNP antiserum did not 
recognize ANP or CNP (< 0.01%). Levels of immunoreactive natriuretic peptides (ANP, 
BNP) in culture medium were normalized in each well to levels measured from pre-
incubation medium collected 24 hours prior experiment to correct potential differences in 
cell density between the wells. 
4.7  Protein synthesis 
[
3H]-leucine-incorporation and total cellular protein content were measured as described 
previously (Berk et al. 1989). Briefly, cells were cultured and transfected in 24-well plates, 
and on the third day of culture, medium was replaced with CSFM supplemented with 5 
µCi/ml of [
3H]leucine and when appropriate, with ET-1 (100 nM). After 24 hours cells were 
washed twice with +4°C phosphate buffered saline, incubated with 10% trichloroacetic acid 
at +4°C for 30 minutes. Thereafter, the cell culture wells were washed twice with 95% 
ethanol and the fixed cellular material was solubilized in 0.1 M NaOH at + 24°C for 2 
hours. Solubilized cellular protein was subjected to the measurement of incorporated [
3H]-
leucine by liquid scintillation counter (Rackbeta II, LKB Wallac, Turku, Finland) and to 
Bradford assay for measurement of total cellular protein concentration. 
4.8  Electrophoretic mobility shift assay 
Nuclear extracts from cardiac myocytes were prepared as previously described (Schreiber 
et al. 1989). Briefly, cells were scraped into phosphate buffered saline, followed by 
centrifugation (1500 rpm, 5 minutes). Cell pellet was resuspended to 400 µl of a low salt 
buffer (10 mM HEPES pH 7.9, 10 mM KCl, 0.1 mM EDTA, 0.1 mM EGTA, 1 mM DTT, 
0.5 mM PMSF, 1 µg/ml of pepstatin, leupeptin and aprotinin) and incubated on ice for 15 
minutes. Thereafter, 25 µl of NP-40 (10% solution) was added into each sample, followed 
by vigorous vortexing for 10 seconds and subsequent centrifugation (12000 rpm, 1 min). 
The nuclei were resuspended to a high salt buffer (20 mM HEPES pH 7.9, 0.4 M NaCl, 1   57
mM EDTA, 1 mM EGTA, 1 mM DTT, 0.5 mM PMSF and 1 µg/ml of pepstatin, leupeptin 
and aprotinin). After 20 minutes of incubation at +4°C on a shaking platform, samples 
were centrifuged (12000 rpm, 5 minutes) and supernatant was collected and stored at 
−70°C until assayed. Protein concentration from each sample was colorimetrically 
determined (Bradford 1976). 
Double stranded-oligonucleotides were used for the analysis of DNA binding activity 
(for sequences see articles I–IV). Probes were end-labeled with [
32P]-dCTP by Klenow 
enzyme. For each reaction mixture, 6 µg of nuclear protein and 2 µg of poly(dI-dC) was 
used in a buffer containing 10 mM HEPES (pH 7.9), 1 mM MgCl2, 50 mM KCl, 1 mM 
DTT, 1 mM EDTA, 10% glycerol, 0.025% NP-40, 0.25 mM PMSF and 1 µg/ml of each 
leupeptin, pepstatin and aprotinin. Reaction mixtures were incubated with a labeled probe 
for 20 minutes followed by non-denaturating gel electrophoresis on 5% polyacrylamide 
gel. Subsequently, the gels were dried and exposed in a PhosphorImager screen and 
analyzed with ImageQuant. To confirm DNA sequence specificity of the protein-DNA 
complex formation, competition experiments with 10-, 50- and 100-molar excesses of 
non-labeled oligonucleotides with intact or mutated binding sites were performed. In 
addition, DNA binding activity assays of Octamer-1 transcription factor were run in 
parallel to control the specificity of the altered DNA binding activity. For competition and 
supershift experiments, appropriate antibodies were added to reaction mixture 20 minutes 
before addition of labeled probe. 
4.9  Western blot analysis 
After treatment with appropriate agonists, cells (approximately 5 × 10
6) were washed 
with phosphate-buffered saline (PBS) at room temperature and collected by scraping into 
500 µl of lysis buffer, which consisted of 20 mM Tris (pH 7.5), 150 mM NaCl, 1 mM 
EDTA, 1 mM EGTA, 1% Triton X-100, 2.5 mM sodium pyrophosphate, 1 mM β-
glycerophosphate, 1 mM Na3VO4, 1 µg/ml leupeptin, 1 µg/ml pepstatin, 1 µg/ml 
aprotinin, 2 mM benzamidine, 1 mM PMSF, 2 mM DTT and 50 mM NaF. Extracts were 
further lysed with sonication and supernatant was collected after centrifugation. Western 
blot assays for p38, Elk-1 and GATA-4 were performed using PhosphoPlus p38 MAP 
Kinase Antibody Kit and phospho-Elk-1 (Ser383) and Elk-1 (binds both phosphorylated 
and dephosphorylated Elk-1) and anti-GATA-4 antibodies. Samples (20–40 µg) were 
loaded on SDS-PAGE and transferred to nitrocellulose filters. The membranes were 
blocked in 5% nonfat milk and then incubated with indicated primary antibody overnight 
at 4°C. Finally, blots were developed with goat anti-Rabbit IgG-HRP and enhanced 
luminescence reagents followed by exposure of film for 1 to 3 minutes (Hyperfilm ECL, 
Amersham Pharmacia Biotech). For a second Western, the membrane was stripped for 30 
minutes at +60°C in stripping buffer (62.5 mM Tris (pH 6.8), 2% SDS and 100 mM β-
mercaptoethanol). 
To determine GATA-4 phosphorylation state, GATA-4 was immunoprecipitated using 
Seize X Protein G Immunoprecipitation Kit. GATA-4 antibody was first bound and 
immobilized to Protein G according to manufacturer´s instructions. Nuclear extracts were   58
then applied to immobilized antibody support, unbound proteins were washed out, and 
finally GATA-4 protein was eluted. Samples were loaded onto SDS-PAGE and subjected 
to western blotting. The primary antibody indicated was incubated at +4°C overnight. 
Antibody binding was detected with a peroxidase-conjugated goat anti-rabbit or bovine 
anti-goat IgG and enhanced chemiluminescence. 
4.10  Protein kinase activity assays 
For immunocomplex kinase assay endogenous p38 was immunoprecipitated with specific 
antibody at 4°C overnight, followed by protein G-Sepharose precipitation. 
Immunoprecipitates were washed three times with buffer containing 50 mM Tris (pH 
7.4), 150 mM NaCl, 5 mM EDTA, 25 mM β-glycerophosphate, 25 mM NaF and 1% 
Triton X-100. Lysates were once more washed with kinase buffer containing 25 mM Tris 
(pH 7.5), 5 mM β-glycerophosphate, 2 mM DTT, 1.0 mM Na3VO4 and 10 mM MgCl2. 
The activity of the immunocomplex was assayed at 30°C for 15 minutes in 30 µl of 
kinase buffer in the presence of 2 µCi [γ-
32P] ATP and 20 µg of myelin basic protein as a 
substrate. The reactions were terminated and the reaction contents electrophoresed on 
15% SDS-polyacrylamide gels followed by PhosphorImager analysis to determine the 
phosphorylation level of myelin basic protein. The effect of p38 inhibitor SB 203580 on 
p38 activity was measured by in vivo kinase assay. 
For ERK activity assays cells were collected with buffer containing 10 mM Tris (pH 
7.5), 150 mM NaCl, 2 mM EGTA, 2 mM DTT, 1 mM orthovanadate, 10 µg/ml leupeptin, 
10 µg/ml aprotinin, 2 µg/ml pepstatin and 5 mM benzamidine. Extracts were sonicated 
and supernatant was collected after centrifugation. 15 µl of protein extract was incubated 
at 30°C for 15 minutes with 10 µl substrate buffer containing specific ERK-substrate 
peptide in the presence of 1 µCi [γ-
32P]ATP. Each reaction was terminated and blotted on 
separate peptide binding paper discs, which were washed with 75 mM orthophosphoric 
acid. Incorporated radioactivity was measured with scintillation counter (Rackbeta II, 
LKB Wallac). 
4.11  Statistical analysis 
The results are expressed as mean±SEM. To determine the statistical significance 
between two groups and for analysis of multiple groups, Student's t-test and one-way 
analysis of variance (ANOVA) followed by least significance difference (LSD) post hoc 
test were used, respectively. Differences at the 95% level were considered statistically 
significant. 5 Results 
5.1  ET-1 activates GATA-4 transcription factor via p38 MAPK (I) 
5.1.1  ET-1 activates p38 and ERK 
First, to investigate the activation of p38 and ERK in cultured neonatal rat cardiac 
myocytes, cells were treated with 100 nM of ET-1. ET-1 enhanced dual phosphorylation 
of p38 at 15 minutes measured by Western blot analysis. Enzyme activity of p38 
measured by immunocomplex kinase assay increased by ET-1, which peaked at 15–20 
minutes. Furthermore, to verify the effect of an inhibitor of p38, SB203580, in vivo 
kinase assay utilizing ATF2 as a substrate was used. Treatment with ET-1 for 24 hours 
increased p38 activity 3.4-fold, and activity was totally inhibited by SB203580, which 
also decreased basal activity of p38 MAP kinase by 50%. Interestingly, treatment of 
myocytes with the MEK1 inhibitor PD98059 increased basal p38 activity, but had no 
effect on ET-1 induced p38 activity. To examine the regulation of ERK by ET-1, an assay 
which measures transfer of phosphate group to a peptide highly selective for ERK 
(p42/44 MAP kinase) was used. ERK activity was maximally increased at 5 minutes and 
declined to almost basal level within 35 minutes. PD98059 (20 µM) was sufficient to 
abolish ET-1 induced ERK activation by 80% as measured at 5 minutes. Taken together, 
both p38 and ERK were activated transiently by ET-1, and activation of either kinase was 
inhibited by their specific inhibitors. 
5.1.2  p38 mediates ET-1 activated protein synthesis 
To examine whether blockade of p38 MAPK or ERK with specific inhibitors is sufficient 
to attenuate ET-1 increased protein synthesis in cultured cardiac myocytes, incorporation 
of [
3H] labeled leucine was investigated. Treatment of myocytes with SB203580 or   60
PD98059 at the dose of 20 µM had no effect on basal protein synthesis, but ET-1 induced 
protein synthesis was totally abolished by SB 203580 (20 µM), whereas ERK inhibition 
with PD 98059 (20 µM) had no effect. Therefore, induction of protein synthesis by ET-1 
requires intact p38 kinase activity, whereas ERK activity is dispensable. 
5.1.3  Activation of GATA-4 transcription factor via MAPKs 
To evaluate whether MAPK cascades were involved in the activation of GATA-4 binding 
activity, pharmacological inhibitors were first used to block either p38 or ERK cascades 
in the presence of ET-1 (100 nM), and secondly, each MAPK cascade was activated by 
overexpression of respective kinases. After stimulation of cells, nuclear proteins were 
extracted and GATA-4 binding to rat BNP promoter was measured by using EMSA. 
Inhibition of p38 MAPK kinase was sufficient to prevent ET-1-induced GATA-4 binding 
activity, whereas ERK inhibitor rather downregulated basal GATA-4 binding activity. 
Vice versa, overexpression of p38α, but not MEK1 (upstream of ERK) or MEKK1 
(upstream of JNK), increased GATA-4 DNA binding activity. To further investigate the 
role of MAP kinases in the regulation of GATA-4, we used COS-1 cells transiently 
expressing GATA-4 and co-transfected the cells with plasmids expressing p38α, MEK1 
or JNK1. p38α overexpression resulted in a 4-fold increase in GATA-4 binding activity, 
whereas MEK1 or JNK1 overexpression had no effect on GATA-4 binding to BNP gene 
promoter. Therefore, p38 was required for ET-1 induced GATA-4 binding activity and 
was also sufficient alone to activate GATA-4. However, ERK activity may be additionally 
required to sustain basal GATA-4 binding activity.  
GATA-4 protein contains a strong recognition motif for MAPKs, and GATA-4 has 
been shown to be phosphorylated via ERK in cardiac myocytes. To examine whether p38 
induces phosphorylation of GATA-4, myocytes were transfected with plasmids 
overexpressing p38α, MEK1, MEKK1 or pUC19 (control). GATA-4 was 
immunoprecipitated from nuclear extracts, and Western blotting analysis was performed. 
Overexpression of MEK1 and p38α exhibited a marked increase in Ser phosphorylation 
of GATA-4, whereas enhanced JNK pathway by overexpression of MEKK1 had no 
effect. p38 induced Ser phosphorylation of GATA-4 was inhibited by p38 inhibitor SB 
203580 and also by ERK inhibitor PD 98059, which was consistent with the finding that 
p38α induced GATA-4 binding was also depressed with PD 98059. These results indicate 
that in cardiac myocytes, both p38 MAP kinase and ERK may increase Ser 
phosphorylation of GATA-4. The effect of p38 MAPK and ERK on GATA-4 
phosphorylation and DNA binding activity is summarized in Fig. 9. 
5.1.4  Activation of rat BNP promoter by p38 via GATA element  
To investigate whether activation of GATA-4 by p38 affects the expression of potential 
target genes of GATA-4, p38 expression plasmid was co-transfected with either intact or   61
BNP promoter with mutated GATA binding sites at −91 bp and −80 bp of 
(∆−534bp/+4bp). Importantly, p38α overexpression increased BNP promoter activity 4-
fold, which was abolished by the mutation of GATA elements, suggesting that activation 
of BNP transcription by p38 requires GATA-4 binding on the promoter elements (I: 
Figure 8). 
Fig. 9. Schematic presentation of the effects of ERK and p38 MAPK on Ser-phosphorylation 
and DNA binding activity of GATA-4. 
5.2  ET-1 induces myocyte hypertrophy independently of GATA-4 
DNA binding (II) 
5.2.1  Decoy ODN strategy 
In order to block GATA DNA binding, the (∆−68/−97) rat BNP promoter sequence was 
used to generate a 30 bp GATA-4 factor binding cis-element decoy oligonucleotide, 
which was transfected to cardiac myocytes. GATA ODN treatment of cardiac myocytes 
abolished both basal and ET-1-induced GATA-4 DNA binding (> 95%) at 24 hours after 
transfection when compared to cells transfected with a scrambled oligonucleotide. In 
vitro GATA-4 DNA binding was totally abolished by preincubation of nuclear extracts of 
cardiac myocytes with a 50-molar excess amount of the GATA ODN, but not with a 50-
molar excess of CONTROL ODN (Fig. 9). Neither of the ODNs competed with Oct-1 
DNA binding. Blockade of GATA element binding factors was specific and had no effect 
on Oct-1 DNA binding in ODN-treated cardiac myocytes. To prove that GATA ODN 
interfered with and specifically blocked the GATA-interaction and function with its target 
promoter, a positive control plasmid containing three GATA response elements linked to 
pXP-1 was co-transfected with CONTROL or GATA ODNs. Co-transfection with GATA 
ODN significantly decreased GATA-dependent promoter activity. Similarly, a 50-molar   62
excess of GATA, but not CONTROL ODN, blocked GATA-4 DNA binding activity on 
(∆−109/−131) rat ANP promoter GATA binding site (Gene Bank accession# J03267).  
Ventricular myocytes were transfected with 3´-FITC-ODNs and subsequently 
examined for 48 hours. After transfection, the cytoplasm contained fluorescent vacuoles, 
and already during the following 3–6 hours fluorescence shifted to the nuclei of 
myocytes. The proportion of FITC-ODN transfected beating myocytes was ~60–70% and 
~40–50% at 24 and 48 hours, respectively. Due to the decrease in the number of 
transfected cardiac myocytes, each experiment was started at 18 hours after transfection 
and completed at 42 hours after transfection. No difference was detected in the nuclear 
localization of FITC-labeled CONTROL or GATA ODN. 
Fig. 10. The effect of GATA or CONTROL ODNs as competitors on GATA and Oct-1 DNA 
binding activity. Nuclear extracts of ventricular myocytes were preincubated with a 50-molar 
excess of ODNs prior to addition of labeled probe and EMSA as indicated. Ventricular 
myocytes were incubated with (+) or without (−) ET-1 (100 nM, 60 minutes) prior to nuclear 
protein extraction.  
5.2.2  Effect of GATA ODN on hypertrophic response 
To study the effect of GATA ODN-treatment on the hypertrophic pattern of gene 
expression, the expression of cardiac natriuretic peptides was evaluated. GATA ODN 
treatment decreased basal secretion of ANP and BNP in myocytes by 40% (P = 0.004) 
and 33% (P = 0.003) at 24 hours, respectively. Importantly, ET-1 augmented the secretion 
of ANP and BNP irrespectively of blocked GATA-4 DNA binding. Similarly, mRNA 
levels of ANP and BNP were downregulated in GATA ODN-treated myocytes, but the 
increase in ANP and BNP mRNA levels by ET-1 remained unaffected at 24 hours. 
Hypertrophy of ventricular myocytes in response to ET-1 involves an accelerated 
protein synthesis and an increased organization of contractile proteins to sarcomeric 
structures. Thus, the effect of GATA ODN-treatment on ET-1 induced de novo protein 
synthesis and total cellular protein content was examined. There was no difference in 
[
3H]leucine incorporation or total cellular protein content between the GATA ODN- and   63
CONTROL ODN-treated ventricular myocytes in response to ET-1. In addition, ET-1 
enhanced assembly of sarcomeric structures similarly in both GATA ODN- and 
CONTROL ODN-treated myocytes. 
5.3  ET-1-specific activation of BNP gene via p38 MAPK and ETS 
factors (III) 
5.3.1  Activation of BNP secretion and transcription by ET-1 
To evaluate whether blockade of the ETA  receptor, the major ET receptor of cardiac 
myocytes, was sufficient to inhibit ET-1 induced synthesis and release of BNP, cultured 
neonatal rat cardiac myocytes were treated together with ET-1 and a specific ETA 
receptor antagonist (BQ 610) or bosentan, a mixed ETA/B receptor antagonist. By using 
BQ 610, both ET-1 induced secretion and transcriptional activity of BNP was inhibited. 
In the context of rBNP promoter, the proximal 5´-flanking region of 534 bp is 
sufficient to confer the induction by GPCR agonist phenylephrine (Thuerauf & 
Glembotski 1997). Proximal −534 bp of BNP promoter contains multiple potential cis-
acting elements, such as GATA elements. Therefore, computer based search for novel cis-
acting elements of rat BNP gene was utilized. An ETS binding sequence (EBS) and AP-1 
binding sequence was identified at −98 bp and −373 bp of rBNP promoter, respectively. 
In order to characterize the role of these elements, site-directed mutations to EBS and 
AP-1 binding sequences, and also to −90/−81 bp tandem GATA elements of rBNP 
promoter were introduced. Activation of proximal −534 bp rBNP promoter was inhibited 
by mutation of EBS, but not by mutation of GATA or AP-1 elements. Importantly, the 
induction of rBNP transcription in myocytes by mechanical stretch or Ang II was 
unaffected by the mutation of EBS. To investigate this ET-1 responsive element further, 
the complex formation of cardiac nuclear proteins with EBS of rBNP promoter was 
examined. 
5.3.2  ET-1 activates cardiac nuclear protein binding on EBS 
To analyze whether there is specific binding activity on EBS of rBNP promoter by 
cardiac nuclear proteins, EMSA was utilized, and when designated, the protein-DNA 
binding reactions were performed in the presence of a 100-molar excess of unlabeled 
competitor oligonucleotides. Three specific shifts (complexes C1-3) were constantly 
formed, of which C1 and C2 were migrating closely to each other separately from a faster 
migrating complex, C3. Competitor oligonucleotides with mutated nucleotides from −497 
bp (mut 2) to −491 bp (mut 8) failed to compete against intact EBS and were found to be 
essential for formation of complexes C1-3 (i.e. 5´-cCCGGAAGtg-3´), suggesting 
similarity of binding proteins in these complexes. Interestingly, a labeled high affinity   64
ETS binding sequence (SC1) formed complexes similar to C1-3. The core sequence for 
ETS factor binding of SC1 is similar to EBS of the rBNP promoter. When SC1 
oligonucleotide was used as a unlabeled competitor against nuclear protein binding on 
EBS of rBNP promoter, SC1 inhibited protein binding on EBS in a dose-dependent 
manner, and the competition was abolished by single nucleotide mutation of SC1 (i.e. 5´-
CCGaAAGTG-3´). An NFκB binding oligonucleotide, as another potential GGA-
sequence binding element, was not able to compete against binding on EBS of rBNP 
promoter. 
In view of the specific complex formation of cardiac nuclear proteins with EBS of 
BNP promoter, it was analyzed whether ET-1 treatment of cardiac myocytes had any 
effect on the nuclear protein binding activity in EBS. Initially, a rapid and transient 
increase in formation of complex C2 was detected at 5 and 15 minutes. Later, a sustained 
increase of EBS binding activity was observed at 3 hours for complexes C1 and C3, 
which remained elevated for 24 hours. All the nuclear extracts were tested in parallel for 
Octamer-1 binding activity, which was not altered by ET-1, suggesting a specific 
activation of EBS binding. Taken together, ET-1 treatment of cardiac myocytes initiated a 
biphasic activation of protein binding on the EBS of rBNP, and these specific complexes 
closely resembled complex formation of nuclear proteins with a high affinity ETS 
binding sequence. 
EBS of rat BNP gene promoter has special features: (i) −2.2 kb of 5´-flanking region 
of rat BNP gene contains no potential SRE for TCF (ternary complex factor)-SRF factor 
synergy and (ii) EBS functions as an activator element of rat BNP gene transcription 
exclusively by ET-1. In order to identify the transcription factors binding on EBS, 
specific antibodies were added to the binding reaction prior to radioactively labeled EBS 
and subsequent EMSA. Antibodies for NFκB (p50 and p65), AP-1 complex (c-fos, c-jun, 
jun-B, jun-D), Nkx-2.5, SRF, ETS-1/-2 (DNA binding domain), Fli-1 (a member of ETS 
transcription factor family) and activated Ser383-phosphorylated Elk-1 (Phospho-Elk-1) 
were used. It was found that ET-1 activated C2 complex was supershifted by antibody 
raised against Phospho-Elk-1. To investigate activation of Elk-1 through site-specific 
phosphorylation (Ser-383) western blot analysis was used. The phosphorylation of Elk-1 
transiently increased at 5 minutes and 15 minutes in cardiac myocytes treated with ET-1 
(III: Figure 5B). Therefore, Elk-1 phosphorylation is temporally related to increased 
formation of complex C2 in EMSA. In conclusion, ET-1 induces phosphorylation and 
binding of Elk-1 on EBS of rBNP (complex C2), and it likely activates additional ETS 
related proteins whose identity remains unknown by using specific antibodies against 
ETS related or other transcription factors.  
5.3.3  ET-1 activates rat BNP promoter via p38 MAPK and EBS 
Elk-1 transcription factor is a known downstream target for MAPKs (Yang et al. 1998) 
and thus their potential role in activation rBNP transcription via EBS was investigated by 
using expression plasmids for each MAPK pathway. A minimal amount of expression 
plasmids (0.05 µg) was selected to prevent quenching and to confirm that the effects of   65
overexpression were specific for each MAPK cascade. Dominant negative (dn) kinases of 
MEK1 (upstream of ERK), MAPKK6 (MKK6, upstream of p38) and c-Jun N-terminal 
kinase-1 (JNK) were utilized to inhibit each pathway specifically. Interestingly, only the 
inhibition of p38 MAPK dependent mechanism attenuated the activation of rBNP 
transcription by ET-1. Vice versa, the activation of p38 MAPK resulted in EBS dependent 
activation of rBNP promoter activity. In contrast, activation of ERK signaling by forced 
expression of MEK1 activated rBNP transcription only when signaling via EBS was 
blocked by mutation.  
Next, it was examined whether activation of Ca
2+ dependent pathways induced rat 
BNP promoter similarly via the p38 MAPK and EBS dependent mechanism as ET-1. 
Cells were exposed to dihydropyridine agonist Bay K8644 to activate Ca
2+ influx via L-
type Ca
2+ channels. Bay K8644 induced rBNP transcription independently of EBS, and 
the induction was equally inhibited by dominant negative expression plasmids of each 
MAPK cascade. Conclusively, these results suggest that ET-1 activates rBNP gene 
transcription via EBS in a p38 MAPK dependent mechanism, whereas induction of BNP 
gene by robust activation of Ca
2+ dependent signaling is likely required activity of all 
three MAPK cascades in parallel. In contrast, intact EBS of rBNP promoter inhibits the 
activation of transcription by the ERK pathway alone. 
Fig. 11. Schematic presentation of the ET-1-specific pathway converging via p38 MAPK and 
nuclear ETS factors on rat BNP promoter. 
5.4  GATA-4 is a nuclear mediator of stretch-induced myocyte 
hypertrophy (IV) 
5.4.1  Activation of cardiac gene expression by mechanical stretch 
To validate the experimental system of stretched neonatal rat cardiac myocytes, first the 
effect of mechanical stretch on the expression of BNP, ANP and α-skA was studied.   66
Cyclic mechanical stretch elevated BNP mRNA levels significantly already after 4 hours, 
peaking at 24 hours. Similarly, mechanical stretch increased ANP and α-skA mRNA 
levels. Elevated natriuretic peptide mRNA levels were accompanied by increased Ir-ANP 
and Ir-BNP release from cardiac myocytes. Conclusively, in stretched cardiac myocytes, 
BNP provides a sensitive target gene to mechanical load, and therefore rat BNP promoter 
was used to identify stretch-inducible signaling mechanisms. 
Cardiac myocytes were transfected with luciferase reporter constructs driven by 
various lengths of the rat BNP 5’-flanking sequence. First the effect of promoter deletions 
on basal activity was evaluated, and thereafter the effect of deletions on the response to 
mechanical stretch was studied. Deletion of rBNP promoter region from −2.2 kb to −940 
bp resulted in a 30% decrease of the basal reporter activity. Yet, further deletion down to 
−520 bp increased basal promoter activity, suggesting the presence of a negative 
regulatory element between −2.2 kb to −520 bp. However, this deletion from −2200 to 
−520 bp did not alter inducibility by mechanical stretch. Additional deletion up to −114 
bp of rBNP promoter decreased the basal and stretch-induced promoter activity by 70–
80%. Deletion of rBNP promoter to −60 bp abolished both the stretch-response and basal 
promoter activity. Taken together, given that the −520 bp of 5’-flanking region of BNP 
promoter is sufficient to confer full activation in stretched myocytes, a proximal region 
between −114 bp and −60 bp possessed significant albeit reduced inducibility. Previously, 
proximal −116 bp region of rat BNP promoter had been shown to retain full activation in 
the volume-overloaded hearts of nefrectomized rats, and the induction was abolished by 
mutation of the GATA elements (Marttila et al. 2001). Therefore, to further investigate 
the stretch-responsive elements, mutations on rBNP promoter were introduced. 
Site-directed mutations were generated to reporter construct containing the proximal 
534 bp of rBNP promoter sufficient to confer full stretch-inducibility. Mutation of the 
tandem  −90 GATA sites resulted in a 40% decrease in the stretch-induced reporter 
activity compared with intact −534 bp rBNP promoter. Since a number of co-factors for 
GATA-4 have been identified, we investigated the possibility that stretch-induced rBNP 
transcription could involve recruitment of co-factors for GATA. To study potential co-
operation, additional elements of rBNP promoter were mutated. Computer based search 
for cis-acting elements of proximal −534 bp of rBNP was utilized, and an AP-1 element 
at −373 bp and two sequences with high homology to Nkx-2.5-binding element (NKE) at 
−387 and −496 bp were identified. Despite the fact that GATA and AP-1 elements have 
been suggested to activate together AT1A gene transcription in pressure-overloaded rat 
hearts (Herzig et al. 1997), the mutation of the −373 AP-1 site had no effect either alone 
or together with mutation of GATA elements. In addition, previous studies have indicated 
synergism of GATA and Nkx-2.5 binding elements on various promoters of cardiac genes 
including BNP (Durocher et al. 1997). To investigate the role of potential NKEs in the 
stretch-response, mutations on NKE consensus sequences of −534 rBNP promoter 
located at −387 bp and to −498 bp were introduced. Mutation of the −387 NKE element 
alone had no effect on stretch-induced rBNP promoter activity, but importantly, when 
combined with mutation of the tandem −90 GATA sites the stretch-response was 
abolished. In contrast, mutation of the −498 NKE consensus element site had no effect on 
basal or stretch induced rBNP promoter activity. In conclusion, −90 GATA elements 
appear to mediate induction of rBNP in stretched myocytes, a mechanism that involves 
co-operation with −387 NKE.   67
5.4.2  Verification of NKEs in rBNP promoter 
Since −387 and −498 NKEs of BNP differentially co-regulate with −90 GATA element, it 
was studied whether these elements bind Nkx-2.5. COS-1 cells were transfected with the 
Nkx-2.5 expression plasmid or with an empty expression plasmid, which was followed 
by nuclear protein extraction after 48 hours. Nuclear protein extracts were incubated with 
labeled ds DNA probes corresponding to −387 and −496 NKEs of rBNP and a previously 
described high affinity Nkx-2.5 binding element of rat ANP gene (ANP NKE) prior to 
performing EMSAs. −387 NKE and ANP NKE probes formed complexes that were 
specifically supershifted by an antibody raised against Nkx-2.5, although the affinity of 
−387 NKE to Nkx-2.5 was significantly weaker than that of ANP NKE, which contains 
duplicate NKE consensus sequence. Under the same conditions, neither −498 NKE 
consensus sequence nor any of the mutated probes were able to bind Nkx-2.5.  
5.4.3  GATA-4 is essential for stretch-induced hypertrophic response 
The tandem GATA elements within the proximal −116 bp of BNP promoter are well 
conserved between mammalian species (mouse, rat, dog and man) (Grepin et al. 1994). 
The DNA binding affinity of GATA-4 has been shown to increase in pressure-overloaded 
rat heart (Herzig et al. 1997, Hautala et al. 2001). To investigate the effect of direct 
mechanical load on GATA-4 binding on −90 GATA element of the rBNP gene, we 
utilized a radioactively labeled binding element in EMSA. It was found that stretch 
activated transiently GATA-4 binding, while Oct-1 binding activity did not alter. To 
examine the effect of mechanical stretch on GATA-4 gene expression, northern blot 
analysis using rat GATA-4 cDNA probe was performed. The activation of GATA-4 
binding was accompanied by an increase in GATA-4 mRNA levels peaking at 4 hours 
(1.6-fold). Western blot analysis of nuclear extracts showed additionally a trend towards 
increase in nuclear accumulation of GATA-4 protein in stretched cardiac myocytes. Taken 
together, mechanical stretch increases transiently DNA binding affinity, nuclear 
accumulation and mRNA levels of GATA-4, suggesting a specific role for this 
transcription factor in stretched cardiac myocytes. 
In addition to specific changes in gene expression, hypertrophic phenotype of cultured 
cardiomyocytes is characterized by morphologic changes including increased 
organization of sarcomeres. To test whether the activation of GATA-4 had functional 
consequences on stretched cardiac myocytes, production of GATA-4 protein was 
inhibited by employing an adenovirus expressing antisense GATA-4 cDNA (GATA-4as). 
As described previously, GATA-4 protein levels decreased significantly in cells infected 
with GATA-4as when compared with cells infected with control adenovirus expressing an 
NLS-lacZ cDNA (LacZ). In agreement with the important role of GATA binding elements 
on rBNP promoter activity, downregulation of GATA-4 in cardiac myocytes blocked 
stretch-induced increase in BNP mRNA levels. Notably, decreased GATA-4 protein levels 
inhibited the organization of sarcomeres in cardiac myocytes. Quantification of 
reorganized cardiomyocytes showed that stretch robustly increased the number of cells   68
with organized sarcomeres in LacZ-infected cultures 4.1-fold, and this effect was 
significantly smaller (2.0-fold) in GATA-4as-treated cells. GATA-4as treatment also 
decreased the basal sarcomere assembly in non-stretched cells compared with cells 
infected with LacZ. In conclusion, GATA-4 appears essential for both the induction of 
BNP transcription and for the morphological adaptation of cardiac myocytes during 
mechanical load.  
Fig. 12. Schematic presentation of the mechanical stretch-activated GATA-4 and myocyte 
hypertrophic response. 
5.5  Mechanical stretch activates ET-1 production in cardiac myocytes 
via ERK (V) 
5.5.1  Regulation of ET-1 generation by mechanical stretch 
Induction of hypertrophic phenotype and BNP gene expression by exogenous ET-1 and 
mechanical stretch appeared to use distinct nuclear pathways (Studies I-IV), while the 
cardiac cells may generate also ET-1 themselves. Therefore, in Study V the effect of 
mechanical stretch on endogenous ET-1 synthesis was examined. First, cyclic mechanical 
stretch was applied on HUVEC culture and secretion of ET-1 was measured with RIA. As 
compared with static cultures, cyclic stretch increased already at 3 hours the levels of ir-
ET-1 in culture medium 1.4-fold, and ir-ET-1 levels were elevated 1.8-fold and 1.4-fold at 
6 hours and 24 hours, respectively. Thereafter mechanical stretch was applied on rat non-
myocyte (NMC) and myocyte (MC) cultures for 24 hours. Interestingly, ir-ET-1 levels 
decreased 0.5-fold in NMCs and increased 3-fold in MCs, respectively. The basal levels 
of ir-ET-1 in cell culture media after 24-hour incubation were 120 pM, 60 pM and 1 pM   69
in HUVECs, neonatal rat NMCs and MCs, respectively. Taken together, it appears that 
cyclic mechanical stretch augments ET-1 release in endothelial cells and myocytes, but 
decreases its secretion in cardiac non-myocyte (fibroblast) culture. 
Previous studies have suggested that while there may exist intracellular storages of 
ET-1 in endothelial cells (Macarthur et al. 1994), its generation and release depend 
mainly on ppET-1 gene transcriptional activity. Therefore, the ET-1 mRNA levels in 
NMCs and MCs were evaluated after different durations of mechanical stretch. In 
stretched NMCs, ET-1 mRNA levels were not significantly changed at 1 hour, but were 
downregulated by 0.6-fold, 0.5-fold and 0.6-fold at 6, 12 and 24 hours, respectively. In 
contrast, mechanical stretch elevated ET-1 mRNA levels transiently by 1.9-fold at 1 hour, 
but the levels returned to basal at 4 hours and remained unchanged at 12 and 24 hours in 
MC culture. To verify normal ET-1 generation in NMC culture, we utilized phorbol ester 
(PMA) as a positive control that has previously been described to increase ET-1 synthesis 
(Lauth et al. 2000). In non-myocyte culture, PMA (100 nM, 24 hours) increased the 
release of ir-ET-1 by 5.5-fold and activated rat ppET-1 promoter by 1.7-fold. However, 
mechanical stretch of non-myocytes for 24 hours inhibited ppET-1 promoter activity 0.4-
fold. Mechanical stretch increased rat ppET-1 activity in myocyte culture 1.8-fold and 
1.4-fold at 6 and 24 hours, respectively. Therefore, in agreement with the rate of ET-1 
release during mechanical stretch, the ET-1 mRNA levels and ppET-1 promoter activity 
increase in cardiac myocytes, but decrease in fibroblasts in response to mechanical 
stretch. 
5.5.2  Role of ERK in regulation of ET-1 transcription 
Recently, it has been reported that the ERK pathway may be involved in the activation of 
ppET-1 gene transcription in cardiac myocytes by α-adrenergic stimulation (Morimoto et 
al. 2000). To examine the regulation of ERK by mechanical stretch in MC culture, an 
assay which measures transfer of a phosphate group to a peptide highly selective for ERK 
was used. Mechanical stretch elevated ERK activity already at 1 minute, and it peaked at 
10 minutes. PD98059 inhibited the activation of ERK by mechanical stretch. When 
PD98059 was added to incubation media, activation of ppET-1 promoter activity was 
abolished. As a control, SB203580 had no effect on ppET-1 promoter induction by 
mechanical stretch. To confirm that ERK is capable of activating ppET-1 promoter, we 
co-transfected ppET-1-luc and MEK1 with RSV-βgal control plasmid. In agreement with 
a previous report (Morimoto et al. 2000), MEK1 overexpression was sufficient to activate 
ppET-1 promoter activity 1.8-fold. In conclusion, our results suggest that ET-1 
transcription is activated via ERK in stretched cardiac myocytes.   70
Fig. 13. Schematic presentation of the effects of mechanical stretch on ET-1 generation by 
different cell types. 6 Discussion 
6.1  The regulation of GATA-4 by MAPKs 
Recent studies have shown that GATA binding sequences of cardiac promoters may 
mediate induction by hypertrophic agonists such as PE, while the levels of GATA-4 
protein and/or mRNA remain static (Morimoto et al. 2000, Liang et al. 2001a). 
Therefore, it has been hypothesized that GATA-4 protein is regulated via post-
translational modifications leading to subsequent transactivation of its target genes. The 
murine GATA-4 protein contains at least 7 potential sites for MAPK-mediated 
phosphorylation, of which the strongest candidate for recognition domain based on the 
amino acid sequence is located at Ser-105 (Arceci et al. 1993, Sugden 1999). GATA-4 
phosphorylation has been shown to increase via ERK pathway after PE stimulation of 
cardiac myocytes (Morimoto et al. 2000).  
In Study I, the regulation of GATA-4 binding activity by MAPKs was examined. 
Inhibition of ERK decreased GATA-4 phosphorylation and downregulated endogenous 
GATA-4 DNA binding. However, inhibition of ERK was not sufficient to prevent 
activation of GATA-4 binding by ET-1. Blockade of p38 pathway similarly decreased 
Ser-phosphorylation of GATA-4, and in contrast to ERK inhibition, totally abolished ET-
1 induced GATA-4 binding on BNP gene. To support these findings, GATA-4 has been 
identified as a target for RhoA activated p38α MAPK resulting in phosphorylation of Ser-
105 of GATA-4 protein (Charron et al. 2001). Moreover, an inhibitor (Y-27632) against 
downstream kinases of RhoA has been shown to prevent PE-induced ERK1/2 
phosphorylation together with GATA-4 DNA binding activity (Morimoto et al. 2000). 
Similarly, ERK1/2 have been shown to mediate phosphorylation of Ser-105 of GATA-4 
protein in response to PE treatment of cardiac myocytes (Liang et al. 2001b). 
Furthermore, studies using fusion protein of GATA-4 activation domain (amino acids 33-
227) with intact or mutated Ser-105 linked to GAL4 DNA binding domain have shown 
that Ser-105 is essential for GATA-4-mediated transcriptional activation (Liang et al. 
2001b). In addition, mutation of Ser-105 of GATA-4 reduces its basal DNA binding 
activity, inhibiting ERK-enhanced DNA binding (Liang et al. 2001b). Taken together, 
both ERK and p38 MAPK appear capable of inducing Ser-phosphorylation of GATA-4,   72
but Study I suggests that ERK may function as a regulator of basal GATA-4 DNA binding 
activity. In contrast, p38 MAPK may in turn mediate activation of GATA-4 by ET-1 (I) 
(Charron et al. 2001). However, controversial reports exist about the relative importance 
of ERK and/or p38 pathways as activators of GATA-4 in PE and/or RhoA stimulated 
cardiac myocytes (Charron et al. 2001, Liang et al. 2001b). Taken together, GATA-4 is 
subject to Ser-phosphorylation by distinct MAPK cascades, resulting in upregulated 
GATA-4 DNA binding activity. Importantly, GATA binding sequences are required to rat 
BNP promoter induction by p38 MAPK. Therefore, at least in the context of rat BNP 
gene, functional interaction between GATA-4 and p38 may dominate over the induction 
by ERK. To examine whether this hypothesis holds true in vivo, additional studies in 
adult animal models are required. 
6.2  The role of GATA-4 DNA binding in ET-1-induced hypertrophic 
response  
The functional significance of activated GATA-4 in cardiac myocytes was explored in 
Studies II-IV. In Study II, a decoy oligonucleotide approach was utilized, allowing 
competetive inhibition of the binding activity on desired cis-acting element (Mann & 
Dzau 2000). The occupation of DNA-binding domain by the GATA ODN left GATA 
motif binding protein(s) incapable of binding to promoter regions of target genes, such as 
ANP and BNP. This approach provided advantages as compared to downregulation of 
GATA-4 protein levels by antisense strategy, since it eliminated potential compensation 
via GATA-6 as seen in GATA-4 null mice (Kuo et al. 1997, Molkentin et al. 1997). In 
agreement with previous studies (Grepin et al. 1994), the blockade of GATA-4 DNA 
binding resulted in inhibition of basal cardiac gene expression (Charron et al. 1999), thus 
showing the importance of GATA-4 in the cardiac gene program. Furthermore, GATA 
ODN treatment in Study II and adenovirus-mediated GATA-4-antisense strategy (Charron 
et al. 1999) downregulated baseline secretion of ANP to a similar extent. The effect of 
decoy ODN treatment, however, was more rapid than that obtained with adenovirus-
mediated antisense strategy (2
nd vs. 3
rd day after transfection, respectively), probably 
because of the decoy ODNs block the DNA binding activity of existing transcription 
factors. The adenoviral transfection may increase the percentage of transfected cells, 
while the expression of antisense may be sustained longer than decoy ODNs in cells (II, 
Charron et al. 1999).  
Previously, it has been demonstrated that inducibility of rat BNP promoter by α-
adrenergic agonist or GATA-4 overexpression maps to proximal −110 bp region of rat 
BNP promoter (Thuerauf et al. 1994). Further, deletions of both GATA regions at −91 bp 
and  −80 bp of the −110 bp rat BNP promoter decreased response to GATA-4 
overexpression by 50% (Thuerauf et al. 1994). In Study II, ET-1 increased the activity of 
a full-length BNP promoter 2.2-fold. The deletion of −5 kb to −538 bp upstream region of 
BNP promoter had no significant effect on the inducibility. Thus, the −538 bp BNP 
promoter was employed to study the role of −91 bp and −80 bp GATA sites in BNP 
promoter. When GATA binding to (∆−68/−97) BNP region was disrupted by mutation,   73
the basal activity of the BNP promoter decreased (II). In contrast, ET-1 induced −538 bp 
BNP promoter activity was independent of −91 and −80 GATA sites (II, III). These 
findings further confirm that in the context of rat BNP promoter, induction by ET-1 does 
not require binding of GATA-4 on specific GATA elements of the promoter. Similarly, 
blockade of GATA-4 DNA binding was insufficient to prevent induction of ANP and 
BNP gene expression by Ang II or PE (II). In Study II, GATA ODN-treatment had no 
significant effect on basal or ET-1 induced protein synthesis and morphology of cardiac 
myocytes, suggesting that while GATA-4 is activated by ET-1, GATA-4-DNA interaction 
is not required for the hypertrophic response. One possible explanation for the differential 
role of GATA-4 in basal and ET-1-stimulated cardiac myocytes is the complex formation 
of GATA proteins with other transcription factors, which has been proposed as a potential 
mechanism that targets actions of GATA-4 (Molkentin 2000). Hypothetically, 
hypertrophic stimuli such as ET-1 could affect on complex formation between GATA-4 
and its cofactors that might, in turn, lead to transactivation of cardiac gene promoters also 
via other cis-elements than typical GATA sites. This is of fundamental interest, because 
depletion of GATA-4 protein in cultured neonatal cardiac myocytes by adenoviral 
antisense strategy was sufficient to inhibit sarcomeric protein organization during 
hypertrophic growth (IV, Charron et al. 2001). Taken together, Study II suggests that 
normal GATA DNA-binding activity may not be essentially required for ET-1 induced 
myocyte hypertrophy, yet the significance and regulation of interactions between GATA-
4 and its multiple co-factors remain to be addressed. 
6.3  The role of GATA-4 in mechanical stretch-induced hypertrophic 
response 
The in vitro stretch of cultured neonatal rat cardiac myocytes provides a valuable and 
well documented model for the study of the molecular mechanisms activated by 
mechanical stretch (Sadoshima et al. 1992). By using culture of myocytes, the effects of 
direct mechanical load and growth factors released from non-myocytes may be better 
separated. It was recently reported that mechanical stretch-activated transcription of BNP 
was mediated partly by NFκB binding on shear stress response elements present in 
human BNP promoter. However, these elements are not conserved in rat BNP promoter, 
demonstrating different regulation between human and rat BNP genes (Tokola et al. 
2001). In Study IV, it was shown for the first time that mechanical stretch per se activates 
GATA-4 binding on the well-conserved proximal GATA element of BNP promoter. A 
major finding was that mutations of the tandem GATA sites in combination with mutation 
of the NKE-like-element at −387 of rBNP promoter almost completely abolished the 
stretch inducibility of rBNP promoter, while the latter mutation alone had no effect. This 
suggests that −387 NKE binds a trans-acting factor that synergistically orchestrates 
GATA-4 in stretch-induced rBNP transcription. Cumulative evidence suggests that this 
factor is Nkx-2.5 or some related homeobox transcription factor. Firstly, this element was 
able to bind Nkx-2.5 expressed in COS-1 cells unlike −498 EBS possessing similar core 
sequence and shown to specifically bind Elk-1 (III, IV). Secondly, this putative NKE was   74
reported to confer the synergy between Nkx-2.5 and GATA-4 in rBNP transcription in 
non-stimulated HeLa cells (Durocher et al. 1997).  
Previous studies have shown that autocrine/paracrine factors play a significant role in 
the development of load-induced cardiac hypertrophy. It has been reported that 
mechanical stretch is coupled with cellular release of Ang II and ET-1, and that they act 
as chemical mediators of stretch-induced myocyte hypertrophy in cultured rat 
cardiomyocytes (Sadoshima et al. 1993, Yamazaki et al. 1996, Harada et al. 1997a). In 
Studies I-III, it was shown that ET-1 stimulates GATA-4 binding activity, thus raising the 
question whether mutation of the GATA sites decreased the activation of rBNP promoter 
through ET-1. Liang and coworkers proposed that stretch-triggered release of Ang II 
sequentially stimulates secretion of ET-1, which accounts for 50% of the stretch-induced 
human BNP gene transcription (Liang et al. 2000b). However, it was noted that mutation 
of the tandem GATA sites of rBNP promoter does not inhibit transcriptional activation by 
either ET-1 or Ang II (II-III). In addition, an ET receptor antagonist has been shown to 
fail to inhibit the early activation of BNP gene expression in ventricles (Magga et al. 
1997a), despite the fact that it blocked the induction in GATA-4 binding activity in vivo 
(Hautala et al. 2001), suggesting that GATA-4 acts through a direct rather than by an ET-
1-dependent mechanism. Yet, since increased DNA binding activity of GATA-4 is 
detected in both mechanically stretched and ET-1 stimulated cardiac myocytes (I-IV), 
there may exist additional mechanisms, such as variable cofactors of GATA-4, tuning the 
eventual effect of GATA-4 activation. 
To directly assess the role GATA-4 in hypertrophic response of stretched myocytes, we 
used adenoviral antisense strategy to attenuate GATA-4 protein levels (IV, Charron et al. 
1999). Previously, adenoviral GATA-4-as has been shown to downregulate cardiac gene 
expression, including BNP, α- and β-MHC and cardiac troponin I (Charron et al. 1999). 
The lack of GATA-4 did not inhibit all cardiac genes, since cardiac α-actin and MLC-1 
mRNAs were not decreased (Charron et al. 1999). In Study IV, decreased GATA-4 
protein levels inhibited stretch-induced BNP mRNA levels and sarcomeric protein 
assembly. This is in agreement with a previous finding that GATA-4 levels are critical for 
sarcomeric protein assembly in response to PE (Charron et al. 2001). Importantly, the 
attenuation of protein levels of GATA-4 may also inhibit the potential interactions and 
thus transactivation with cofactors GATA-4. However, at least in the context of rBNP 
promoter, direct binding on GATA element is required for the complete induction, but an 
interaction with −387 NKE is additionally involved (IV). In stretched myocytes, mRNA 
levels of GATA-4 increased transiently at 4 hours, while the DNA binding activity was 
transiently upregulated at 1 hour, together with a trend towards nuclear accumulation of 
GATA-4 detected already at 15 minutes. Therefore, it is likely that multiple levels of 
regulation of and via GATA-4 exist. In addition to the MAPK cascades, other upstream 
regulators of GATA-4 have been identified. Glycogen synthase kinase-3β (GSK-3β) has 
been shown to act as a negative regulator of cardiac hypertrophy, and its decreased 
activity has been associated with cardiac hypertrophy (for review, see Hardt & 
Sadoshima 2002). Interestingly, in a manner analogical to NFAT (Hardt & Sadoshima 
2002), GSK-3β has been shown to phosphorylate and activate nuclear export of GATA-4 
in cardiac myocytes, leading to inhibition of GATA-4 dependent transcription (Morisco et 
al. 2001). Therefore, GATA-4 is subjected to a complex regulation that probably occurs   75
at the level of synthesis, localization and post-translational modifications of GATA-4 
protein, which may in turn alter its interactions with a pattern of cofactors. 
6.4  ETS factors in the regulation of BNP gene 
The founding member of the ETS family in mammals, Ets-1, was originally discovered 
due to homology to v-ets, an oncogene of avian E26 ("E-Twenty-Six") retrovirus genome 
(Leprince et al. 1983). ETS factors share a winged helix-turn-helix domain for DNA 
binding and they bind to 5´-GGAT/A-3´ ETS binding sequence (EBS) (Nye et al. 1992, 
Donaldson et al. 1996). Although there are multiple ETS factors in the heart (Maroulakou 
& Bowe 2000), their functional role has not been revealed. Activation of c-fos promoter 
via Elk-1 together with SRF composes a regulatory mechanism of c-fos gene present in 
most eukaryotic cell types including cardiac myocytes (Aoyagi & Izumo 1993, Babu et 
al. 2000). In addition, ETS-domain transcription factors act through EBS containing no 
adjacent SREs, likely in complex with alternative co-factors, but only a single report is 
available of such a regulatory EBS acting on a gene expressed in myocytes (α-MHC) 
(Gupta et al. 1998). Yet, multiple genes activated during hypertrophic growth of cardiac 
myocytes contain potential EBS in their 5´-flanking regulatory region, such as genes for 
β-MHC and ANP (Gupta et al. 1998). In Study III, a novel EBS at −498 bp of rBNP 
promoter was identified, constituting the rBNP gene as the first cardiac target for ETS 
signaling that is activated during hypertrophic growth.  
Elk-1, identified in a protein complex binding on EBS of rBNP, is directly regulated 
via site-specific phosphorylation by MAPK pathways (Price et al. 1996, Yang et al. 
1998), and conversely inactivated by dephosphorylation by phosphatases including 
calcineurin (Sugimoto et al. 1997). Interestingly, inactivation of Elk-1 and the subsequent 
decrease in c-fos mRNA may accompany recruitment of an HDAC corepressor complex 
(Yang et al. 2001). In Study III, activation of calcium signaling via L-type calcium 
channels resulted in the activation of BNP promoter independently of EBS, and all three 
MAPK cascades were equally required. Therefore, increased calcium signaling, 
mechanical stretch and Ang II activated rBNP promoter via mechanisms that appear to 
uncouple the requirement of EBS of BNP gene (III). Calcineurin has been shown to direct 
signaling through JNK and ERK cascades (De Windt et al. 2000, Lim et al. 2001) and to 
inactivate signaling via Elk-1 through dephosphorylation (Yordy & Muise-Helmericks 
2000). In addition, accumulation of intracellular calcium may lead to autoinhibition of 
DNA binding activity of ETS factors via site-specific CaMK mediated phosphorylation 
(Cowley & Graves 2000). In conclusion, recent studies (Murat et al. 2000, Haq et al. 
2001) combined with the present results suggest an intimate relationship between 
MAPKs and Ca
2+-dependent pathways in the development of cardiac hypertrophy. 
In Study III, a novel signaling mechanism initiating from cell membrane ETA receptor 
and leading to p38 MAPK and ETS factor dependent induction of rBNP was identified. 
Present results suggested that ET-1 activates the gene via mechanisms distinct from those 
of increased calcium influx via L-type calcium channels, Ang II or mechanical stretch of 
myocytes. p38 MAPK dependent mechanism mediated activation of rBNP transcription   76
via EBS, whereas activation of the rBNP promoter via MEK1/ERK pathway was 
inhibited by intact EBS. While p38 and ERK are activated by ET-1 in parallel (I), Study 
III suggests an example of a downstream mechanism leading to an exclusively p38-
dependent activation of the BNP gene. Furthermore, given the fundamental role of the 
interaction of MAPKs and ETS factors in the regulation of eukaryotic cells, Study III 
provides evidence for an ET-1 specific and MAPK-regulated ETS factor pathway for 
cardiac myocytes. 
6.5  The parallel nuclear signaling mechanisms  
Activity of BNP gene transcription in cardiac myocytes is regulated by a complex array 
of intracellular signaling cascades, which are switched on and off by numerous 
extracellular stimuli. While in cultured cardiac myocytes it may be possible to distinguish 
the signaling mediators to a given stimuli, in vivo the diversity arises from a number of 
stimuli that may act simultaneously and with varying intensity, e.g. ET-1, Ang II and 
adrenergic systems as well as oxygen tension and mechanical stretch. However, in the 
context of gene transcription, a wide pattern of signaling mechanisms converges to a 
limited number of gene regulatory elements. Thus, transcription factors provide a point of 
convergence in the signaling network and may prove attractive targets for drug research 
(Emery et al. 2001). 
This work provides detailed information of the regulation of GATA-4 as well as 
evidence for the role of GATA-4 as a mediator of mechanical load-induced cardiac 
myocyte hypertrophy. In this work, ETS factors (Elk-1) were identified as novel 
mediators for ET-1 specific signaling in cardiac myocytes. Future in vivo studies may 
indicate whether GATA-4 and ETS factors act by interacting or antagonizing each other 
in regulation of cardiac gene expression and phenotype, and whether these nuclear 
signaling mechanisms exist only in cardiac myocytes. It is noteworthy that the 
pathophysiological effects of ET-1 extend beyond myocardium to the regulation of 
proliferation (Hafizi et al. 1999) and contraction (Cain et al. 2002) of vascular smooth 
muscle cells. Therefore, it is intriguing to speculate that ET-1 activated ETS factors and 
GATA-4 may not be limited to the regulation of cardiac gene expression. Hypothetically, 
the pathways described in this work might extend to involve additional ETS factors as 
well as other tissues with prominent levels of GATA-4. A potential candidate in 
vasculature is Ets-1, an oncogene which is activated by ET-1 in cultured vascular smooth 
muscle cells (Naito et al. 1998) and in human endothelial cells during tumor angiogenesis 
(Calmels et al. 1995). Furthermore, ET-1 is an endogenously produced growth factor 
implicated in tumour cell proliferation (Shichiri et al. 1991), and ETA receptor 
antagonism may prove a useful treatment strategy in malignancies where this protein is 
overexpressed (Stephenson 2001). ET-1 increases vascular endothelial growth factor 
(VEGF) production in ovarian cancer cells via ETA receptor (Salani et al. 2000), while 
ETS factors activate genes regulating angiogenesis, such as VEGF receptor R1 (Wakiya 
et al. 1996) and -2 (Kappel et al. 2000). In addition, GATA-4 downregulation has been 
shown to associate with increased apoptosis in cultured mouse granulosa cells   77
(Heikinheimo et al. 1997), while GATA-4 overexpression has been found to protect 
cardiac myocytes from apoptosis (Kim et al. 2003). Enhanced levels of GATA-4 have 
been detected during adrenocortical tumorigenesis in mice and humans (Kiiveri et al. 
1999). Indeed, MAPK regulated ETS factors and GATA-4 signaling provide an attractive 
target for the ongoing study of cellular growth, proliferation and oncogenesis. 
6.6  ET-1 production in mechanically loaded cardiac cells 
Emerging evidence has indicated that a complex pattern of humoral and 
autocrine/paracrine factors, including ET-1 and Ang II, participate in the pathophysiology 
of the cardiovascular system (Levin 1995). It has been found that the increase in ANP and 
BNP production in stretched cardiac myocytes was more pronounced in a co-culture with 
non-myocytes, and this was successfully inhibited with AT1a and ETA receptor 
antagonists (Harada et al. 1997b). The basic hypothesis underlying this phenomenon is 
that during increased mechanical load cardiomyocytes and adjacent non-myocytes (i.e. 
fibroblasts and endothelial cells) release factors that may bind on cell membrane 
receptors of cardiomyocytes and activate growth-promoting signaling mechanisms and 
gene expression. Cyclic mechanical stretch of cultured cardiomyocytes has been shown 
to elevate mRNA levels of angiotensinogen, angiotensin converting enzyme and ET-1 
(Liang & Gardner 1998). In similar model, mechanical stretch has been reported to 
increase the release of Ang II within 10–30 minutes (Sadoshima et al. 1993), and the 
blockade of angiotensin 1a (AT1a) receptor by CV-11974 was shown to inhibit activation 
of ERK by 70% (Yamazaki et al. 1995a). Furthermore, losartan (an AT1a blocker), inhibits 
the induction of human BNP promoter activity in stretched cultured cardiomyocytes 
(Liang & Gardner 1998). In addition, it has been suggested that in the heart, locally 
released ET-1 may act as a mediator in the Ang II or TGF-β1 induced hypertrophic 
responses of myocytes (Ito et al. 1993, Harada et al. 1997a, Liang & Gardner 1998). In 
agreement with this hypothesis, pharmacological blockade of endothelin-A (ETA) 
receptor with BQ-123 inhibited Ang II and stretch-activated BNP gene transcription by 
50%, while AT1a blockade had no effect on ET-1 induced BNP gene activation (Liang & 
Gardner 1998). However, endogenous production of ET-1 in cardiomyocytes is relatively 
low and addition of exogenous ET-1 into culture medium results in potentiation of BNP 
promoter activity in stretched cultured cardiomyocytes (Liang & Gardner 1998). 
Transgenic approaches have provided evidence that while Ang II may be a mediating 
factor, it is not a prerequisite for cardiac mechanotransduction, since AT1a null mice 
develop marked hypertrophy in response to pressure overload (Harada et al. 1998), and 
mechanical stretch may activate MAPK kinases in cultured angiotensinogen or AT1a 
deficient cardiomyocytes via alternative mechanisms (Nyui et al. 1997, Kudoh et al. 
1998).  
Pulsatile stretch of endothelial cells has been shown to increase the release and 
synthesis of ET-1 (Macarthur et al. 1994). Rat hypertrophied myocardium due to pressure 
overload (Ito et al. 1994) or by transgenic expression of human angiotensinogen and 
renin genes (Zolk et al. 2002) contained increased ET-1 mRNA levels. In addition, as a   78
local growth factor, ET-1 is able to evoke potent growth-promoting effects on cardiac 
myocytes and in addition to pathological remodeling of the heart, upregulated ET-1 
system may contribute to the preservation of contractile response to increased mechanical 
load in rat hearts with compensated phase of cardiac hypertrophy (Piuhola et al. 2003). In 
agreement with previous studies (Yamazaki et al. 1996, Liang & Gardner 1998), Study V 
suggests that in the heart, cardiac myocytes may increase autocrine production of ET-1 
during mechanical load. The levels of ET-1 released into culture medium by rat neonatal 
cardiac myocytes (1 pM) is lower than that of fibroblasts (60 pM) and HUVECs (120 
pM), and may therefore activate different signaling cascades than exogenously 
administered higher dose of ET-1 (1–100 nM). However, in response to mechanical 
loading of the heart, it is likely that myocytes and endothelial cells contribute to the 
increased ET-1 generation, which may be accompanied by a downregulation of ET-1 
release by fibroblasts. In vivo the ET-1 generation may further decrease in stretched 
fibroblasts due to a negative effect of natriuretic peptides released by loaded myocytes 
(Fujisaki et al. 1995). 
In Study V, it was found that the ERK pathway is necessary for activation of ET-1 
transcription in stretched cardiac myocytes. In addition, activation of ERK pathway alone 
was sufficient to promote ET-1 transcription. Therefore, while it appears that ET-1 
activates p38 MAPK to regulate the BNP gene, the activation mechanisms for the ET-1 
gene itself may be different. The activation of cardiac ET system may enhance 
hypertrophy of the loaded heart, and while this is of fundamental interest for cardiac 
pathophysiology, it may also complicate interpretation of some transgenic approaches. 
For instance, supra-physiologically increased ERK activity or GATA-4 protein levels may 
activate ET-1 production and secondarily recruit cardiac ET system and its intracellular 
downstream effectors. Therefore, there may be a complex network of interacting 
signaling mechanisms that ultimately secure signal transduction.  7 Summary and conclusions 
The aim of the present study was to evaluate regulatory mechanisms of BNP gene 
transcription and hypertrophy of cardiac myocytes. More specifically, the role and 
regulation via GATA-4 transcription factor was examined and the cellular mechanisms 
mediating the effects of ET-1 and mechanical stretch were studied. 
1.  To identify mechanisms activating GATA-4 in ET-1 stimulated cardiac myocytes, the 
role of MAPKs was examined. It was found that both p38 and ERK were activated 
by ET-1, but only the inhibition of p38 reduced ET-1-induced GATA-4 DNA binding. 
In contrast, the inhibition of ERK reduced basal GATA-4 binding activity. However, 
inhibition of ERK reduced also p38 kinase-activated GATA-4 Ser phosphorylation 
and DNA binding activity. MEK1 overexpression increased GATA-4 Ser 
phosphorylation, but it was not sufficient to enhance DNA binding activity. 
Overexpression of the p38 kinase pathway activated GATA-4 Ser phosphorylation 
and binding to BNP gene followed by induction of BNP promoter activity via GATA 
binding sites. These findings suggest that the p38 pathway mediates Ser 
phosphorylation and activation of GATA-4 in ET-1 stimulated cardiac myocytes, 
whereas a functional ERK pathway may be additionally required in the regulation of 
GATA-4.  
2.  To directly address the role GATA-4 DNA binding in ET-1 induced hypertrophic 
response of cardiac myocytes, a decoy oligonucleotide strategy to block GATA-4 
DNA binding activity was utilized. A synthetic decoy oligonucleotide, GATA ODN, 
was used to bind GATA-4. GATA-4 DNA binding activity in EMSA was blocked by 
GATA ODN in vitro and in vivo. GATA ODN-treatment decreased baseline 
expression of ANP and BNP. In contrast, GATA ODN-treatment did not prevent ET-1 
induced expression of ANP and BNP. Mutation of GATA binding sites 
downregulated the baseline BNP promoter activity, but ET-1-inducibility persisted 
also in the mutated promoter. Moreover, GATA ODN-treatment was insufficient to 
block ET-1 activated protein synthesis and sarcomeric protein assembly. According 
to these findings, a targeted disruption of GATA DNA binding activity may be 
insufficient to prevent ET-1-induced hypertrophic response in cardiac myocytes.   80
3.  To examine the role of GATA-4 in hypertrophic response activated by direct myocyte 
stretch, an in vitro mechanical stretch model of cultured cardiac myocytes was 
employed. Stretch increased transiently GATA-4 DNA binding activity and mRNA 
levels, which was followed by an increase in the expression of BNP and ANP as well 
as in sarcomere reorganization. Inhibition of GATA-4 protein production by 
adenovirus-mediated transfer of GATA-4 antisense cDNA significantly inhibited the 
stretch-activated sarcomeric assembly and BNP mRNA levels. More specifically, to 
study the role of GATA-4 in stretch-activated transcription, rat BNP promoter 
provided a stretch-sensitive reporter gene containing GATA binding response 
elements. The inducibility mapped primarily to the proximal 520 bp of BNP 5' 
flanking sequence. Mutational studies showed that the tandem GATA consensus sites 
of the proximal promoter, in combination with an NKE-like element, are critical for 
stretch-activated BNP transcription. These results suggest that activation of GATA-4, 
in cooperation with a factor binding on the NKE-like element, is crucial for the 
mechanical stretch-induced hypertrophic program (Fig. 14).  
4.  To evaluate ET-1 responsive elements within the BNP gene promoter, mutation 
analysis of BNP promoter was used together with cultured cardiac myocytes 
resulting in the identification of a novel EBS. Nuclear protein binding on EBS of 
BNP was activated by ET-1. This sequence bound Elk-1 and mediated ET-1-specific 
activation of transcription, but not responses to increased calcium signaling via L-
type calcium channels, Ang II treatment or mechanical stretch of myocytes. 
Interestingly, ET-1 activated signaling converged via p38 on EBS, whereas this 
element inhibited ERK activated transcription (Fig. 14). In conclusion, given the 
fundamental role of the interaction of MAPK and ETS factors in the regulation of 
eukaryotic cell differentiation, growth and oncogenesis, these results provide 
evidence for an ET-1 and MAPK regulated ETS factor pathway in cardiac myocytes. 
Fig. 14. Summary of ET-1 and mechanical stretch-activated BNP gene expression.  
5.  To evaluate production of ET-1 in mechanically loaded cardiac cells, an in vitro 
mechanical stretch model of cultured cardiac myocytes, non-myocytes (fibroblasts) 
and HUVECs was used. It was found that ET-1 synthesis is increased in loaded 
myocytes and endothelial cells, whereas ET-1 generation decreases in fibroblasts. In   81
addition, ERK was activated in stretched myocytes and this activity was necessary 
and sufficient for the induction of ET-1 transcription. In conclusion, these results 
suggest that in the loaded heart, both myocytes and endothelial cells contribute to 
activated ET-1 generation.  References 
Abdellatif M, Packer SE, Michael LH, Zhang D, Charng MJ & Schneider MD (1998) A Ras-
Dependent Pathway Regulates RNA Polymerase II Phosphorylation in Cardiac Myocytes: 
Implications for Cardiac Hypertrophy. Mol Cell Biol 18: 6729–6736. 
Adams JW & Brown JH (2001) G-Proteins in Growth and Apoptosis: Lessons From the Heart. 
Oncogene 20: 1626–1634. 
Aikawa R, Nagai T, Kudoh S, Zou Y, Tanaka M, Tamura M, Akazawa H, Takano H, Nagai R & 
Komuro I (2002) Integrins Play a Critical Role in Mechanical Stress-Induced P38 MAPK 
Activation. Hypertension 39: 233–238. 
Aikawa R, Nagai T, Tanaka M, Zou Y, Ishihara T, Takano H, Hasegawa H, Akazawa H, Mizukami 
M, Nagai R & Komuro I (2001) Reactive Oxygen Species in Mechanical Stress-Induced 
Cardiac Hypertrophy. Biochem Biophys Res Commun 289: 901–907. 
Akhter SA, Luttrell LM, Rockman HA, Iaccarino G, Lefkowitz RJ & Koch WJ (1998) Targeting 
the Receptor-Gq Interface to Inhibit in Vivo Pressure Overload Myocardial Hypertrophy. 
Science 280: 574–577. 
Alwine JC, Kemp DJ, Parker BA, Reiser J, Renart J, Stark GR & Wahl GM (1979) Detection of 
Specific RNAs or Specific Fragments of DNA by Fractionation in Gels and Transfer to 
Diazobenzyloxymethyl Paper. Methods Enzymol 68: 220–242. 
Aoki H, Sadoshima J & Izumo S (2000) Myosin Light Chain Kinase Mediates Sarcomere 
Organization During Cardiac Hypertrophy in Vitro. Nat Med 6: 183–188. 
Aoyagi T & Izumo S (1993) Mapping of the Pressure Response Element of the C-Fos Gene by 
Direct DNA Injection into Beating Hearts. J Biol Chem 268: 27176–27179. 
Arai H, Hori S, Aramori I, Ohkubo H & Nakanishi S (1990) Cloning and Expression of a CDNA 
Encoding an Endothelin Receptor. Nature 348: 730–732. 
Arceci RJ, King AA, Simon MC, Orkin SH & Wilson DB (1993) Mouse GATA-4: a Retinoic 
Acid-Inducible GATA-Binding Transcription Factor Expressed in Endodermally Derived 
Tissues and Heart. Mol Cell Biol 13: 2235–2246. 
Babu GJ, Lalli MJ, Sussman MA, Sadoshima J & Periasamy M (2000) Phosphorylation of Elk-1 by 
MEK/ERK Pathway Is Necessary for C-Fos Gene Activation During Cardiac Myocyte 
Hypertrophy. J Mol Cell Cardiol 32: 1447–1457. 
Bar-Sagi D (2001) A Ras by Any Other Name. Mol Cell Biol 21: 1441–1443. 
Barbee RW, Perry BD, Re RN, Murgo JP & Field LJ (1994) Hemodynamics in Transgenic Mice 
With Overexpression of Atrial Natriuretic Factor. Circ Res 74: 747–751. 
Bartel FO, Higuchi T & Spyropoulos DD (2000) Mouse Models in the Study of the Ets Family of 
Transcription Factors. Oncogene 19: 6443–6454. 
Batra VK, McNeill JR, Xu Y, Wilson TW & Gopalakrishnan V (1993) ETB Receptors on Aortic 
Smooth Muscle Cells of Spontaneously Hypertensive Rats. Am J Physiol 264: C479–C484.   83
Baynash AG, Hosoda K, Giaid A, Richardson JA, Emoto N, Hammer RE & Yanagisawa M (1994) 
Interaction of Endothelin-3 With Endothelin-B Receptor Is Essential for Development of 
Epidermal Melanocytes and Enteric Neurons. Cell 79: 1277–1285. 
Belaguli NS, Sepulveda JL, Nigam V, Charron F, Nemer M & Schwartz RJ (2000) Cardiac Tissue 
Enriched Factors Serum Response Factor and GATA-4 Are Mutual Coregulators. Mol Cell Biol 
20: 7550–7558. 
Berk BC, Vekshtein V, Gordon HM & Tsuda T (1989) Angiotensin II-Stimulated Protein Synthesis 
in Cultured Vascular Smooth Muscle Cells. Hypertension 13: 305–314. 
Bhalla SS, Robitaille L & Nemer M (2001) Cooperative Activation by GATA-4 and YY1 of the 
Cardiac B-Type Natriuretic Peptide Promoter. J Biol Chem 276: 11439–11445. 
Bishopric NH, Jayasena V & Webster KA (1992) Positive Regulation of the Skeletal Alpha-Actin 
Gene by Fos and Jun in Cardiac Myocytes. J Biol Chem 267: 25535–25540. 
Bloch KD, Eddy RL, Shows TB & Quertermous T (1989) CDNA Cloning and Chromosomal 
Assignment of the Gene Encoding Endothelin 3. J Biol Chem 264: 18156–18161. 
Bogoyevitch MA, Clerk A & Sugden PH (1995) Activation of the Mitogen-Activated Protein 
Kinase Cascade by Pertussis Toxin-Sensitive and -Insensitive Pathways in Cultured Ventricular 
Cardiomyocytes. Biochem J 309 ( Pt 2) : 437–443. 
Boulton TG, Nye SH, Robbins DJ, Ip NY, Radziejewska E, Morgenbesser SD, DePinho RA, 
Panayotatos N, Cobb MH & Yancopoulos GD (1991) ERKs: a Family of Protein-
Serine/Threonine Kinases That Are Activated and Tyrosine Phosphorylated in Response to 
Insulin and NGF. Cell 65: 663–675. 
Boulton TG, Yancopoulos GD, Gregory JS, Slaughter C, Moomaw C, Hsu J & Cobb MH (1990) 
An Insulin-Stimulated Protein Kinase Similar to Yeast Kinases Involved in Cell Cycle Control. 
Science 249: 64–67. 
Bowling N, Walsh RA, Song G, Estridge T, Sandusky GE, Fouts RL, Mintze K, Pickard T, Roden 
R, Bristow MR, Sabbah HN, Mizrahi JL, Gromo G, King GL & Vlahos CJ (1999) Increased 
Protein Kinase C Activity and Expression of Ca2+-Sensitive Isoforms in the Failing Human 
Heart. Circulation 99: 384–391. 
Bowman JC, Steinberg SF, Jiang T, Geenen DL, Fishman GI & Buttrick PM (1997) Expression of 
Protein Kinase C Beta in the Heart Causes Hypertrophy in Adult Mice and Sudden Death in 
Neonates. J Clin Invest 100: 2189–2195. 
Bradford MM (1976) A Rapid and Sensitive Method for the Quantitation of Microgram Quantities 
of Protein Utilizing the Principle of Protein-Dye Binding. Anal Biochem 72: 248–254. 
Braz JC, Bueno OF, De Windt LJ & Molkentin JD (2002) PKC Alpha Regulates the Hypertrophic 
Growth of Cardiomyocytes Through Extracellular Signal-Regulated Kinase1/2 (ERK1/2). J Cell 
Biol 156: 905–919. 
Brivanlou AH & Darnell JE, Jr. (2002) Signal Transduction and the Control of Gene Expression. 
Science 295: 813–818. 
Bueno OF, De Windt LJ, Lim HW, Tymitz KM, Witt SA, Kimball TR & Molkentin JD (2001) The 
Dual-Specificity Phosphatase MKP-1 Limits the Cardiac Hypertrophic Response in Vitro and in 
Vivo. Circ Res 88: 88–96. 
Bueno OF & Molkentin JD (2002) Involvement of Extracellular Signal-Regulated Kinases 1/2 in 
Cardiac Hypertrophy and Cell Death. Circ Res 91: 776–781. 
Bueno OF, Van Rooij E, Molkentin JD, Doevendans PA & De Windt LJ (2002) Calcineurin and 
Hypertrophic Heart Disease: Novel Insights and Remaining Questions. Cardiovasc Res 53: 806–
821. 
Cain AE, Tanner DM & Khalil RA (2002) Endothelin-1--Induced Enhancement of Coronary 
Smooth Muscle Contraction Via MAPK-Dependent and MAPK-Independent [Ca(2+)](i) 
Sensitization Pathways. Hypertension 39: 543–549. 
Calmels TP, Mattot V, Wernert N, Vandenbunder B & Stehelin D (1995) Invasive Tumors Induce 
C-Ets1 Transcription Factor Expression in Adjacent Stroma. Biol Cell 84: 53–61. 
Charron F & Nemer M (1999) GATA Transcription Factors and Cardiac Development. Semin Cell 
Dev Biol 10: 85–91. 
Charron F, Paradis P, Bronchain O, Nemer G & Nemer M (1999) Cooperative Interaction Between 
GATA-4 and GATA-6 Regulates Myocardial Gene Expression. Mol Cell Biol 19: 4355–4365.   84
Charron F, Tsimiklis G, Arcand M, Robitaille L, Liang Q, Molkentin JD, Meloche S & Nemer M 
(2001) Tissue-Specific GATA Factors Are Transcriptional Effectors of the Small GTPase 
RhoA. Genes Dev 15: 2702–2719. 
Chen L, Hahn H, Wu G, Chen CH, Liron T, Schechtman D, Cavallaro G, Banci L, Guo Y, Bolli R, 
Dorn GW & Mochly-Rosen D (2001) Opposing Cardioprotective Actions and Parallel 
Hypertrophic Effects of Delta PKC and Epsilon PKC. Proc Natl Acad Sci U S A 98: 11114–
11119. 
Chien KR (2000) Meeting Koch's Postulates for Calcium Signaling in Cardiac Hypertrophy. J Clin 
Invest 105: 1339–1342. 
Chiloeches A, Paterson HF, Marais R, Clerk A, Marshall CJ & Sugden PH (1999) Regulation of 
Ras.GTP Loading and Ras-Raf Association in Neonatal Rat Ventricular Myocytes by G Protein-
Coupled Receptor Agonists and Phorbol Ester. Activation of the Extracellular Signal-Regulated 
Kinase Cascade by Phorbol Ester Is Mediated by Ras. J Biol Chem 274: 19762–19770. 
Chin D & Means AR (2000) Calmodulin: a Prototypical Calcium Sensor. Trends Cell Biol 10: 
322–328. 
Chirgwin JM, Przybyla AE, MacDonald RJ & Rutter WJ (1979) Isolation of Biologically Active 
Ribonucleic Acid From Sources Enriched in Ribonuclease. Biochemistry 18: 5294–5299. 
Choukroun G, Hajjar R, Fry S, del Monte F, Haq S, Guerrero JL, Picard M, Rosenzweig A & Force 
T (1999) Regulation of Cardiac Hypertrophy in Vivo by the Stress-Activated Protein Kinases/c-
Jun NH(2)-Terminal Kinases. J Clin Invest 104: 391–398. 
Choukroun G, Hajjar R, Kyriakis JM, Bonventre JV, Rosenzweig A & Force T (1998) Role of the 
Stress-Activated Protein Kinases in Endothelin-Induced Cardiomyocyte Hypertrophy. J Clin 
Invest 102: 1311–1320. 
Chusho H, Tamura N, Ogawa Y, Yasoda A, Suda M, Miyazawa T, Nakamura K, Nakao K, 
Kurihara T, Komatsu Y, Itoh H, Tanaka K, Saito Y, Katsuki M & Nakao K (2001) Dwarfism 
and Early Death in Mice Lacking C-Type Natriuretic Peptide. Proc Natl Acad Sci U S A 98: 
4016–4021. 
Clerk A, Michael A & Sugden PH (1998) Stimulation of the P38 Mitogen-Activated Protein Kinase 
Pathway in Neonatal Rat Ventricular Myocytes by the G Protein-Coupled Receptor Agonists, 
Endothelin-1 and Phenylephrine: a Role in Cardiac Myocyte Hypertrophy? J Cell Biol 142: 
523–535. 
Clerk A, Pham FH, Fuller SJ, Sahai E, Aktories K, Marais R, Marshall C & Sugden PH (2001) 
Regulation of Mitogen-Activated Protein Kinases in Cardiac Myocytes Through the Small G 
Protein Rac1. Mol Cell Biol 21: 1173–1184. 
Clerk A & Sugden PH (2000) Small Guanine Nucleotide-Binding Proteins and Myocardial 
Hypertrophy. Circ Res 86: 1019–1023. 
Communal C, Colucci WS, Remondino A, Sawyer DB, Port JD, Wichman SE, Bristow MR & 
Singh K (2002) Reciprocal Modulation of Mitogen-Activated Protein Kinases and Mitogen- 
Activated Protein Kinase Phosphatase 1 and 2 in Failing Human Myocardium. J Card Fail 8: 
86–92. 
Cook SA, Sugden PH & Clerk A (1999) Activation of C-Jun N-Terminal Kinases and P38-
Mitogen-Activated Protein Kinases in Human Heart Failure Secondary to Ischaemic Heart 
Disease. J Mol Cell Cardiol 31: 1429–1434. 
Cooper JA, Bowen-Pope DF, Raines E, Ross R & Hunter T (1982) Similar Effects of Platelet-
Derived Growth Factor and Epidermal Growth Factor on the Phosphorylation of Tyrosine in 
Cellular Proteins. Cell 31: 263–273. 
Cornelius T, Holmer SR, Muller FU, Riegger GA & Schunkert H (1997) Regulation of the Rat 
Atrial Natriuretic Peptide Gene After Acute Imposition of Left Ventricular Pressure Overload. 
Hypertension 30: 1348–1355. 
Courey AJ & Jia S (2001) Transcriptional Repression: the Long and the Short of It. Genes Dev 15: 
2786–2796. 
Cowley DO & Graves BJ (2000) Phosphorylation Represses Ets-1 DNA Binding by Reinforcing 
Autoinhibition. Genes Dev 14: 366–376.   85
Crispino JD, Lodish MB, Thurberg BL, Litovsky SH, Collins T, Molkentin JD & Orkin SH (2001) 
Proper Coronary Vascular Development and Heart Morphogenesis Depend on Interaction of 
GATA-4 With FOG Cofactors. Genes Dev 15: 839–844. 
Dagnino L, Drouin J & Nemer M (1991) Differential Expression of Natriuretic Peptide Genes in 
Cardiac and Extracardiac Tissues. Mol Endocrinol 5: 1292–1300. 
Dai YS, Cserjesi P, Markham BE & Molkentin JD (2002) The Transcription Factors GATA4 and 
DHAND Physically Interact to Synergistically Activate Cardiac Gene Expression Through a 
P300- Dependent Mechanism. J Biol Chem 277: 24390–24398. 
Davis M, Espiner E, Richards G, Billings J, Town I, Neill A, Drennan C, Richards M, Turner J & 
Yandle T (1994) Plasma Brain Natriuretic Peptide in Assessment of Acute Dyspnoea. Lancet 
343: 440–444. 
de Boer RA, Henning RH, Suurmeijer AJ, Pinto YM, Olthof E, Kirkels JH, van Gilst WH, Crijns 
HJ & van Veldhuisen DJ (2001) Early Expression of Natriuretic Peptides and SERCA in Mild 
Heart Failure: Association With Severity of the Disease. Int J Cardiol 78: 5–12. 
de Bold AJ, Borenstein HB, Veress AT & Sonnenberg H (1981) A Rapid and Potent Natriuretic 
Response to Intravenous Injection of Atrial Myocardial Extract in Rats. Life Sci 28: 89–94. 
de Bold AJ, Bruneau BG & Kuroski de Bold ML (1996) Mechanical and Neuroendocrine 
Regulation of the Endocrine Heart. Cardiovasc Res 31: 7–18. 
de Nucci G, Thomas R, D'Orleans-Juste P, Antunes E, Walder C, Warner TD & Vane JR (1988) 
Pressor Effects of Circulating Endothelin Are Limited by Its Removal in the Pulmonary 
Circulation and by the Release of Prostacyclin and Endothelium-Derived Relaxing Factor. Proc 
Natl Acad Sci U S A 85: 9797–9800. 
De Windt LJ, Lim HW, Haq S, Force T & Molkentin JD (2000) Calcineurin Promotes Protein 
Kinase C and C-Jun NH2-Terminal Kinase Activation in the Heart. Cross-Talk Between 
Cardiac Hypertrophic Signaling Pathways. J Biol Chem 275: 13571–13579. 
Dhanasekaran N & Dermott JM (1996) Signaling by the G12 Class of G Proteins. Cell Signal 8: 
235–245. 
Doi T, Sugimoto H, Arimoto I, Hiroaki Y & Fujiyoshi Y (1999) Interactions of Endothelin 
Receptor Subtypes A and B With Gi, Go, and Gq in Reconstituted Phospholipid Vesicles. 
Biochemistry 38: 3090–3099. 
Donaldson LW, Petersen JM, Graves BJ & McIntosh LP (1996) Solution Structure of the ETS 
Domain From Murine Ets-1: a Winged Helix- Turn-Helix DNA Binding Motif. EMBO J 15: 
125–134. 
Douglas SA & Hiley CR (1990) Endothelium-Dependent Vascular Activities of Endothelin-Like 
Peptides in the Isolated Superior Mesenteric Arterial Bed of the Rat. Br J Pharmacol 101: 81-88. 
Durocher D, Charron F, Warren R, Schwartz RJ & Nemer M (1997) The Cardiac Transcription 
Factors Nkx2-5 and GATA-4 Are Mutual Cofactors. EMBO J 16: 5687–5696. 
Emery JG, Ohlstein EH & Jaye M (2001) Therapeutic Modulation of Transcription Factor Activity. 
Trends Pharmacol Sci 22: 233–240. 
Esposito G, Prasad SV, Rapacciuolo A, Mao L, Koch WJ & Rockman HA (2001) Cardiac 
Overexpression of a G(q) Inhibitor Blocks Induction of Extracellular Signal-Regulated Kinase 
and C-Jun NH(2)-Terminal Kinase Activity in in Vivo Pressure Overload. Circulation 103: 
1453–1458. 
Evans T & Felsenfeld G (1989) The Erythroid-Specific Transcription Factor Eryf1: a New Finger 
Protein. Cell 58: 877–885. 
Fiebeler A, Schmidt F, Muller DN, Park JK, Dechend R, Bieringer M, Shagdarsuren E, Breu V, 
Haller H & Luft FC (2001) Mineralocorticoid Receptor Affects AP-1 and Nuclear Factor-
Kappab Activation in Angiotensin II-Induced Cardiac Injury. Hypertension 37: 787–793. 
Flesch M, Margulies KB, Mochmann HC, Engel D, Sivasubramanian N & Mann DL (2001) 
Differential Regulation of Mitogen-Activated Protein Kinases in the Failing Human Heart in 
Response to Mechanical Unloading. Circulation 104: 2273–2276. 
Flynn TG, Davies PL, Kennedy BP, de Bold ML & de Bold AJ (1985) Alignment of Rat 
Cardionatrin Sequences With the Preprocardionatrin Sequence From Complementary DNA. 
Science 228: 323–325.   86
Frey N, McKinsey TA & Olson EN (2000) Decoding Calcium Signals Involved in Cardiac Growth 
and Function. Nat Med 6: 1221–1227. 
Fujikura J, Yamato E, Yonemura S, Hosoda K, Masui S, Nakao K, Miyazaki JJ & Niwa H (2002) 
Differentiation of Embryonic Stem Cells Is Induced by GATA Factors. Genes Dev 16: 784–
789. 
Fujisaki H, Ito H, Hirata Y, Tanaka M, Hata M, Lin M, Adachi S, Akimoto H, Marumo F & Hiroe 
M (1995) Natriuretic Peptides Inhibit Angiotensin II-Induced Proliferation of Rat Cardiac 
Fibroblasts by Blocking Endothelin-1 Gene Expression. J Clin Invest 96: 1059–1065. 
Fuller SJ, Davies EL, Gillespie-Brown J, Sun H & Tonks NK (1997) Mitogen-Activated Protein 
Kinase Phosphatase 1 Inhibits the Stimulation of Gene Expression by Hypertrophic Agonists in 
Cardiac Myocytes. Biochem J 323 ( Pt 2): 313–319. 
Fuller SJ, Finn SG, Downward J & Sugden PH (1998a) Stimulation of Gene Expression in 
Neonatal Rat Ventricular Myocytes by Ras Is Mediated by Ral Guanine Nucleotide Dissociation 
Stimulator (Ral.GDS) and Phosphatidylinositol 3-Kinase in Addition to Raf. Biochem J 335 ( Pt 
2): 241–246. 
Fuller SJ, Gillespie-Brown J & Sugden PH (1998b) Oncogenic Src, Raf, and Ras Stimulate a 
Hypertrophic Pattern of Gene Expression and Increase Cell Size in Neonatal Rat Ventricular 
Myocytes. J Biol Chem 273: 18146–18152. 
Gariepy CE, Ohuchi T, Williams SC, Richardson JA & Yanagisawa M (2000) Salt-Sensitive 
Hypertension in Endothelin-B Receptor-Deficient Rats. J Clin Invest 105: 925–933. 
Gariepy CE, Williams SC, Richardson JA, Hammer RE & Yanagisawa M (1998) Transgenic 
Expression of the Endothelin-B Receptor Prevents Congenital Intestinal Aganglionosis in a Rat 
Model of Hirschsprung Disease. J Clin Invest 102: 1092–1101. 
Gerbes AL, Dagnino L, Nguyen T & Nemer M (1994) Transcription of Brain Natriuretic Peptide 
and Atrial Natriuretic Peptide Genes in Human Tissues. J Clin Endocrinol Metab 78: 1307–
1311. 
Giannessi D, Del Ry S & Vitale RL (2001) The Role of Endothelins and Their Receptors in Heart 
Failure. Pharmacol Res 43: 111–126. 
Gillespie-Brown J, Fuller SJ, Bogoyevitch MA, Cowley S & Sugden PH (1995) The Mitogen-
Activated Protein Kinase Kinase MEK1 Stimulates a Pattern of Gene Expression Typical of the 
Hypertrophic Phenotype in Rat Ventricular Cardiomyocytes. J Biol Chem 270: 28092–28096. 
Greenberg BD, Bencen GH, Seilhamer JJ, Lewicki JA & Fiddes JC (1984) Nucleotide Sequence of 
the Gene Encoding Human Atrial Natriuretic Factor Precursor. Nature 312: 656–658. 
Grepin C, Dagnino L, Robitaille L, Haberstroh L, Antakly T & Nemer M (1994) A Hormone-
Encoding Gene Identifies a Pathway for Cardiac but Not Skeletal Muscle Gene Transcription. 
Mol Cell Biol 14: 3115–3129. 
Gupta M, Zak R, Libermann TA & Gupta MP (1998) Tissue-Restricted Expression of the Cardiac 
Alpha-Myosin Heavy Chain Gene Is Controlled by a Downstream Repressor Element 
Containing a Palindrome of Two Ets-Binding Sites. Mol Cell Biol 18: 7243–7258. 
Hafizi S, Allen SP, Goodwin AT, Chester AH & Yacoub MH (1999) Endothelin-1 Stimulates 
Proliferation of Human Coronary Smooth Muscle Cells Via the ET(A) Receptor and Is Co-
Mitogenic With Growth Factors. Atherosclerosis 146: 351–359. 
Hall RA & Lefkowitz RJ (2002) Regulation of g Protein-Coupled Receptor Signaling by Scaffold 
Proteins. Circ Res 91: 672–680. 
Haneda M, Sugimoto T & Kikkawa R (1999) Mitogen-Activated Protein Kinase Phosphatase: a 
Negative Regulator of the Mitogen-Activated Protein Kinase Cascade. Eur J Pharmacol 365: 1–
7. 
Hanford DS & Glembotski CC (1996) Stabilization of the B-Type Natriuretic Peptide MRNA in 
Cardiac Myocytes by Alpha-Adrenergic Receptor Activation: Potential Roles for Protein Kinase 
C and Mitogen-Activated Protein Kinase. Mol Endocrinol 10: 1719–1727. 
Haq S, Choukroun G, Lim H, Tymitz KM, del Monte F, Gwathmey J, Grazette L, Michael A, 
Hajjar R, Force T & Molkentin JD (2001) Differential Activation of Signal Transduction 
Pathways in Human Hearts With Hypertrophy Versus Advanced Heart Failure. Circulation 103: 
670–677.   87
Harada K, Komuro I, Shiojima I, Hayashi D, Kudoh S, Mizuno T, Kijima K, Matsubara H, Sugaya 
T, Murakami K & Yazaki Y (1998) Pressure Overload Induces Cardiac Hypertrophy in 
Angiotensin II Type 1A Receptor Knockout Mice. Circulation 97: 1952–1959. 
Harada M, Itoh H, Nakagawa O, Ogawa Y, Miyamoto Y, Kuwahara K, Ogawa E, Igaki T, 
Yamashita J, Masuda I, Yoshimasa T, Tanaka I, Saito Y & Nakao K (1997a) Significance of 
Ventricular Myocytes and Nonmyocytes Interaction During Cardiocyte Hypertrophy: Evidence 
for Endothelin-1 As a Paracrine Hypertrophic Factor From Cardiac Nonmyocytes. Circulation 
96: 3737–3744. 
Harada M, Saito Y, Nakagawa O, Miyamoto Y, Ishikawa M, Kuwahara K, Ogawa E, Nakayama 
M, Kamitani S, Hamanaka I, Kajiyama N, Masuda I, Itoh H, Tanaka I & Nakao K (1997b) Role 
of Cardiac Nonmyocytes in Cyclic Mechanical Stretch-Induced Myocyte Hypertrophy. Heart 
Vessels Suppl 12: 198–200. 
Hardt SE & Sadoshima J (2002) Glycogen Synthase Kinase-3beta: a Novel Regulator of Cardiac 
Hypertrophy and Development. Circ Res 90: 1055–1063. 
Harrison DG (1996) Endothelial Control of Vasomotion and Nitric Oxide Production: a Potential 
Target for Risk Factor Management. Cardiol Clin 14: 1–15. 
Harrison DG (1997) Cellular and Molecular Mechanisms of Endothelial Cell Dysfunction. J Clin 
Invest 100: 2153–2157. 
Hasegawa K, Lee SJ, Jobe SM, Markham BE & Kitsis RN (1997) Cis-Acting Sequences That 
Mediate Induction of Beta-Myosin Heavy Chain Gene Expression During Left Ventricular 
Hypertrophy Due to Aortic Constriction. Circulation 96: 3943–3953. 
Hautala N, Tenhunen O, Szokodi I & Ruskoaho H (2002) Direct Left Ventricular Wall Stretch 
Activates GATA4 Binding in Perfused Rat Heart: Involvement of Autocrine/Paracrine 
Pathways. Pflugers Arch 443: 362–369. 
Hautala N, Tokola H, Luodonpää M, Puhakka J, Romppanen H, Vuolteenaho O & Ruskoaho H 
(2001) Pressure Overload Increases GATA4 Binding Activity Via Endothelin-1. Circulation 
103: 730–735. 
Hawes BE, van Biesen T, Koch WJ, Luttrell LM & Lefkowitz RJ (1995) Distinct Pathways of Gi- 
and Gq-Mediated Mitogen-Activated Protein Kinase Activation. J Biol Chem 270: 17148–
17153. 
Haynes WG & Webb DJ (1998) Endothelin As a Regulator of Cardiovascular Function in Health 
and Disease. J Hypertens 16: 1081–1098. 
He Q & Lapointe MC (1999) Interleukin-1beta Regulation of the Human Brain Natriuretic Peptide 
Promoter Involves Ras-, Rac-, and P38 Kinase-Dependent Pathways in Cardiac Myocytes. 
Hypertension 33: 283–289. 
He Q & Lapointe MC (2001) Src and Rac Mediate Endothelin-1 and Lysophosphatidic Acid 
Stimulation of the Human Brain Natriuretic Peptide Promoter. Hypertension 37: 478–484. 
He Q, Mendez M & Lapointe MC (2002) Regulation of the Human Brain Natriuretic Peptide Gene 
by GATA-4. Am J Physiol Endocrinol Metab 283: E50–E57. 
He Q, Wang D, Yang XP, Carretero OA & Lapointe MC (2001) Inducible Regulation of Human 
Brain Natriuretic Peptide Promoter in Transgenic Mice. Am J Physiol Heart Circ Physiol 280: 
H368–H376. 
He Q, Wu G & Lapointe MC (2000) Isoproterenol and CAMP Regulation of the Human Brain 
Natriuretic Peptide Gene Involves Src and Rac. Am J Physiol Endocrinol Metab 278: E1115–
E1123. 
Heikinheimo M, Ermolaeva M, Bielinska M, Rahman NA, Narita N, Huhtaniemi IT, Tapanainen 
JS & Wilson DB (1997) Expression and Hormonal Regulation of Transcription Factors GATA-
4 and GATA-6 in the Mouse Ovary. Endocrinology 138: 3505–3514. 
Heikinheimo M, Scandrett JM & Wilson DB (1994) Localization of Transcription Factor GATA-4 
to Regions of the Mouse Embryo Involved in Cardiac Development. Dev Biol 164: 361–373. 
Herzig TC, Jobe SM, Aoki H, Molkentin JD, Cowley AW, Jr., Izumo S & Markham BE (1997) 
Angiotensin II Type1a Receptor Gene Expression in the Heart: AP-1 and GATA-4 Participate 
in the Response to Pressure Overload. Proc Natl Acad Sci U S A 94: 7543–7548. 
Hines WA & Thorburn A (1998) Ras and Rho Are Required for Galphaq-Induced Hypertrophic 
Gene Expression in Neonatal Rat Cardiac Myocytes. J Mol Cell Cardiol 30: 485–494.   88
Hines WA, Thorburn J & Thorburn A (1999) Cell Density and Contraction Regulate P38 MAP 
Kinase-Dependent Responses in Neonatal Rat Cardiac Myocytes. Am J Physiol 277: H331–
H341. 
Hocher B, Thone-Reineke C, Rohmeiss P, Schmager F, Slowinski T, Burst V, Siegmund F, 
Quertermous T, Bauer C, Neumayer HH, Schleuning WD & Theuring F (1997) Endothelin-1 
Transgenic Mice Develop Glomerulosclerosis, Interstitial Fibrosis, and Renal Cysts but Not 
Hypertension. J Clin Invest 99: 1380–1389. 
Hosoda K, Hammer RE, Richardson JA, Baynash AG, Cheung JC, Giaid A & Yanagisawa M 
(1994) Targeted and Natural (Piebald-Lethal) Mutations of Endothelin-B Receptor Gene 
Produce Megacolon Associated With Spotted Coat Color in Mice. Cell 79: 1267–1276. 
Hunley TE & Kon V (2001) Update on Endothelins - Biology and Clinical Implications. Pediatr 
Nephrol 16: 752–762. 
Hunter JJ & Chien KR (1999) Signaling Pathways for Cardiac Hypertrophy and Failure. N Engl J 
Med 341: 1276–1283. 
Hunter JJ, Tanaka N, Rockman HA, Ross J, Jr. & Chien KR (1995) Ventricular Expression of a 
MLC-2v-Ras Fusion Gene Induces Cardiac Hypertrophy and Selective Diastolic Dysfunction in 
Transgenic Mice. J Biol Chem 270: 23173–23178. 
Inoue A, Yanagisawa M, Kimura S, Kasuya Y, Miyauchi T, Goto K & Masaki T (1989) The 
Human Endothelin Family: Three Structurally and Pharmacologically Distinct Isopeptides 
Predicted by Three Separate Genes. Proc Natl Acad Sci U S A 86: 2863–2867. 
Ishikawa T, Yanagisawa M, Kimura S, Goto K & Masaki T (1988a) Positive Chronotropic Effects 
of Endothelin, a Novel Endothelium- Derived Vasoconstrictor Peptide. Pflugers Arch 413: 108–
110. 
Ishikawa T, Yanagisawa M, Kimura S, Goto K & Masaki T (1988b) Positive Inotropic Action of 
Novel Vasoconstrictor Peptide Endothelin on Guinea Pig Atria. Am J Physiol 255: H970–H973. 
Ito H, Hirata Y, Adachi S, Tanaka M, Tsujino M, Koike A, Nogami A, Murumo F & Hiroe M 
(1993) Endothelin-1 Is an Autocrine/Paracrine Factor in the Mechanism of Angiotensin II-
Induced Hypertrophy in Cultured Rat Cardiomyocytes. J Clin Invest 92: 398–403. 
Ito H, Hirata Y, Hiroe M, Tsujino M, Adachi S, Takamoto T, Nitta M, Taniguchi K & Marumo F 
(1991) Endothelin-1 Induces Hypertrophy With Enhanced Expression of Muscle- Specific 
Genes in Cultured Neonatal Rat Cardiomyocytes. Circ Res 69: 209–215. 
Ito H, Hiroe M, Hirata Y, Fujisaki H, Adachi S, Akimoto H, Ohta Y & Marumo F (1994) 
Endothelin ETA Receptor Antagonist Blocks Cardiac Hypertrophy Provoked by Hemodynamic 
Overload. Circulation 89: 2198–2203. 
Izumo S, Lompre AM, Matsuoka R, Koren G, Schwartz K, Nadal-Ginard B & Mahdavi V (1987) 
Myosin Heavy Chain Messenger RNA and Protein Isoform Transitions During Cardiac 
Hypertrophy. Interaction Between Hemodynamic and Thyroid Hormone-Induced Signals. J Clin 
Invest 79: 970–977. 
Jaffe EA, Nachman RL, Becker CG & Minick CR (1973) Culture of Human Endothelial Cells 
Derived From Umbilical Veins. Identification by Morphologic and Immunologic Criteria. J Clin 
Invest 52: 2745–2756. 
Jain J, McCaffrey PG, Miner Z, Kerppola TK, Lambert JN, Verdine GL, Curran T & Rao A (1993) 
The T-Cell Transcription Factor NFATp Is a Substrate for Calcineurin and Interacts With Fos 
and Jun. Nature 365: 352–355. 
Kappel A, Schlaeger TM, Flamme I, Orkin SH, Risau W & Breier G (2000) Role of SCL/Tal-1, 
GATA, and Ets Transcription Factor Binding Sites for the Regulation of Flk-1 Expression 
During Murine Vascular Development. Blood 96: 3078–3085. 
Karin M, Liu Z & Zandi E (1997) AP-1 Function and Regulation. Curr Opin Cell Biol 9: 240-246. 
Kasahara H, Lee B, Schott JJ, Benson DW, Seidman JG, Seidman CE & Izumo S (2000) Loss of 
Function and Inhibitory Effects of Human CSX/NKX2.5 Homeoprotein Mutations Associated 
With Congenital Heart Disease. J Clin Invest 106: 299–308. 
Kasahara H, Wakimoto H, Liu M, Maguire CT, Converso KL, Shioi T, Huang WY, Manning WJ, 
Paul D, Lawitts J, Berul CI & Izumo S (2001) Progressive Atrioventricular Conduction Defects 
and Heart Failure in Mice Expressing a Mutant Csx/Nkx2.5 Homeoprotein. J Clin Invest 108: 
189–201.   89
Kawana M, Lee ME, Quertermous EE & Quertermous T (1995) Cooperative Interaction of GATA-
2 and AP1 Regulates Transcription of the Endothelin-1 Gene. Mol Cell Biol 15: 4225–4231. 
Kaye D, Pimental D, Prasad S, Maki T, Berger HJ, McNeil PL, Smith TW & Kelly RA (1996) Role 
of Transiently Altered Sarcolemmal Membrane Permeability and Basic Fibroblast Growth 
Factor Release in the Hypertrophic Response of Adult Rat Ventricular Myocytes to Increased 
Mechanical Activity in Vitro. J Clin Invest 97: 281–291. 
Kedzierski RM & Yanagisawa M (2001) Endothelin System: the Double-Edged Sword in Health 
and Disease. Annu Rev Pharmacol Toxicol 41: 851–876. 
Kerkelä R, Ilves M, Pikkarainen S, Tokola H, Ronkainen J, Vuolteenaho O, Leppäluoto J & 
Ruskoaho H (2002) Identification of PKCalpha Isoform-Specific Effects in Cardiac Myocytes 
Using Antisense Phosphorothioate Oligonucleotides. Mol Pharmacol 62: 1482–1491. 
Keyse SM (2000) Protein Phosphatases and the Regulation of Mitogen-Activated Protein Kinase 
Signaling. Curr Opin Cell Biol 12: 186–192. 
Kiiveri S, Siltanen S, Rahman N, Bielinska M, Lehto VP, Huhtaniemi IT, Muglia LJ, Wilson DB & 
Heikinheimo M (1999) Reciprocal Changes in the Expression of Transcription Factors GATA-4 
and GATA-6 Accompany Adrenocortical Tumorigenesis in Mice and Humans. Mol Med 5: 
490–501. 
Kim Y, Ma AG, Kitta K, Fitch SN, Ikeda T, Ihara Y, Simon AR, Evans T & Suzuki YJ (2003) 
Anthracycline-Induced Suppression of GATA-4 Transcription Factor: Implication in the 
Regulation of Cardiac Myocyte Apoptosis. Mol Pharmacol 63: 368–377. 
Kimura S, Kasuya Y, Sawamura T, Shinimi O, Sugita Y, Yanagisawa M, Goto K & Masaki T 
(1989) Conversion of Big Endothelin-1 to 21-Residue Endothelin-1 Is Essential for Expression 
of Full Vasoconstrictor Activity: Structure-Activity Relationships of Big Endothelin-1. J 
Cardiovasc Pharmacol 13 Suppl 5: S5–S7. 
Kinnunen P, Vuolteenaho O & Ruskoaho H (1993) Mechanisms of Atrial and Brain Natriuretic 
Peptide Release From Rat Ventricular Myocardium: Effect of Stretching. Endocrinology 132: 
1961–1970. 
Kinnunen P, Vuolteenaho O, Uusimaa P & Ruskoaho H (1992) Passive Mechanical Stretch 
Releases Atrial Natriuretic Peptide From Rat Ventricular Myocardium. Circ Res 70: 1244–
1253. 
Kishimoto I, Rossi K & Garbers DL (2001) A Genetic Model Provides Evidence That the Receptor 
for Atrial Natriuretic Peptide (Guanylyl Cyclase-A) Inhibits Cardiac Ventricular Myocyte 
Hypertrophy. Proc Natl Acad Sci U S A 98: 2703–2706. 
Kitamura K, Shiraishi N, Singer WD, Handlogten ME, Tomita K & Miller RT (1999) Endothelin-B 
Receptors Activate Galpha13. Am J Physiol 276: C930–C937. 
Komatsu Y, Nakao K, Suga S, Ogawa Y, Mukoyama M, Arai H, Shirakami G, Hosoda K, 
Nakagawa O, Hama N & . (1991) C-Type Natriuretic Peptide (CNP) in Rats and Humans. 
Endocrinology 129: 1104–1106. 
Komuro I, Kaida T, Shibazaki Y, Kurabayashi M, Katoh Y, Hoh E, Takaku F & Yazaki Y (1990) 
Stretching Cardiac Myocytes Stimulates Protooncogene Expression. J Biol Chem 265: 3595–
3598. 
Komuro I, Kudo S, Yamazaki T, Zou Y, Shiojima I & Yazaki Y (1996) Mechanical Stretch 
Activates the Stress-Activated Protein Kinases in Cardiac Myocytes. FASEB J 10: 631–636. 
Kourembanas S, Marsden PA, McQuillan LP & Faller DV (1991) Hypoxia Induces Endothelin 
Gene Expression and Secretion in Cultured Human Endothelium. J Clin Invest 88: 1054–1057. 
Kovacic-Milivojevic B & Gardner DG (1993) Regulation of the Human Atrial Natriuretic Peptide 
Gene in Atrial Cardiocytes by the Transcription Factor AP-1. Am J Hypertens 6: 258–263. 
Kovacic B, Ilic D, Damsky CH & Gardner DG (1998) C-Src Activation Plays a Role in Endothelin-
Dependent Hypertrophy of the Cardiac Myocyte. J Biol Chem 273: 35185–35193. 
Krum H, Viskoper RJ, Lacourciere Y, Budde M & Charlon V (1998) The Effect of an Endothelin-
Receptor Antagonist, Bosentan, on Blood Pressure in Patients With Essential Hypertension. 
Bosentan Hypertension Investigators. N Engl J Med 338: 784–790. 
Kudoh S, Komuro I, Hiroi Y, Zou Y, Harada K, Sugaya T, Takekoshi N, Murakami K, Kadowaki 
T & Yazaki Y (1998) Mechanical Stretch Induces Hypertrophic Responses in Cardiac Myocytes 
of Angiotensin II Type 1a Receptor Knockout Mice. J Biol Chem 273: 24037–24043.   90
Kuo CT, Morrisey EE, Anandappa R, Sigrist K, Lu MM, Parmacek MS, Soudais C & Leiden JM 
(1997) GATA4 Transcription Factor Is Required for Ventral Morphogenesis and Heart Tube 
Formation. Genes Dev 11: 1048–1060. 
Kuppuswamy D, Kerr C, Narishige T, Kasi VS, Menick DR & Cooper G (1997) Association of 
Tyrosine-Phosphorylated C-Src With the Cytoskeleton of Hypertrophying Myocardium. J Biol 
Chem 272: 4500–4508. 
Kurihara Y, Kurihara H, Maemura K, Kuwaki T, Kumada M & Yazaki Y (1995a) Impaired 
Development of the Thyroid and Thymus in Endothelin-1 Knockout Mice. J Cardiovasc 
Pharmacol 26 Suppl 3: S13–S16. 
Kurihara Y, Kurihara H, Oda H, Maemura K, Nagai R, Ishikawa T & Yazaki Y (1995b) Aortic 
Arch Malformations and Ventricular Septal Defect in Mice Deficient in Endothelin-1. J Clin 
Invest 96: 293–300. 
Kurihara Y, Kurihara H, Suzuki H, Kodama T, Maemura K, Nagai R, Oda H, Kuwaki T, Cao WH, 
Kamada N & . (1994) Elevated Blood Pressure and Craniofacial Abnormalities in Mice 
Deficient in Endothelin-1. Nature 368: 703–710. 
Laine M, Id L, Vuolteenaho O, Ruskoaho H & Weckström M (1996) Role of Calcium in Stretch-
Induced Release and MRNA Synthesis of Natriuretic Peptides in Isolated Rat Atrium. Pflugers 
Arch 432: 953–960. 
LaMorte VJ, Thorburn J, Absher D, Spiegel A, Brown JH, Chien KR, Feramisco JR & Knowlton 
KU (1994) Gq- and Ras-Dependent Pathways Mediate Hypertrophy of Neonatal Rat Ventricular 
Myocytes Following Alpha 1-Adrenergic Stimulation. J Biol Chem 269: 13490–13496. 
Lang RE, Tholken H, Ganten D, Luft FC, Ruskoaho H & Unger T (1985) Atrial Natriuretic Factor-
-a Circulating Hormone Stimulated by Volume Loading. Nature 314: 264–266. 
Lapointe MC, Wu G, Garami M, Yang XP & Gardner DG (1996) Tissue-Specific Expression of the 
Human Brain Natriuretic Peptide Gene in Cardiac Myocytes. Hypertension 27: 715–722. 
Laser M, Willey CD, Jiang W, Cooper G, Menick DR, Zile MR & Kuppuswamy D (2000) Integrin 
Activation and Focal Complex Formation in Cardiac Hypertrophy. J Biol Chem 275: 35624–
35630. 
Latini R, Masson S, Anand I, Judd D, Maggioni AP, Chiang YT, Bevilacqua M, Salio M, Cardano 
P, Dunselman PH, Holwerda NJ, Tognoni G & Cohn JN (2002) Effects of Valsartan on 
Circulating Brain Natriuretic Peptide and Norepinephrine in Symptomatic Chronic Heart 
Failure: the Valsartan Heart Failure Trial (Val-HeFT). Circulation 106: 2454–2458. 
Lauth M, Wagner AH, Cattaruzza M, Orzechowski HD, Paul M & Hecker M (2000) 
Transcriptional Control of Deformation-Induced Preproendothelin-1 Gene Expression in 
Endothelial Cells. J Mol Med 78: 441–450. 
Lemke LE, Bloem LJ, Fouts R, Esterman M, Sandusky G & Vlahos CJ (2001) Decreased P38 
MAPK Activity in End-Stage Failing Human Myocardium: P38 MAPK Alpha Is the 
Predominant Isoform Expressed in Human Heart. J Mol Cell Cardiol 33: 1527–1540. 
Leprince D, Gegonne A, Coll J, de Taisne C, Schneeberger A, Lagrou C & Stehelin D (1983) A 
Putative Second Cell-Derived Oncogene of the Avian Leukaemia Retrovirus E26. Nature 306: 
395–397. 
Lerman A, Edwards BS, Hallett JW, Heublein DM, Sandberg SM & Burnett JC, Jr. (1991) 
Circulating and Tissue Endothelin Immunoreactivity in Advanced Atherosclerosis. N Engl J 
Med 325: 997–1001. 
Levin ER (1995) Endothelins. N Engl J Med 333: 356–363. 
Levin ER, Gardner DG & Samson WK (1998) Natriuretic Peptides. N Engl J Med 339: 321–328. 
Li JS & Schiffrin EL (1995) Effect of Chronic Treatment of Adult Spontaneously Hypertensive 
Rats With an Endothelin Receptor Antagonist. Hypertension 25: 495–500. 
Liang F, Atakilit A & Gardner DG (2000a) Integrin Dependence of Brain Natriuretic Peptide Gene 
Promoter Activation by Mechanical Strain. J Biol Chem 275: 20355–20360. 
Liang F & Gardner DG (1998) Autocrine/Paracrine Determinants of Strain-Activated Brain 
Natriuretic Peptide Gene Expression in Cultured Cardiac Myocytes. J Biol Chem 273: 14612–
14619. 
Liang F & Gardner DG (1999) Mechanical Strain Activates BNP Gene Transcription Through a 
P38/NF- KappaB-Dependent Mechanism. J Clin Invest 104: 1603–1612.   91
Liang F, Lu S & Gardner DG (2000b) Endothelin-Dependent and -Independent Components of 
Strain-Activated Brain Natriuretic Peptide Gene Transcription Require Extracellular Signal 
Regulated Kinase and P38 Mitogen-Activated Protein Kinase. Hypertension 35: 188–192. 
Liang F, Wu J, Garami M & Gardner DG (1997) Mechanical Strain Increases Expression of the 
Brain Natriuretic Peptide Gene in Rat Cardiac Myocytes. J Biol Chem 272: 28050–28056. 
Liang Q, De Windt LJ, Witt SA, Kimball TR, Markham BE & Molkentin JD (2001a) The 
Transcription Factors GATA4 and GATA6 Regulate Cardiomyocyte Hypertrophy in Vitro and 
in Vivo. J Biol Chem 276: 30245–30253. 
Liang Q & Molkentin JD (2002) Divergent Signaling Pathways Converge on GATA4 to Regulate 
Cardiac Hypertrophic Gene Expression. J Mol Cell Cardiol 34: 611–616. 
Liang Q, Wiese RJ, Bueno OF, Dai YS, Markham BE & Molkentin JD (2001b) The Transcription 
Factor GATA4 Is Activated by Extracellular Signal- Regulated Kinase 1- and 2-Mediated 
Phosphorylation of Serine 105 in Cardiomyocytes. Mol Cell Biol 21: 7460–7469. 
Liao P, Georgakopoulos D, Kovacs A, Zheng M, Lerner D, Pu H, Saffitz J, Chien K, Xiao RP, 
Kass DA & Wang Y (2001) The in Vivo Role of P38 MAP Kinases in Cardiac Remodeling and 
Restrictive Cardiomyopathy. Proc Natl Acad Sci U S A 98: 12283–12288. 
Liefeldt L, Schonfelder G, Bocker W, Hocher B, Talsness CE, Rettig R & Paul M (1999) 
Transgenic Rats Expressing the Human ET-2 Gene: a Model for the Study of Endothelin 
Actions in Vivo. J Mol Med 77: 565–574. 
Lim HW, New L, Han J & Molkentin JD (2001) Calcineurin Enhances MAPK Phosphatase-1 
Expression and P38 MAPK Inactivation in Cardiac Myocytes. J Biol Chem 276: 15913–15919. 
Lints TJ, Parsons LM, Hartley L, Lyons I & Harvey RP (1993) Nkx-2.5: a Novel Murine 
Homeobox Gene Expressed in Early Heart Progenitor Cells and Their Myogenic Descendants. 
Development 119: 419–431. 
Lopez MJ, Wong SK, Kishimoto I, Dubois S, Mach V, Friesen J, Garbers DL & Beuve A (1995) 
Salt-Resistant Hypertension in Mice Lacking the Guanylyl Cyclase-A Receptor for Atrial 
Natriuretic Peptide. Nature 378: 65–68. 
Lorell BH & Carabello BA (2000) Left Ventricular Hypertrophy: Pathogenesis, Detection, and 
Prognosis. Circulation 102: 470–479. 
Luodonpää M, Vuolteenaho O, Eskelinen S & Ruskoaho H (2001) Effects of Adrenomedullin on 
Hypertrophic Responses Induced by Angiotensin II, Endothelin-1 and Phenylephrine. Peptides 
22: 1859–1866. 
Luscher TF & Barton M (2000) Endothelins and Endothelin Receptor Antagonists: Therapeutic 
Considerations for a Novel Class of Cardiovascular Drugs. Circulation 102: 2434–2440. 
Lyons I, Parsons LM, Hartley L, Li R, Andrews JE, Robb L & Harvey RP (1995) Myogenic and 
Morphogenetic Defects in the Heart Tubes of Murine Embryos Lacking the Homeo Box Gene 
Nkx2-5. Genes Dev 9: 1654–1666. 
Macarthur H, Warner TD, Wood EG, Corder R & Vane JR (1994) Endothelin-1 Release From 
Endothelial Cells in Culture Is Elevated Both Acutely and Chronically by Short Periods of 
Mechanical Stretch. Biochem Biophys Res Commun 200: 395–400. 
Mackay K & Mochly-Rosen D (2001) Localization, Anchoring, and Functions of Protein Kinase C 
Isozymes in the Heart. J Mol Cell Cardiol 33: 1301–1307. 
Maemura K, Kurihara H, Morita T, Oh-hashi Y & Yazaki Y (1992) Production of Endothelin-1 in 
Vascular Endothelial Cells Is Regulated by Factors Associated With Vascular Injury. 
Gerontology 38 Suppl 1: 29–35. 
Magga J, Marttila M, Mäntymaa P, Vuolteenaho O & Ruskoaho H (1994) Brain Natriuretic Peptide 
in Plasma, Atria, and Ventricles of Vasopre. Endocrinology 134: 2505–2515. 
Magga J, Vuolteenaho O, Marttila M & Ruskoaho H (1997a) Endothelin-1 Is Involved in Stretch-
Induced Early Activation of B-Type Natriuretic Peptide Gene Expression in Atrial but Not in 
Ventricular Myocytes: Acute Effects of Mixed ET(A)/ET(B) and AT1 Receptor Antagonists in 
Vivo and in Vitro. Circulation 96: 3053–3062. 
Magga J, Vuolteenaho O, Tokola H, Marttila M & Ruskoaho H (1997b) Involvement of 
Transcriptional and Posttranscriptional Mechanisms in Cardiac Overload-Induced Increase of B-
Type Natriuretic Peptide Gene Expression. Circ Res 81: 694–702.   92
Magga J, Vuolteenaho O, Tokola H, Marttila M & Ruskoaho H (1998) B-Type Natriuretic Peptide: 
a Myocyte-Specific Marker for Characterizing Load-Induced Alterations in Cardiac Gene 
Expression. Ann Med 30 Suppl 1: 39–45. 
Majalahti-Palviainen T, Hirvinen M, Tervonen V, Ilves M, Ruskoaho H & Vuolteenaho O (2000) 
Gene Structure of a New Cardiac Peptide Hormone: a Model for Heart- Specific Gene 
Expression. Endocrinology 141: 731–740. 
Mann MJ & Dzau VJ (2000) Therapeutic Applications of Transcription Factor Decoy 
Oligonucleotides. J Clin Invest 106: 1071–1075. 
Mäntymaa P, Vuolteenaho O, Marttila M & Ruskoaho H (1993) Atrial Stretch Induces Rapid 
Increase in Brain Natriuretic Peptide but Not in Atrial Natriuretic Peptide Gene Expression in 
Vitro. Endocrinology 133: 1470–1473. 
Mao J, Yuan H, Xie W, Simon MI & Wu D (1998) Specific Involvement of G Proteins in 
Regulation of Serum Response Factor-Mediated Gene Transcription by Different Receptors. J 
Biol Chem 273: 27118–27123. 
Maroulakou IG & Bowe DB (2000) Expression and Function of Ets Transcription Factors in 
Mammalian Development: a Regulatory Network. Oncogene 19: 6432–6442. 
Marttila M, Hautala N, Paradis P, Toth M, Vuolteenaho O, Nemer M & Ruskoaho H (2001) 
GATA4 Mediates Activation of the B-Type Natriuretic Peptide Gene Expression in Response to 
Hemodynamic Stress. Endocrinology 142: 4693–4700. 
Matsumoto H, Suzuki N, Onda H & Fujino M (1989) Abundance of Endothelin-3 in Rat Intestine, 
Pituitary Gland and Brain. Biochem Biophys Res Commun 164: 74–80. 
McKinsey TA & Olson EN (1999) Cardiac Hypertrophy: Sorting Out the Circuitry. Curr Opin 
Genet Dev 9: 267–274. 
Michel MC, Li Y & Heusch G (2001) Mitogen-Activated Protein Kinases in the Heart. Naunyn 
Schmiedebergs Arch Pharmacol 363: 245–266. 
Modesti PA, Vanni S, Paniccia R, Bandinelli B, Bertolozzi I, Polidori G, Sani G & Neri Serneri 
GG (1999) Characterization of Endothelin-1 Receptor Subtypes in Isolated Human 
Cardiomyocytes. J Cardiovasc Pharmacol 34: 333–339. 
Molkentin JD (2000) The Zinc Finger-Containing Transcription Factors GATA-4, -5, and -6. 
Ubiquitously Expressed Regulators of Tissue-Specific Gene Expression. J Biol Chem 275: 
38949–38952. 
Molkentin JD & Dorn II GW (2001) Cytoplasmic Signaling Pathways That Regulate Cardiac 
Hypertrophy. Annu Rev Physiol 63: 391–426. 
Molkentin JD, Kalvakolanu DV & Markham BE (1994) Transcription Factor GATA-4 Regulates 
Cardiac Muscle-Specific Expression of the Alpha-Myosin Heavy-Chain Gene. Mol Cell Biol 
14: 4947–4957. 
Molkentin JD, Lin Q, Duncan SA & Olson EN (1997) Requirement of the Transcription Factor 
GATA4 for Heart Tube Formation and Ventral Morphogenesis. Genes Dev 11: 1061–1072. 
Molkentin JD, Lu JR, Antos CL, Markham B, Richardson J, Robbins J, Grant SR & Olson EN 
(1998) A Calcineurin-Dependent Transcriptional Pathway for Cardiac Hypertrophy. Cell 93: 
215–228. 
Montagnani M, Vulpis V, Nazzaro P, Potenza MA, Rinaldi R, Nacci C, De Salvia MA, Siro BG, 
Pirrelli A & Mitolo-Chieppa D (2000) Endothelin-1-Receptor-Mediated Responses in 
Resistance Vessels of Young and Adult Spontaneously Hypertensive Rats. J Hypertens 18: 893–
900. 
Moravec CS, Reynolds EE, Stewart RW & Bond M (1989) Endothelin Is a Positive Inotropic 
Agent in Human and Rat Heart in Vitro. Biochem Biophys Res Commun 159: 14–18. 
Morgan JP (1991) Abnormal Intracellular Modulation of Calcium As a Major Cause of Cardiac 
Contractile Dysfunction. N Engl J Med 325: 625–632. 
Morimoto T, Hasegawa K, Kaburagi S, Kakita T, Wada H, Yanazume T & Sasayama S (2000) 
Phosphorylation of GATA-4 Is Involved in Alpha 1-Adrenergic Agonist- Responsive 
Transcription of the Endothelin-1 Gene in Cardiac Myocytes. J Biol Chem 275: 13721–13726. 
Morin S, Charron F, Robitaille L & Nemer M (2000) GATA-Dependent Recruitment of MEF2 
Proteins to Target Promoters. EMBO J 19: 2046–2055.   93
Morisco C, Seta K, Hardt SE, Lee Y, Vatner SF & Sadoshima J (2001) Glycogen Synthase Kinase 
3beta Regulates GATA4 in Cardiac Myocytes. J Biol Chem 276: 28586–28597. 
Morrisey EE, Ip HS, Tang Z & Parmacek MS (1997) GATA-4 Activates Transcription Via Two 
Novel Domains That Are Conserved Within the GATA-4/5/6 Subfamily. J Biol Chem 272: 
8515–8524. 
Mulder P, Boujedaini H, Richard V, Derumeaux G, Henry JP, Renet S, Wessale J, Opgenorth T & 
Thuillez C (2000) Selective Endothelin-A Versus Combined Endothelin-A/Endothelin-B 
Receptor Blockade in Rat Chronic Heart Failure. Circulation 102: 491–493. 
Mulder P, Richard V, Derumeaux G, Hogie M, Henry JP, Lallemand F, Compagnon P, Mace B, 
Comoy E, Letac B & Thuillez C (1997) Role of Endogenous Endothelin in Chronic Heart 
Failure: Effect of Long- Term Treatment With an Endothelin Antagonist on Survival, 
Hemodynamics, and Cardiac Remodeling. Circulation 96: 1976–1982. 
Murat A, Pellieux C, Brunner HR & Pedrazzini T (2000) Calcineurin Blockade Prevents Cardiac 
Mitogen-Activated Protein Kinase Activation and Hypertrophy in Renovascular Hypertension. J 
Biol Chem 275: 40867–40873. 
Muth JN, Bodi I, Lewis W, Varadi G & Schwartz A (2001) A Ca(2+)-Dependent Transgenic 
Model of Cardiac Hypertrophy: A Role for Protein Kinase Calpha. Circulation 103: 140–147. 
Mylona P & Cleland JG (1999) Update of REACH-1 and MERIT-HF Clinical Trials in Heart 
Failure. Cardio.Net Editorial Team. Eur J Heart Fail 1: 197–200. 
Naito S, Shimizu S, Maeda S, Wang J, Paul R & Fagin JA (1998) Ets-1 Is an Early Response Gene 
Activated by ET-1 and PDGF-BB in Vascular Smooth Muscle Cells. Am J Physiol 274: C472–
C480. 
Nakao K, Itoh H, Saito Y, Mukoyama M & Ogawa Y (1996) The Natriuretic Peptide Family. Curr 
Opin Nephrol Hypertens 5: 4–11. 
Nakao K, Minobe W, Roden R, Bristow MR & Leinwand LA (1997) Myosin Heavy Chain Gene 
Expression in Human Heart Failure. J Clin Invest 100: 2362–2370. 
Nakao K, Ogawa Y, Suga S & Imura H (1992a) Molecular Biology and Biochemistry of the 
Natriuretic Peptide System. I: Natriuretic Peptides. J Hypertens 10: 907–912. 
Nakao K, Ogawa Y, Suga S & Imura H (1992b) Molecular Biology and Biochemistry of the 
Natriuretic Peptide System. II: Natriuretic Peptide Receptors. J Hypertens 10: 1111–1114. 
Nakayama K, Ohkubo H, Hirose T, Inayama S & Nakanishi S (1984) MRNA Sequence for Human 
Cardiodilatin-Atrial Natriuretic Factor Precursor and Regulation of Precursor MRNA in Rat 
Atria. Nature 310: 699–701. 
Narita N, Bielinska M & Wilson DB (1997) Wild-Type Endoderm Abrogates the Ventral 
Developmental Defects Associated With GATA-4 Deficiency in the Mouse. Dev Biol 189: 
270–274. 
Nemoto S, Sheng Z & Lin A (1998) Opposing Effects of Jun Kinase and P38 Mitogen-Activated 
Protein Kinases on Cardiomyocyte Hypertrophy. Mol Cell Biol 18: 3518–3526. 
Neves SR, Ram PT & Iyengar R (2002) G Protein Pathways. Science 296: 1636–1639. 
Nicol RL, Frey N & Olson EN (2000) From the Sarcomere to the Nucleus: Role of Genetics and 
Signaling in Structural Heart Disease. Annu Rev Genomics Hum Genet 1: 179–223. 
Nishida W, Nakamura M, Mori S, Takahashi M, Ohkawa Y, Tadokoro S, Yoshida K, Hiwada K, 
Hayashi K & Sobue K (2002) A Triad of Serum Response Factor and the GATA and NK 
Families Governs the Transcription of Smooth and Cardiac Muscle Genes. J Biol Chem 277: 
7308–7317. 
Nishizuka Y (1984) Turnover of Inositol Phospholipids and Signal Transduction. Science 225: 
1365–1370. 
Nishizuka Y (1986) Studies and Perspectives of Protein Kinase C. Science 233: 305–312. 
Nye JA, Petersen JM, Gunther CV, Jonsen MD & Graves BJ (1992) Interaction of Murine Ets-1 
With GGA-Binding Sites Establishes the ETS Domain As a New DNA-Binding Motif. Genes 
Dev 6: 975–990. 
Nyui N, Tamura K, Mizuno K, Ishigami T, Hibi K, Yabana M, Kihara M, Fukamizu A, Ochiai H, 
Umemura S, Murakami K, Ohno S & Ishii M (1997) Stretch-Induced MAP Kinase Activation in 
Cardiomyocytes of Angiotensinogen-Deficient Mice. Biochem Biophys Res Commun 235: 36–
41.   94
Ogawa E, Saito Y, Kuwahara K, Harada M, Miyamoto Y, Hamanaka I, Kajiyama N, Takahashi N, 
Izumi T, Kawakami R, Kishimoto I, Naruse Y, Mori N & Nakao K (2002) Fibronectin 
Signaling Stimulates BNP Gene Transcription by Inhibiting Neuron-Restrictive Silencer 
Element-Dependent Repression. Cardiovasc Res 53: 451–459. 
Ogawa Y, Itoh H, Tamura N, Suga S, Yoshimasa T, Uehira M, Matsuda S, Shiono S, Nishimoto H 
& Nakao K (1994) Molecular Cloning of the Complementary DNA and Gene That Encode 
Mouse Brain Natriuretic Peptide and Generation of Transgenic Mice That Overexpress the 
Brain Natriuretic Peptide Gene. J Clin Invest 93: 1911–1921. 
Ogawa Y, Nakao K, Arai H, Nakagawa O, Hosoda K, Suga S, Nakanishi S & Imura H (1991a) 
Molecular Cloning of a Non-Isopeptide-Selective Human Endothelin Receptor. Biochem 
Biophys Res Commun 178: 248–255. 
Ogawa Y, Nakao K, Mukoyama M, Hosoda K, Shirakami G, Arai H, Saito Y, Suga S, Jougasaki M 
& Imura H (1991b) Natriuretic Peptides As Cardiac Hormones in Normotensive and 
Spontaneously Hypertensive Rats. The Ventricle Is a Major Site of Synthesis and Secretion of 
Brain Natriuretic Peptide. Circ Res 69: 491–500. 
Oliver PM, Fox JE, Kim R, Rockman HA, Kim HS, Reddick RL, Pandey KN, Milgram SL, 
Smithies O & Maeda N (1997) Hypertension, Cardiac Hypertrophy, and Sudden Death in Mice 
Lacking Natriuretic Peptide Receptor A. Proc Natl Acad Sci U S A 94: 14730–14735. 
Oliver PM, John SW, Purdy KE, Kim R, Maeda N, Goy MF & Smithies O (1998) Natriuretic 
Peptide Receptor 1 Expression Influences Blood Pressures of Mice in a Dose-Dependent 
Manner. Proc Natl Acad Sci U S A 95: 2547–2551. 
Olson EN & Molkentin JD (1999) Prevention of Cardiac Hypertrophy by Calcineurin Inhibition: 
Hope or Hype?. Circ Res 84: 623–632. 
Omura T, Yoshiyama M, Yoshida K, Nakamura Y, Kim S, Iwao H, Takeuchi K & Yoshikawa J 
(2002) Dominant Negative Mutant of C-Jun Inhibits Cardiomyocyte Hypertrophy Induced by 
Endothelin 1 and Phenylephrine. Hypertension 39: 81–86. 
Orkin SH (1998) Embryonic Stem Cells and Transgenic Mice in the Study of Hematopoiesis. Int J 
Dev Biol 42: 927–934. 
Pan J, Hinzmann B, Yan W, Wu F, Morser J & Wu Q (2002) Genomic Structures of the Human 
and Murine Corin Genes and Functional GATA Elements in Their Promoters. J Biol Chem 277: 
38390–38398. 
Parsons JT (1996) Integrin-Mediated Signaling: Regulation by Protein Tyrosine Kinases and Small 
GTP-Binding Proteins. Curr Opin Cell Biol 8: 146–152. 
Passier R, Zeng H, Frey N, Naya FJ, Nicol RL, McKinsey TA, Overbeek P, Richardson JA, Grant 
SR & Olson EN (2000) CaM Kinase Signaling Induces Cardiac Hypertrophy and Activates the 
MEF2 Transcription Factor in Vivo. J Clin Invest 105: 1395–1406. 
Paul M, Zintz M, Bocker W & Dyer M (1995) Characterization and Functional Analysis of the Rat 
Endothelin-1 Promoter. Hypertension 25: 683–693. 
Pitkänen M, Mäntymaa P & Ruskoaho H (1991) Staurosporine, a Protein Kinase C Inhibitor, 
Inhibits Atrial Natriuretic Peptide Secretion Induced by Sarafotoxin, Endothelin and Phorbol 
Ester. Eur J Pharmacol 195: 307–315. 
Piuhola J, Szokodi I, Kinnunen P, Ilves M, deChatel R, Vuolteenaho O & Ruskoaho H (2003) 
Endothelin-1 Contributes to the Frank-Starling Response in Hypertrophic Rat Hearts. 
Hypertension 41: 93–98. 
Pönicke K, Heinroth-Hoffmann I, Becker K, Osten B & Brodde OE (1999) Gq/11-Coupled 
Receptors and Protein Synthesis in Rat Cardiomyocytes: Role of Gi-Proteins and Protein Kinase 
C-Isozymes. Naunyn Schmiedebergs Arch Pharmacol 360: 301–308. 
Potter LR & Hunter T (2001) Guanylyl Cyclase-Linked Natriuretic Peptide Receptors: Structure 
and Regulation. J Biol Chem 276: 6057–6060. 
Pracyk JB, Tanaka K, Hegland DD, Kim KS, Sethi R, Rovira II, Blazina DR, Lee L, Bruder JT, 
Kovesdi I, Goldshmidt-Clermont PJ, Irani K & Finkel T (1998) A Requirement for the Rac1 
GTPase in the Signal Transduction Pathway Leading to Cardiac Myocyte Hypertrophy. J Clin 
Invest 102: 929–937.   95
Price MA, Cruzalegui FH & Treisman R (1996) The P38 and ERK MAP Kinase Pathways 
Cooperate to Activate Ternary Complex Factors and C-Fos Transcription in Response to UV 
Light. EMBO J 15: 6552–6563. 
Ray A, Aumont MC, Aussedat J, Bercovici J, Rossi A & Swynghedauw B (1987) Protein and 28S 
Ribosomal RNA Fractional Turnover Rates in the Rat Heart After Abdominal Aortic Stenosis. 
Cardiovasc Res 21: 587–592. 
Ray LB & Sturgill TW (1988) Insulin-Stimulated Microtubule-Associated Protein Kinase Is 
Phosphorylated on Tyrosine and Threonine in Vivo. Proc Natl Acad Sci U S A 85: 3753–3757. 
Richards AM, Doughty R, Nicholls MG, MacMahon S, Sharpe N, Murphy J, Espiner EA, 
Frampton C & Yandle TG (2001) Plasma N-Terminal Pro-Brain Natriuretic Peptide and 
Adrenomedullin: Prognostic Utility and Prediction of Benefit From Carvedilol in Chronic 
Ischemic Left Ventricular Dysfunction. Australia-New Zealand Heart Failure Group. J Am Coll 
Cardiol 37: 1781–1787. 
Ritter O, Hack S, Schuh K, Rothlein N, Perrot A, Osterziel KJ, Schulte HD & Neyses L (2002) 
Calcineurin in Human Heart Hypertrophy. Circulation 105: 2265–2269. 
Robinson MJ & Cobb MH (1997) Mitogen-Activated Protein Kinase Pathways. Curr Opin Cell 
Biol 9: 180–186. 
Rockman HA, Koch WJ & Lefkowitz RJ (2002) Seven-Transmembrane-Spanning Receptors and 
Heart Function. Nature 415: 206–212. 
Roman BB, Geenen DL, Leitges M & Buttrick PM (2001) PKC-Beta Is Not Necessary for Cardiac 
Hypertrophy. Am J Physiol Heart Circ Physiol 280 : H2264–H2270. 
Ross RS & Borg TK (2001) Integrins and the Myocardium. Circ Res 88: 1112–1119. 
Ross RS, Pham C, Shai SY, Goldhaber JI, Fenczik C, Glembotski CC, Ginsberg MH & Loftus JC 
(1998) Beta1 Integrins Participate in the Hypertrophic Response of Rat Ventricular Myocytes. 
Circ Res 82: 1160–1172. 
Rubin LJ, Badesch DB, Barst RJ, Galie N, Black CM, Keogh A, Pulido T, Frost A, Roux S, 
Leconte I, Landzberg M & Simonneau G (2002) Bosentan Therapy for Pulmonary Arterial 
Hypertension. N Engl J Med 346: 896–903. 
Ruskoaho H (1992) Atrial Natriuretic Peptide: Synthesis, Release, and Metabolism. Pharmacol Rev 
44: 479–602. 
Russell FD & Davenport AP (1999) Secretory Pathways in Endothelin Synthesis. Br J Pharmacol 
126: 391–398. 
Russell FD, Skepper JN & Davenport AP (1997) Detection of Endothelin Receptors in Human 
Coronary Artery Vascular Smooth Muscle Cells but Not Endothelial Cells by Using Electron 
Microscope Autoradiography. J Cardiovasc Pharmacol 29: 820–826. 
Sadoshima J & Izumo S (1993) Mechanical Stretch Rapidly Activates Multiple Signal 
Transduction Pathways in Cardiac Myocytes: Potential Involvement of an Autocrine/Paracrine 
Mechanism. EMBO J 12: 1681–1692. 
Sadoshima J & Izumo S (1996) The Heterotrimeric G q Protein-Coupled Angiotensin II Receptor 
Activates P21 Ras Via the Tyrosine Kinase-Shc-Grb2-Sos Pathway in Cardiac Myocytes. 
EMBO J 15: 775–787. 
Sadoshima J & Izumo S (1997) The Cellular and Molecular Response of Cardiac Myocytes to 
Mechanical Stress. Annu Rev Physiol 59: 551–571. 
Sadoshima J, Jahn L, Takahashi T, Kulik TJ & Izumo S (1992) Molecular Characterization of the 
Stretch-Induced Adaptation of Cultured Cardiac Cells. An in Vitro Model of Load-Induced 
Cardiac Hypertrophy. J Biol Chem 267 : 10551–10560. 
Sadoshima J, Montagne O, Wang Q, Yang G, Warden J, Liu J, Takagi G, Karoor V, Hong C, 
Johnson GL, Vatner DE & Vatner SF (2002) The MEKK1-JNK Pathway Plays a Protective 
Role in Pressure Overload but Does Not Mediate Cardiac Hypertrophy. J Clin Invest 110: 271–
279. 
Sadoshima J, Xu Y, Slayter HS & Izumo S (1993) Autocrine Release of Angiotensin II Mediates 
Stretch-Induced Hypertrophy of Cardiac Myocytes in Vitro. Cell 75: 977–984. 
Sah VP, Hoshijima M, Chien KR & Brown JH (1996) Rho Is Required for Galphaq and Alpha1-
Adrenergic Receptor Signaling in Cardiomyocytes. Dissociation of Ras and Rho Pathways. J 
Biol Chem 271: 31185–31190.   96
Sah VP, Minamisawa S, Tam SP, Wu TH, Dorn GW, Ross J, Jr., Chien KR & Brown JH (1999) 
Cardiac-Specific Overexpression of RhoA Results in Sinus and Atrioventricular Nodal 
Dysfunction and Contractile Failure. J Clin Invest 103: 1627–1634. 
Sah VP, Seasholtz TM, Sagi SA & Brown JH (2000) The Role of Rho in G Protein-Coupled 
Receptor Signal Transduction. Annu Rev Pharmacol Toxicol 40: 459–489. 
Saida K, Mitsui Y & Ishida N (1989) A Novel Peptide, Vasoactive Intestinal Contractor, of a New 
(Endothelin) Peptide Family. Molecular Cloning, Expression, and Biological Activity. J Biol 
Chem 264: 14613–14616. 
Saito A, Shiba R, Yanagisawa M, Masaki T, Kimura S, Yamada K, Mima T, Shigeno T & Goto K 
(1991) Endothelins: Vasoconstrictor Effects and Localization in Canine Cerebral Arteries. Br J 
Pharmacol 103: 1129–1135. 
Sakai S, Miyauchi T, Kobayashi M, Yamaguchi I, Goto K & Sugishita Y (1996) Inhibition of 
Myocardial Endothelin Pathway Improves Long-Term Survival in Heart Failure. Nature 384: 
353–355. 
Sakurai T, Yanagisawa M, Takuwa Y, Miyazaki H, Kimura S, Goto K & Masaki T (1990) Cloning 
of a CDNA Encoding a Non-Isopeptide-Selective Subtype of the Endothelin Receptor. Nature 
348: 732–735. 
Salani D, Di C, V, Nicotra MR, Rosano L, Tecce R, Venuti A, Natali PG & Bagnato A (2000) Role 
of Endothelin-1 in Neovascularization of Ovarian Carcinoma. Am J Pathol 157: 1537–1547. 
Schaeffer HJ & Weber MJ (1999) Mitogen-Activated Protein Kinases: Specific Messages From 
Ubiquitous Messengers. Mol Cell Biol 19: 2435–2444. 
Schiffrin EL (2001) Role of Endothelin-1 in Hypertension and Vascular Disease. Am J Hypertens 
14: 83S–89S. 
Schnabel P & Bohm M (1996) Heterotrimeric G Proteins in Heart Disease. Cell Signal 8: 413–423. 
Schreiber E, Matthias P, Muller MM & Schaffner W (1989) Rapid Detection of Octamer Binding 
Proteins With 'Mini-Extracts', Prepared From a Small Number of Cells. Nucleic Acids Res 17: 
6419. 
Schreiber SS, Oratz M, Evans CD, Gueyikian I & Rothschild MA (1970) Myosin, Myoglobin, and 
Collagen Synthesis in Acute Cardiac Overload. Am J Physiol 219: 481–486. 
Schweitz H, Vigne P, Moinier D, Frelin C & Lazdunski M (1992) A New Member of the 
Natriuretic Peptide Family Is Present in the Venom of the Green Mamba (Dendroaspis 
Angusticeps). J Biol Chem 267: 13928–13932. 
Sementchenko VI & Watson DK (2000) Ets Target Genes: Past, Present and Future. Oncogene 19: 
6533–6548. 
Shaulian E & Karin M (2002) AP-1 As a Regulator of Cell Life and Death. Nat Cell Biol 4: E131–
E136. 
Shichiri M, Hirata Y, Nakajima T, Ando K, Imai T, Yanagisawa M, Masaki T & Marumo F (1991) 
Endothelin-1 Is an Autocrine/Paracrine Growth Factor for Human Cancer Cell Lines. J Clin 
Invest 87: 1867–1871. 
Shindo T, Kurihara H, Maemura K, Kurihara Y, Ueda O, Suzuki H, Kuwaki T, Ju KH, Wang Y, 
Ebihara A, Nishimatsu H, Moriyama N, Fukuda M, Akimoto Y, Hirano H, Morita H, Kumada 
M, Yazaki Y, Nagai R & Kimura K (2002) Renal Damage and Salt-Dependent Hypertension in 
Aged Transgenic Mice Overexpressing Endothelin-1. J Mol Med 80: 105–116. 
Shubeita HE, McDonough PM, Harris AN, Knowlton KU, Glembotski CC, Brown JH & Chien KR 
(1990) Endothelin Induction of Inositol Phospholipid Hydrolysis, Sarcomere Assembly, and 
Cardiac Gene Expression in Ventricular Myocytes. A Paracrine Mechanism for Myocardial Cell 
Hypertrophy. J Biol Chem 265: 20555–20562. 
Sigurdson W, Ruknudin A & Sachs F (1992) Calcium Imaging of Mechanically Induced Fluxes in 
Tissue-Cultured Chick Heart: Role of Stretch-Activated Ion Channels. Am J Physiol 262: 
H1110–H1115. 
Simon MI, Strathmann MP & Gautam N (1991) Diversity of G Proteins in Signal Transduction. 
Science 252: 802–808. 
Stein B, Yang MX, Young DB, Janknecht R, Hunter T, Murray BW & Barbosa MS (1997) P38-2, 
a Novel Mitogen-Activated Protein Kinase With Distinct Properties. J Biol Chem 272: 19509–
19517.   97
Steinhelper ME, Cochrane KL & Field LJ (1990) Hypotension in Transgenic Mice Expressing 
Atrial Natriuretic Factor Fusion Genes. Hypertension 16: 301–307. 
Stephenson J (2001) Experimental Prostate Cancer Drugs Slow Disease Progression. JAMA 286: 
34. 
Suda M, Ogawa Y, Tanaka K, Tamura N, Yasoda A, Takigawa T, Uehira M, Nishimoto H, Itoh H, 
Saito Y, Shiota K & Nakao K (1998) Skeletal Overgrowth in Transgenic Mice That 
Overexpress Brain Natriuretic Peptide. Proc Natl Acad Sci U S A 95: 2337–2342. 
Sudoh T, Kangawa K, Minamino N & Matsuo H (1988) A New Natriuretic Peptide in Porcine 
Brain. Nature 332: 78–81. 
Sudoh T, Minamino N, Kangawa K & Matsuo H (1990) C-Type Natriuretic Peptide (CNP): a New 
Member of Natriuretic Peptide Family Identified in Porcine Brain. Biochem Biophys Res 
Commun 168: 863–870. 
Sugden PH (1999) Signaling in Myocardial Hypertrophy: Life After Calcineurin? Circ Res 84: 
633–646. 
Sugden PH & Clerk A (1998a) "Stress-Responsive" Mitogen-Activated Protein Kinases (c-Jun N-
Terminal Kinases and P38 Mitogen-Activated Protein Kinases) in the Myocardium. Circ Res 
83: 345–352. 
Sugden PH & Clerk A (1998b) Cellular Mechanisms of Cardiac Hypertrophy. J Mol Med 76: 725–
746. 
Sugden PH & Clerk A (2000) Activation of the Small GTP-Binding Protein Ras in the Heart by 
Hypertrophic Agonists. Trends Cardiovasc Med 10 : 1–8. 
Sugimoto T, Stewart S & Guan KL (1997) The Calcium/Calmodulin-Dependent Protein 
Phosphatase Calcineurin Is the Major Elk-1 Phosphatase. J Biol Chem 272: 29415–29418. 
Suo M, Hautala N, Foldes G, Szokodi I, Toth M, Leskinen H, Uusimaa P, Vuolteenaho O, Nemer 
M & Ruskoaho H (2002) Posttranscriptional Control of BNP Gene Expression in Angiotensin 
II- Induced Hypertension. Hypertension 39: 803–808. 
Suzuki T, Kumazaki T & Mitsui Y (1993) Endothelin-1 Is Produced and Secreted by Neonatal Rat 
Cardiac Myocytes in Vitro. Biochem Biophys Res Commun 191: 823–830. 
Swynghedauw B (1999) Molecular Mechanisms of Myocardial Remodeling. Physiol Rev 79: 215–
262. 
Taigen T, De Windt LJ, Lim HW & Molkentin JD (2000) Targeted Inhibition of Calcineurin 
Prevents Agonist-Induced Cardiomyocyte Hypertrophy. Proc Natl Acad Sci U S A 97: 1196–
1201. 
Takagi Y, Ninomiya H, Sakamoto A, Miwa S & Masaki T (1995) Structural Basis of G Protein 
Specificity of Human Endothelin Receptors. A Study With EndothelinA/B Chimeras. J Biol 
Chem 270: 10072–10078. 
Takeishi Y, Huang Q, Abe J, Che W, Lee JD, Kawakatsu H, Hoit BD, Berk BC & Walsh RA 
(2002) Activation of Mitogen-Activated Protein Kinases and P90 Ribosomal S6 Kinase in 
Failing Human Hearts With Dilated Cardiomyopathy. Cardiovasc Res 53: 131–137. 
Takeishi Y, Ping P, Bolli R, Kirkpatrick DL, Hoit BD & Walsh RA (2000) Transgenic 
Overexpression of Constitutively Active Protein Kinase C Epsilon Causes Concentric Cardiac 
Hypertrophy. Circ Res 86: 1218–1223. 
Takemoto Y, Yoshiyama M, Takeuchi K, Omura T, Komatsu R, Izumi Y, Kim S & Yoshikawa J 
(1999) Increased JNK, AP-1 and NF-Kappa B DNA Binding Activities in Isoproterenol-
Induced Cardiac Remodeling. J Mol Cell Cardiol 31: 2017–2030. 
Takeuchi Y, Kihara Y, Inagaki K, Yoneda T & Sasayama S (2001) Endothelin-1 Has a Unique 
Oxygen-Saving Effect by Increasing Contractile Efficiency in the Isolated Rat Heart. 
Circulation 103: 1557–1563. 
Takigawa M, Sakurai T, Kasuya Y, Abe Y, Masaki T & Goto K (1995) Molecular Identification of 
Guanine-Nucleotide-Binding Regulatory Proteins Which Couple to Endothelin Receptors. Eur J 
Biochem 228: 102–108. 
Takimoto E, Mizuno T, Terasaki F, Shimoyama M, Honda H, Shiojima I, Hiroi Y, Oka T, Hayashi 
D, Hirai H, Kudoh S, Toko H, Kawamura K, Nagai R, Yazaki Y & Komuro I (2000) Up-
Regulation of Natriuretic Peptides in the Ventricle of Csx/Nkx2-5 Transgenic Mice. Biochem 
Biophys Res Commun 270: 1074–1079.   98
Tamura N, Ogawa Y, Chusho H, Nakamura K, Nakao K, Suda M, Kasahara M, Hashimoto R, 
Katsuura G, Mukoyama M, Itoh H, Saito Y, Tanaka I, Otani H & Katsuki M (2000) Cardiac 
Fibrosis in Mice Lacking Brain Natriuretic Peptide. Proc Natl Acad Sci U S A 97: 4239–4244. 
Tavi P, Laine M, Weckström M & Ruskoaho H (2001) Cardiac Mechanotransduction: From 
Sensing to Disease and Treatment. Trends Pharmacol Sci 22: 254–260. 
Tevosian SG, Deconinck AE, Cantor AB, Rieff HI, Fujiwara Y, Corfas G & Orkin SH (1999) 
FOG-2: A Novel GATA-Family Cofactor Related to Multitype Zinc-Finger Proteins Friend of 
GATA-1 and U-Shaped. Proc Natl Acad Sci U S A 96: 950–955. 
Thorburn A, Thorburn J, Chen SY, Powers S, Shubeita HE, Feramisco JR & Chien KR (1993) 
HRas-Dependent Pathways Can Activate Morphological and Genetic Markers of Cardiac 
Muscle Cell Hypertrophy. J Biol Chem 268: 2244–2249. 
Thorburn J, Carlson M, Mansour SJ, Chien KR, Ahn NG & Thorburn A (1995) Inhibition of a 
Signaling Pathway in Cardiac Muscle Cells by Active Mitogen-Activated Protein Kinase 
Kinase. Mol Biol Cell 6: 1479–1490. 
Thorburn J, Xu S & Thorburn A (1997) MAP Kinase- and Rho-Dependent Signals Interact to 
Regulate Gene Expression but Not Actin Morphology in Cardiac Muscle Cells. EMBO J 16: 
1888–1900. 
Thuerauf DJ & Glembotski CC (1997) Differential Effects of Protein Kinase C, Ras, and Raf-1 
Kinase on the Induction of the Cardiac B-Type Natriuretic Peptide Gene Through a Critical 
Promoter-Proximal M-CAT Element. J Biol Chem 272: 7464–7472. 
Thuerauf DJ, Hanford DS & Glembotski CC (1994) Regulation of Rat Brain Natriuretic Peptide 
Transcription. A Potential Role for GATA-Related Transcription Factors in Myocardial Cell 
Gene Expression. J Biol Chem 269: 17772–17775. 
Tokola H, Hautala N, Marttila M, Magga J, Pikkarainen S, Kerkelä R, Vuolteenaho O & Ruskoaho 
H (2001) Mechanical Load-Induced Alterations in B-Type Natriuretic Peptide Gene Expression. 
Can J Physiol Pharmacol 79: 646–653. 
Tokola H, Salo K, Vuolteenaho O & Ruskoaho H (1994) Basal and Acidic Fibroblast Growth 
Factor-Induced Atrial Natriuretic Peptide Gene Expression and Secretion Is Inhibited by 
Staurosporine. Eur J Pharmacol 267: 195–206. 
Treisman R (1994) Ternary Complex Factors: Growth Factor Regulated Transcriptional Activators. 
Curr Opin Genet Dev 4: 96–101. 
Troughton RW, Frampton CM, Yandle TG, Espiner EA, Nicholls MG & Richards AM (2000) 
Treatment of Heart Failure Guided by Plasma Aminoterminal Brain Natriuretic Peptide (N-
BNP) Concentrations. Lancet 355: 1126–1130. 
van Biesen T, Hawes BE, Luttrell DK, Krueger KM, Touhara K, Porfiri E, Sakaue M, Luttrell LM 
& Lefkowitz RJ (1995) Receptor-Tyrosine-Kinase- and G Beta Gamma-Mediated MAP Kinase 
Activation by a Common Signaling Pathway. Nature 376: 781–784. 
Vasan RS, Benjamin EJ, Larson MG, Leip EP, Wang TJ, Wilson PW & Levy D (2002) Plasma 
Natriuretic Peptides for Community Screening for Left Ventricular Hypertrophy and Systolic 
Dysfunction: the Framingham Heart Study. JAMA 288: 1252–1259. 
Vojtek AB & Der CJ (1998) Increasing Complexity of the Ras Signaling Pathway. J Biol Chem 
273: 19925–19928. 
Vuolteenaho O, Arjamaa O & Ling N (1985) Atrial Natriuretic Polypeptides (ANP): Rat Atria 
Store High Molecular Weight Precursor but Secrete Processed Peptides of 25-35 Amino Acids. 
Biochem Biophys Res Commun 129: 82–88. 
Wagner OF, Christ G, Wojta J, Vierhapper H, Parzer S, Nowotny PJ, Schneider B, Waldhausl W & 
Binder BR (1992) Polar Secretion of Endothelin-1 by Cultured Endothelial Cells. J Biol Chem 
267: 16066–16068. 
Wakasaki H, Koya D, Schoen FJ, Jirousek MR, Ways DK, Hoit BD, Walsh RA & King GL (1997) 
Targeted Overexpression of Protein Kinase C Beta2 Isoform in Myocardium Causes 
Cardiomyopathy. Proc Natl Acad Sci U S A 94: 9320–9325. 
Wakiya K, Begue A, Stehelin D & Shibuya M (1996) A CAMP Response Element and an Ets 
Motif Are Involved in the Transcriptional Regulation of Flt-1 Tyrosine Kinase (Vascular 
Endothelial Growth Factor Receptor 1) Gene. J Biol Chem 271: 30823–30828.   99
Wang DL, Chen JJ, Shin NL, Kao YC, Hsu KH, Huang WY & Liew CC (1992) Endothelin 
Stimulates Cardiac Alpha- and Beta- Myosin Heavy Chain Gene Expression. Biochem Biophys 
Res Commun 183: 1260–1265. 
Wang Y, Huang S, Sah VP, Ross J, Jr., Brown JH, Han J & Chien KR (1998a) Cardiac Muscle Cell 
Hypertrophy and Apoptosis Induced by Distinct Members of the P38 Mitogen-Activated Protein 
Kinase Family. J Biol Chem 273: 2161–2168. 
Wang Y, Su B, Sah VP, Brown JH, Han J & Chien KR (1998b) Cardiac Hypertrophy Induced by 
Mitogen-Activated Protein Kinase Kinase 7, a Specific Activator for C-Jun NH2-Terminal 
Kinase in Ventricular Muscle Cells. J Biol Chem 273: 5423–5426. 
Watson N, Linder ME, Druey KM, Kehrl JH & Blumer KJ (1996) RGS Family Members: GTPase-
Activating Proteins for Heterotrimeric G- Protein Alpha-Subunits. Nature 383: 172–175. 
Wei CM, Heublein DM, Perrella MA, Lerman A, Rodeheffer RJ, McGregor CG, Edwards WD, 
Schaff HV & Burnett JC, Jr. (1993) Natriuretic Peptide System in Human Heart Failure. 
Circulation 88: 1004–1009. 
Wei L, Wang L, Carson JA, Agan JE, Imanaka-Yoshida K & Schwartz RJ (2001) Beta1 Integrin 
and Organized Actin Filaments Facilitate Cardiomyocyte- Specific RhoA-Dependent Activation 
of the Skeletal Alpha-Actin Promoter. FASEB J 15: 785–796. 
Wettschureck N, Rutten H, Zywietz A, Gehring D, Wilkie TM, Chen J, Chien KR & Offermanns S 
(2001) Absence of Pressure Overload Induced Myocardial Hypertrophy After Conditional 
Inactivation of Galphaq/Galpha11 in Cardiomyocytes. Nat Med 7: 1236–1240. 
Widmann C, Gibson S, Jarpe MB & Johnson GL (1999) Mitogen-Activated Protein Kinase: 
Conservation of a Three-Kinase Module From Yeast to Human. Physiol Rev 79: 143–180. 
Wilkins BJ, De Windt LJ, Bueno OF, Braz JC, Glascock BJ, Kimball TF & Molkentin JD (2002) 
Targeted Disruption of NFATc3, but Not NFATc4, Reveals an Intrinsic Defect in Calcineurin-
Mediated Cardiac Hypertrophic Growth. Mol Cell Biol 22: 7603–7613. 
Wu F, Yan W, Pan J, Morser J & Wu Q (2002) Processing of Pro-Atrial Natriuretic Peptide by 
Corin in Cardiac Myocytes. J Biol Chem 277: 16900–16905. 
Xia Y, McMillin JB, Lewis A, Moore M, Zhu WG, Williams RS & Kellems RE (2000) Electrical 
Stimulation of Neonatal Cardiac Myocytes Activates the NFAT3 and GATA4 Pathways and 
Up-Regulates the Adenylosuccinate Synthetase 1 Gene. J Biol Chem 275: 1855–1863. 
Yamanaka M, Greenberg B, Johnson L, Seilhamer J, Brewer M, Friedemann T, Miller J, Atlas S, 
Laragh J, Lewicki J & . (1984) Cloning and Sequence Analysis of the CDNA for the Rat Atrial 
Natriuretic Factor Precursor. Nature 309: 719–722. 
Yamazaki T, Komuro I, Kudoh S, Zou Y, Shiojima I, Hiroi Y, Mizuno T, Maemura K, Kurihara H, 
Aikawa R, Takano H & Yazaki Y (1996) Endothelin-1 Is Involved in Mechanical Stress-
Induced Cardiomyocyte Hypertrophy. J Biol Chem 271: 3221–3228. 
Yamazaki T, Komuro I, Kudoh S, Zou Y, Shiojima I, Mizuno T, Takano H, Hiroi Y, Ueki K, Tobe 
K (1995a) Angiotensin II Partly Mediates Mechanical Stress-Induced Cardiac Hypertrophy. 
Circ Res 77: 258–265. 
Yamazaki T, Komuro I & Yazaki Y (1995b) Molecular Mechanism of Cardiac Cellular 
Hypertrophy by Mechanical Stress. J Mol Cell Cardiol 27: 133–140. 
Yan W, Wu F, Morser J & Wu Q (2000) Corin, a Transmembrane Cardiac Serine Protease, Acts As 
a Pro-Atrial Natriuretic Peptide-Converting Enzyme. Proc Natl Acad Sci U S A 97: 8525–8529. 
Yanagisawa H, Hammer RE, Richardson JA, Emoto N, Williams SC, Takeda S, Clouthier DE & 
Yanagisawa M (2000) Disruption of ECE-1 and ECE-2 Reveals a Role for Endothelin-
Converting Enzyme-2 in Murine Cardiac Development. J Clin Invest 105: 1373–1382. 
Yanagisawa H, Yanagisawa M, Kapur RP, Richardson JA, Williams SC, Clouthier DE, de Wit D, 
Emoto N & Hammer RE (1998) Dual Genetic Pathways of Endothelin-Mediated Intercellular 
Signaling Revealed by Targeted Disruption of Endothelin Converting Enzyme-1 Gene. 
Development 125: 825–836. 
Yanagisawa M, Kurihara H, Kimura S, Tomobe Y, Kobayashi M, Mitsui Y, Yazaki Y, Goto K & 
Masaki T (1988) A Novel Potent Vasoconstrictor Peptide Produced by Vascular Endothelial 
Cells. Nature 332: 411–415. 
Yandle TG (1994) Biochemistry of Natriuretic Peptides. J Intern Med 235: 561–576.   100
Yang SH, Shore P, Willingham N, Lakey JH & Sharrocks AD (1999) The Mechanism of 
Phosphorylation-Inducible Activation of the ETS-Domain Transcription Factor Elk-1. EMBO J 
18: 5666–5674. 
Yang SH, Vickers E, Brehm A, Kouzarides T & Sharrocks AD (2001) Temporal Recruitment of 
the MSin3A-Histone Deacetylase Corepressor Complex to the ETS Domain Transcription 
Factor Elk-1. Mol Cell Biol 21: 2802–2814. 
Yang SH, Whitmarsh AJ, Davis RJ & Sharrocks AD (1998) Differential Targeting of MAP Kinases 
to the ETS-Domain Transcription Factor Elk-1. EMBO J 17: 1740–1749. 
Yasaka A & Hayashida W (2001) Alterations of Load-Induced P38 MAP Kinase Activation in 
Failing Rat Hearts. Biochem Biophys Res Commun 285: 503–507. 
Yordy JS & Muise-Helmericks RC (2000) Signal Transduction and the Ets Family of Transcription 
Factors. Oncogene 19: 6503–6513. 
Zhang T, Johnson EN, Gu Y, Morissette MR, Sah VP, Gigena MS, Belke DD, Dillmann WH, 
Rogers TB, Schulman H, Ross J, Jr. & Brown JH (2002) The Cardiac-Specific Nuclear Delta(B) 
Isoform of Ca2+/Calmodulin- Dependent Protein Kinase II Induces Hypertrophy and Dilated 
Cardiomyopathy Associated With Increased Protein Phosphatase 2A Activity. J Biol Chem 277: 
1261–1267. 
Zhang YH, Youm JB, Sung HK, Lee SH, Ryu SY, Ho WK & Earm YE (2000) Stretch-Activated 
and Background Non-Selective Cation Channels in Rat Atrial Myocytes. J Physiol 523 Pt 3: 
607–619. 
Zhu W, Zou Y, Shiojima I, Kudoh S, Aikawa R, Hayashi D, Mizukami M, Toko H, Shibasaki F, 
Yazaki Y, Nagai R & Komuro I (2000) Ca2+/Calmodulin-Dependent Kinase II and Calcineurin 
Play Critical Roles in Endothelin-1-Induced Cardiomyocyte Hypertrophy. J Biol Chem 275: 
15239–15245. 
Zimmer HG, Steinkopff G & Gerlach E (1972) Changes of Protein Synthesis in the Hypertrophying 
Rat Heart. Pflugers Arch 336: 311–325. 
Zolk O, Quattek J, Seeland U, El Armouche A, Eschenhagen T & Bohm M (2002) Activation of 
the Cardiac Endothelin System in Left Ventricular Hypertrophy Before Onset of Heart Failure 
in TG(MREN2)27 Rats. Cardiovasc Res 53: 363–371. 
Zou Y, Komuro I, Yamazaki T, Aikawa R, Kudoh S, Shiojima I, Hiroi Y, Mizuno T & Yazaki Y 
(1996) Protein Kinase C, but Not Tyrosine Kinases or Ras, Plays a Critical Role in Angiotensin 
II-Induced Activation of Raf-1 Kinase and Extracellular Signal-Regulated Protein Kinases in 
Cardiac Myocytes. J Biol Chem 271: 33592–33597. 